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ABSTRACT 
The R563Q Mutation of the Beta Subunit of the Epithelial Sodium Channel: 
Prevalence and Effect 
 
Erika Sherad Wilshire Jones 
January 2009 
 
Hypertension is a major worldwide predictor of morbidity and mortality. The search 
for genes that contribute to blood pressure is ongoing. The epithelial sodium channel 
genes were implicated when the beta subunit (SCNN1B, gene ID 6338) was found to 
have a mutation that caused Liddle’s syndrome. The R563Q mutation in the beta 
subunit has been associated with hypertension and pre-eclampsia in the Xhosa and 
Coloured people in Cape Town.  
 
The thesis consists of a cross-sectional analysis of the prevalence of the R563Q 
mutation in multiple ethnic groups in South Africa and a longitudinal functional 
assessment in response to saline infusion. The objectives were to determine the 
prevalence of the R563Q mutation and association with hypertension, and if it persists 
within families; to speculate as to the origins of the mutation; to determine if there 
were any relevant clinical differences between comparable patients with essential 
hypertension; to determine if the mutation predicted a difference in response to acute 
sodium loading and if a physiological difference is observed in sodium channel 
activity when expressed in oocytes.  
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A high frequency of hypertensives in Johannesburg and Cape Town were found to be 
heterozygous and the mutation associated with hypertension, including within 
families. In the Khoisan the R563Q mutation was found at a high frequency (19%) in 
a random sample, suggesting the mutation originated from this population.  
 
The saline challenge illustrated the in vivo effects of the mutation. The results suggest 
that the sodium channel is innately overactive in heterozygous subjects and that 
counter-regulatory mechanisms are in place to compensate for changes in renal 
sodium handling. However, preliminary in vitro testing in oocytes did not show a 
difference in sodium channel activity. 
 
Conclusion: This thesis has shown that the R563Q mutation is found in multiple 
ethnic groups in South Africa, in which it associates with hypertension; and possibly 
originated from the Khoisan. In vivo effects are described. The results are important 
because hypertension resulting from the R563Q mutation is a common and treatable 
cause of hypertension. It is recommended that hypertension units in South Africa 
screen for the mutation and alter treatment appropriately. A further recommendation 
is that a sodium channel inhibitor, such as amiloride, in an appropriate form, is 
registered in South Africa for the treatment of hypertension. 
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INTRODUCTION TO THE THESIS 
 
 
 
An African Home 
In the traditional lifestyle in Africa sodium is a scarce resource that led to evolutionary 
pressures to conserve sodium. 
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CHAPTER 1 
Introduction 
 
Hypertension: An Epidemiological Nightmare 
Hypertension is a common disorder affecting approximately a quarter of the world‟s 
adult population and is projected to increase to up to 30% by 2025. The prevalence of 
hypertension in 2000 ranged from 5.2% in rural India to 45.1% in Spain. While these 
figures could represent the differences between the more natural rural lifestyle 
compared with the industrialised lifestyle of established market economies, it could 
also be a reflection of the difference in discovery and reporting of diseases. The 
overall rate of hypertension was age related, ranging from 12.7% in the 20-29 year 
age group to 59.5% in those older than 70 years for men and 7.4% to 70% in women 
[Kearney et al., 2005]. 
 
South Africa is similarly affected by hypertension. In 1996, According to Health Stats 
SA, the deaths directly attributed to hypertension were 1.3% for males and 2.8% for 
females, of the total registered deaths in South Africa. This excluded deaths due to 
myocardial infarction or coronary vascular events. In 1998 the prevalence of 
hypertension using the World Health Organisation guidelines of a blood pressure (BP) 
greater than or equal to 140/90 was approximately 21% in South Africa [Steyn et al., 
2001]. This became the recommended cut off defining hypertension for South Africa 
in 2006 [Seedat et al., 2006]. Hypertension is an increasing epidemiological problem 
facing rural South Africa. Thorogood et al. [2007] found hypertension in 42% of a 
group of adults studied in Agincourt (a rural South African town) and also showed 
increased total cholesterol level in 25.6% of subjects. 
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Hypertensive heart disease, ischaemic heart disease (IHD), stroke and kidney disease 
were all in the list of top 20 causes of death in 2000 for South Africa [Bradshaw et al., 
2003]. Hypertension is a major risk factor for all of these diseases. The estimated 
years of life lost as a result of these four causes of death was 823 560, indicating the 
huge impact that hypertension has on the population. Hypertension, itself, was 
estimated to account for 9% of deaths in 2000 in South Africa [Norman et al., 2007]. 
 
Steyn et al. [2005], as part of the global INTERHEART study, assessed the risk 
factors that were associated with acute myocardial infarct in Sub-Saharan Africa. 
Black Africans presenting with first time myocardial infarct were significantly 
younger than the European or Coloured African groups, and hypertension was the 
dominant risk factor.. 
 
South African Population Groups 
South Africa is a multiethnic developing country previously divided by racist policies. 
In 1994 South Africa underwent the first true democratic vote and for the first time 
the South African population demographics were properly documented by a national 
census in 2001, [Lehohla, 2003] which detailed the numbers of the various ethnic 
groups in different geographical areas. Unfortunately this census did not document the 
Khoisan groups. The Khoisan are few in number and often individuals have a mixed 
ancestry which may explain why, coupled with a pale skin colour, they may have 
been classified as “Coloured”. The Khoisan people generally speak Afrikaans as their 
home language. Their native „click‟ languages are spoken by only a few of the elder 
people. This thesis will use the descriptions for ethnic groups and geographical areas 
as described in the 2001 census and according to the suggestions made by Soodyall 
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[1993]. For the purposes of this thesis people of mixed ancestry (including a mixture 
of Khoisan, Caucasoid and Negroid, amongst others) will be called Coloured. In 
referencing, subjects will be referred to as they are in the reference. The Khoisan 
groups are made up of many smaller groups which inhabit different areas in Southern 
Africa. The Khoisan group from the Northern Cape identify themselves as Khomani 
San which was what they were termed for the purposes of this thesis.  
 
South Africa is divided into nine provinces: Eastern Cape, Free State, Gauteng, 
KwaZulu Natal, Limpopo, Mpumalanga, Northern Cape, North West Province and 
the Western Cape (Figure 1.1). The Black African subjects in South Africa make up 
79% of the population. The Coloured subjects amount to 8.9%; White subjects 9.6% 
and the Indian/ Asian subjects 2.5% [Lehohla, 2003]. The Black African subjects in 
each province are, similarly, higher than any of the other population groups except in 
the Northern and Western Cape where the Coloured group is the highest. (These are 
the areas where the Khoisan people traditionally lived.) 
 
The groups according to home language in South Africa are: IsiZulu (23.8%), 
IsiXhosa (17.6%), Afrikaans (13.3%), Sepedi (9.4%), English (8.2%), Setswana 
(8.2%), Xitsonga (4.4%), SiSwati (2.7%), Tshivenda (2.3%), IsiNdebele (1.6%) and 
other languages (0.5%). The home languages spoken are a reflection of the population 
groups in each province with Black African languages being the dominant languages 
in most provinces, excluding the Northern and Western Cape (Afrikaans). The most 
common language spoken in each province is: Eastern Cape, IsiXhosa; Free State, 
SeSotho; Gauteng, IsiZulu (but mixed with Afrikaans, English, Sepedi and SeSotho); 
KwaZulu Natal, IsiZulu; Limpopo, Sepedi (and Xitsonga); Mpumalanga, SiSwati 
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(and IsiZulu); Northern Cape, Afrikaans (and Setswana) North West Province, 
Setswana and the Western Cape, Afrikaans (IsiXhosa and English). 
 
 
Figure 1.1. Map of South Africa showing provinces and major cities 
 
Soodyall [1993] classified the groups in South Africa as Bantu-speaking Negroid, 
Khoisan, Caucasoid and Hybrid (“Coloured”) peoples. She showed that the Coloured 
people were a mixture of Khoisan, Negroid, Caucasoid and Malay ancestry (amongst 
others from imported slave labour) with a difference in frequency of genetic 
admixture depending on the geographical position of the individual. The Bantu-
speaking Negroid groups in South Africa consist of the Nguni (Zulu, Swazi and 
Xhosa), Tsonga, Sotho/ Tswana (Sotho, Pedi, and Tswana), Venda and the Lemba. 
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For the purposes of this thesis, when grouped together, these ethnic groups will be 
called Black African. 
 
This thesis presents the results from subjects originating in Johannesburg, Cape Town 
and the Northern Cape. The subjects from Johannesburg and Cape Town are from 
referral Hypertension Units attached to various teaching hospitals. The major cities in 
South Africa are Pretoria (Gauteng), Johannesburg (Gauteng), Cape Town (Western 
Cape), Durban (KwaZulu Natal), Port Elizabeth (Eastern Cape) and Bloemfontein 
(Free State). These major cities contain the tertiary referral units in South Africa. The 
population groups in Pretoria and Johannesburg are very similar (of the Black African 
groups – SeSotho and IsiZulu) and include the major ethnic groups represented in 
Durban and Bloemfontein. The IsiXhosa is the major Black African group in Port 
Elizabeth and Cape Town. Thus, sampling the population groups in Cape Town and 
Johannesburg gives a good representation of the population groups in the major cities 
in South Africa. 
 
Furthermore, in order to obtain a sample of resistant hypertensives tertiary care 
referral units are required. The remainder of the South African cities do not contain 
referral units, so sampling in provinces like Limpopo and the North West is not 
logistically feasible. However, this thesis has samples from the Caucasian groups 
(English and Afrikaans), Coloured, IsiXhosa, IsiZulu and SeSotho which represent 
about 70% of the people in South Africa. (98.4% of the Coloured people speak either 
English or Afrikaans.) Thus, subjects studied in this thesis are a reasonable 
representation of the people living in South Africa. 
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A Racial Difference in Hypertension 
Hypertension itself has a different disease pattern in the Black Africans when 
compared with those of European ancestry. Apart from the difference in risk for IHD 
and the difference in age, Black African hypertensives appear to be “salt sensitive”, 
responding better to diuretics rather than angiotensin converting enzyme (ACE) 
inhibitors. Black African hypertensive patients were thought to have an increased 
propensity to absorb sodium, which was why diuretics are the mainstay of treatment. 
The difference in origin of hypertension between the different races is ascribed to 
genetics and has resulted in a concerted effort to determine which genes are 
responsible for hypertension. The prevalence of mutations in the epithelial sodium 
channel (ENaC) gene (e.g. T594M) is higher in the Black African population in 
London, but has not been reported in many of the Caucasian populations screened 
[Hannila-Handelberg et al., 2005; Persu et al., 1998; Dong et al., 2001; Ambrosius et 
al., 1999]. The prevalence of sodium channel mutations in Black African 
hypertensives could account for the response to the diuretic amiloride [Saha et al., 
2005].  
 
Amiloride is a potassium sparing diuretic that inhibits the ENaC [Rang et al., 1999]. 
The effect of the inhibition of the sodium channel is to decrease sodium and increase 
potassium reabsorption from the cortical collecting duct lumen in the kidney. A 
further advantage of amiloride is that it promotes the excretion of uric acid (which has 
been shown to have an independent effect on BP [Sundstrom et al., 2005] and 
coronary heart disease [Franse et al., 2000]) and has a duration of action of about 24 
hours making it possible to use once a day. Furthermore, amiloride is well tolerated, 
apart from occasional hyperkalaemia.  
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A Genetic and Environmental Disorder 
Over approximately the last 50 years the causes of hypertension have been 
investigated and questioned by many clinical and research teams. The association 
with micronutrient intake has been studied and sodium has been found more 
commonly to be associated with hypertension than any of the others [MacGregor, 
1985; He and MacGregor, 2002]. Chloride has also been associated with hypertension 
[Whitescarver et al., 1984] whereas potassium has been found to be protective 
[Geleijnse et al., 2003].  
 
Male gender is a risk factor in younger subjects but this changes as the individuals get 
older [Kearney et al., 2005], with females having a higher prevalence over 70 years of 
age. Age is one of the greatest risk factors for hypertension with the residual lifetime 
risk being 90% in middle-aged and elderly individuals [Vasan et al., 2002]. Regular 
exercise has been shown to decrease the risk of developing hypertension [Hayashi et 
al., 1999; Tanasescu et al., 2002] whereas excessive alcohol intake [Nanchahal et al., 
2000] and cigarette smoking [Bowman et al., 2007] increase the risk. Obesity is also a 
known risk factor for hypertension, especially abdominal obesity [Okosun et al., 
1999], and weight loss has been shown to reduce the risk for hypertension [Huang et 
al., 1998]. A healthy diet rich in fresh low fat produce has also been shown to 
improve blood pressure [Appel et al., 1997; Moore et al., 1999].  
 
While the environmental factors are generally accepted, the clinically relevant genes 
associated with essential hypertension (EHT) remain to be elucidated except for rare 
cases of Mendelian forms of hypertension. The Mendelian forms of hypertension have 
highlighted potential candidate genes that may be implicated in common essential 
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hypertension. Many single nucleotide polymorphisms (SNPs) have been described to 
date but few occur in sufficient frequency in the general population and/or exert a 
clinically relevant effect on BP to be meaningfully relevant in the pathogenesis and 
treatment of EHT. Furthermore, some of these SNPs have had conflicting associations 
with hypertension in different geographical regions.  
 
Development of the Thesis 
The R563Q mutation of the beta subunit of the ENaC (β-ENaC or SCNN1B, GeneID 
6338) has been found in many hypertensive patients attending the Groote Schuur 
Hospital (GSH) Hypertension Clinic and has previously been associated with 
hypertension [Rayner et al., 2003] and pre-eclampsia [Dhanjal et al., 2006]. This 
thesis aimed to detail further the association with hypertension, show that the 
mutation causes a change in function of the sodium channel, determine the possible 
origins of the mutation in the South African populations and if hypertensive patients 
with this mutation differ clinically from comparable patients without the mutation. 
 
This thesis is divided into four parts. The first part introduces the thesis and critically 
reviews the relevant literature. In the literature discussion, the progression of 
hypertension as a disorder of individuals to the present day thinking of hypertension 
as a genetic conundrum is presented. The debate that was initiated in the 1960s is yet 
to be resolved and this thesis adds to the debate. Some rare Mendelian forms of 
hypertension are discussed because they introduce various candidate genes that are 
implicated in the origins of hypertension. The interaction between hypertension and 
genetics is then discussed in more detail. 
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Salt sensitivity is discussed as it is a major intermediary phenotype associated with 
hypertension and is of particular importance in the relationship between the sodium 
channel and hypertension. The renin angiotensin system is one of the major control 
systems for BP and salt sensitivity so this system is discussed, including some of the 
genetic findings that have been associated with hypertension. The sodium channel 
(the final regulator of sodium balance and the major area of interest in this thesis) is 
then discussed. This channel has been implicated in Mendelian forms of hypertension, 
EHT and genetic protection from hypertension. The β-subunit of the sodium channel 
is of particular relevance to this thesis.  
 
The hypothesis, aims and methods are then presented. Parts two and three are the 
experimental sections of this thesis. Part two introduces the R563Q mutation as a 
common mutation in South Africa with a strong association with hypertension. This 
section discusses the prevalence in different population groups and tries to determine 
if one of these population groups might have been the original group. The association 
with hypertension is shown to be strong within families and in case-control analyses. 
The mutation is shown to exist in multiple ethnic groups in South Africa. Not all of 
the population groups show an association with hypertension, increasing the interest 
of the discussion. This section demonstrates that the Khoisan could be the population 
group of origin of the R563Q mutation in the South African groups. 
 
Part three aims to show that the mutation alters the activity of the sodium channel 
from a physical and physiological perspective. This section aims to delineate the 
effects of the mutation in treated hypertensive patients with the mutation comparing 
their phenotype with treated hypertensives without the mutation. This is followed by 
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an analysis and discussion of the effects of acutely loading individuals with 
intravenous sodium. Sodium loading was used as a means to compare the renal and 
cardiovascular response of individuals with and without the R563Q mutation. This 
section also describes the effects of the R563Q mutation on sodium current in 
Xenopus oocytes, a well known means of illustrating a physiological alteration in 
sodium conductance. Further, in part three, a few interesting cases are presented, to 
illustrate observations that have been made in hypertensive patients with the R563Q 
mutation. Although case studies do not prove a point, they are useful in presenting 
observations from which further analyses and trials may be undertaken. They are thus 
important to the progression of research.  
 
Part four brings together the whole thesis, presenting the conclusions and discussing 
areas for further research. Recommendations based on the findings are presented. In 
order to ensure certain terminology is understood in relevance to this thesis 
appendices have been compiled. Relevant documents are presented in the appendices.  
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CHAPTER 2 
From an Observation to the Beta Subunit of the  
Sodium Channel 
 
Hypertension: A History of the Developments of an ‘Inherited Disorder’ 
Morgagni [1761] undertook more than 700 human dissections. Amongst his findings 
were the descriptions of a father and son, who both died of apoplexy (or stroke). 
Morgagni had previously noted the association between a rise in BP (or hypertension) 
and apoplexy. He suggested that the rise in BP could be of familial origin and was the 
first person to suggest hypertension was an inherited disorder. 
 
It was about 150 years later before there was an attempt to delineate the genetic or 
familial origins of hypertension. Weitz [1923] studied the association of 
cardiovascular disease and hypertension over three generations. He showed that if 
there was a death in the parent from a cardiovascular disorder, there was hypertension 
in the next two generations which appeared to be independent of other factors. He 
also examined the association with BP and hypertension between monozygotic and 
dizygotic twins [Weitz 1954], and found that there was greater concordance for BP 
between monozygotic twins.  
 
Ayman [1934] showed that hypertension had strong familial associations and 
proposed that heredity was the most important factor for the development of 
hypertension. Allan [1933] tried to determine if hypertension was a dominant or 
recessive trait using statistical modelling, but found there were insufficient data to 
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determine the mode of inheritance. Platt [1947] also tried to delineate the nature of the 
inheritance of hypertension, and suggested that EHT was a simple Mendelian 
dominant disorder with a distinct division between normotension and hypertension. 
 
Pickering [1952] agreed that there was a strong familial association but argued that 
there was insufficient evidence to show the nature of inheritance, and alluded to the 
possibility of failure of homeostatic mechanisms within the kidney. Guyton [1990] 
was the first to describe this failed mechanism in 1966 and published a summary of 
his findings in 1990. He called the mechanism that controlled BP the Infinite Gain 
Mechanism of the kidney. Using a mathematical formula Guyton showed that only if 
there was failure in kidney homeostasis, would there be a long term disruption in BP 
control resulting in a rise in BP and hypertension. This was supported by clinical 
observations. In contrast, if there was normal renal function but abnormal cardiac or 
vascular function BP would change acutely, but would return to normal through the 
infinite gain mechanism of salt and water retention by the kidney. 
 
The assumption was that abnormal kidney function would cause a resetting of BP 
homeostasis and could cause hypertension. Thus, in the early studies of EHT 
scientists were correct to exclude patients with chronic pyelonephritis (a known form 
of kidney disease caused specifically by environmental factors).  
 
Pickering [1955a] proposed that hypertension was the extreme of the normal 
distribution of BP (the general population displays a Gaussian curve) which showed 
continuous variation. As there was no evidence for two populations, he argued against 
having an arbitrary division between normotension and hypertension. He believed that 
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hypertension had a multifactorial genetic and environmental basis with each 
individual trait having a small effect on BP. He suggested that the Mendelian 
dominance was seen due to an artefact by the artificial and arbitrary division between 
the normal BP and the hypertension. Rather, hypertension should be defined as 
deviance from the norm in each age group. He developed a complex formula 
involving the standard deviation (SD) for the age, which would then give the clinician 
a score that expressed the degree of hypertension or hypotension [Pickering, 1955b]. 
This method was never adopted due to the obvious clinical impracticalities.  
 
In contrast, Platt [1964] showed that hypertension was not just an extreme of the 
normal distribution of BP. This was not the case in the normal population or in the 
families of known hypertensives across all age groups. Platt [1963], using twin 
studies, proposed a single gene theory: when inherited in the heterozygous form there 
would be a moderate rise in BP and when inherited in the homozygous form there 
would be a marked rise in BP causing severe hypertension. Platt suggested that the 
mutation could have created a survival advantage in the original population, who 
developed the mutation.  
 
Platt‟s single gene theory has not been widely accepted. However, Liddle [1963] 
described a family who presented with a syndrome that was characterised by severe 
hypertension, hypokalaemic alkalosis and suppressed plasma aldosterone levels. They 
responded to triamterene – an inhibitor if renal ion transport in the ENaC, but not to 
an aldosterone antagonist. The BP response to triamterene was most effective when 
combined with a low sodium diet. The family tree demonstrated an autosomal 
dominant pattern of inheritance, and it was named Liddle‟s syndrome. 
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Shimkets et al. [1994] defined the mutation in the ENaC of this family. (The ENaC is 
found in the distal convoluted tubule and cortical collecting duct and is the final and 
rate limiting step in sodium reabsorption.) It was a mutation, R566X, which causes 
truncation of the carboxyterminal of the β subunit of the ENaC and increases activity 
of the β-ENaC resulting in sodium retention, hypokalaemia and hypertension. This 
mutation does not fully support Platt‟s single gene theory as it is only described in the 
heterozygous form with no homozygous cases reported, perhaps because of the 
extreme rarity of the mutation. However, in the heterozygous form the phenotypic 
presentation is extremely variable. 
 
The biggest difficulty for the proponents of the single gene theory is the extreme 
rarity with which these single gene defects present and thus cannot account for the 
common condition of EHT. 
 
Mendelian Forms of hypertension 
The Mendelian forms of hypertension are rare and influence sodium retention or 
reabsorption. However, these forms of hypertension do bring to our attention 
candidate genes that could be responsible, or at least in part responsible, for a major 
portion of EHT. Searching for single nucleotide polymorphisms (SNPs) in these 
candidate genes may prove to be fruitful when trying to determine the genetic causes 
of hypertension. Figure 2.1 illustrates the interaction of multiple pathways that control 
BP and highlights known Mendelian forms of hypertension which will be discussed 
further. 
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Figure 2.1. The renin angiotensin aldosterone system and the positions where 
Mendelian forms of hypertension occur. (ACE, angiotensin converting enzyme; AT1, 
angiotensin receptor 1; AD, autosomal dominant; AR, autosomal recessive; GRA, 
glucocorticoid remedial aldosteronism; ACTH, adrenocorticotropic hormone; MCR, 
mineralocorticoid receptor; AME, apparent mineralocorticoid excess; +, stimulates; - 
inhibits. Image created from information by Luft [2003]) 
 
Glucocorticoid Remedial Aldosteronism  
Glucocorticoid Remedial Aldosteronism (GRA) is an autosomal dominant form of 
hypertension that presents with signs and symptoms similar to primary aldosteronism. 
The defect is a chimeric gene combining the aldosterone synthase gene and the 11β 
hydroxylase gene and has been described in 18 families [Pascoe et al., 1992]. A later 
study found a GRA-causing mutation in three subjects, one of whom was 
normotensive [Fardella et al., 2000]. (The production of the chimeric gene is shown in 
Figure 2.2.) These two genes are found on the same chromosome (8q) and unequal 
crossing over occurs with the aldosterone synthase gene gaining an 
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adrenocorticotropic (ACTH) sensitive promoter. Suppression of steroidogenesis with 
oral corticosteroids treats the hypertension as ACTH production is suppressed.  
 
 
Figure 2.2. The production of the chimeric gene causing GRA. Image taken from The 
Atlas of Heart Diseases, Hypertension: Mechanisms and Therapy, Hollenberg [1994], 
p1.9 
 
Apparent Mineralocorticoid Excess 
Apparent mineralocorticoid excess (AME) is an autosomal recessive disorder which 
results from mutations in the 11 β-hydroxysteroid dehydrogenase gene, decreasing its 
function [Stewart et al., 1996]. Fewer than 100 cases have been reported [Palermo et 
al., 2004]. This enzyme converts cortisol to inactive cortisone.  As cortisol and 
Hollenberg [1994] 
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aldosterone both stimulate the mineralocorticoid receptor and cortisol is present in 
higher concentrations, this enzyme is essential to prevent cortisol acting as a potent 
mineralocorticoid. Thus a deficiency of function of this enzyme will lead to constant 
stimulation of the receptor. This inherited disorder is mimicked by excess intake of 
liquorice which contains glycyrrhetinic acid which inhibits the enzyme. 
 
Mineralocorticoid Receptor 
The S810L mutation of the mineralocorticoid receptor [Geller et al., 2000] has been 
described in a family with early onset hypertension. The mutation changes the 
structure of the receptor making it innately active and sensitive to stimulation by 
mineralocorticoids that do not have the 21-hydroxyl group, especially progesterone. 
(Aldosterone has the 21-hydroxyl group.)  
 
Liddle‟s Syndrome 
Liddle‟s syndrome (as discussed above) is an autosomal dominant form of 
hypertension that is associated with hypokalaemia, hypoaldosteronism and metabolic 
alkalosis. It is the result of a defect in one of the sodium channel subunit genes. About 
30 families have been described with this disorder [Rossier and Schild, 2008]. This 
syndrome will be discussed in detail later. 
 
Gordon‟s Syndrome 
Pseudohypoaldosteronism Type II (or Gordon‟s syndrome) is due to mutations in the 
WNK (with no lysine) kinase genes [Wilson et al., 2001]. These kinases alter the 
function of the sodium chloride cotransporter and mutations can increase its activity. 
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The genetic defect in this disorder has not been completely described but families 
have been described who exhibit clear autosomal dominant inheritance [Luft, 2003]. 
 
Autosomal Dominant Hypertension with Brachydactyly 
Three families have been described with an autosomal dominant hypertensive 
disorder associated with shortened phalanges and metacarpals [Toka et al., 1998; Luft 
1998]. The genetic defect has not been described but has been linked to chromosome 
12p [Gong et al., 2003]. Neurovascular compression of the posterior inferior 
cerebellar artery has been found in some of these patients and has been suggested as 
the cause of the hypertension. 
 
Congenital Adrenal Hyperplasia 
Congenital adrenal hyperplasia (CAH) is a disorder resulting from a deficiency of the 
enzymes involved in cortisol synthesis, such as 11 β-hydroxylase [White et al., 1991], 
17-α-hydroxylase [Yanase et al., 1989] or, more commonly, 21 hydroxylase [Morel et 
al., 1989]. This is a more common disorder with frequencies between 1 in 5000 and 1 
in 15 000 births in western communities [Fauci et al., 1998]. The enzymes convert 
steroid precursors into cortisol and, if dysfunctional, cause a build up in the steroid 
precursors. (See Figure 2.3 for defects causing cortisol deficiency and CAH.) These 
deficiencies are a result of either autosomal dominant or recessive mutations. 
Mutations that cause this syndrome result in a protein with little or no enzymatic 
activity. The lack of cortisol stimulates the production of corticotrophin in the anterior 
pituitary which stimulates the adrenal gland. The build up of precursors is the likely 
cause of the hypertension. 11-β-hydroxylase deficiency also causes androgen excess 
but in 17-α-hydroxylase deficiency there tends to be an androgen deficiency. 
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Figure 2.3. Defects causing CAH (AR, autosomal recessive. Image created with 
information from White [1996]) 
 
The above disorders illustrate the multiple possibilities for Mendelian forms of 
hypertension. These disorders are rare and often present with severe hypertension, but 
EHT is a common disorder that presents with a range of BP levels. More common 
SNPs in these genes with less dominant functional effects may form a reasonable 
approach to understanding the genetics of EHT. 
 
Hypertension – A Geneticist’s Nightmare 
BP is a continuous variable resulting in an ongoing debate about the definition of 
hypertension. Platt and Pickering started off the debate in the 1960s and there have 
been differences of opinions ever since. Until recently, hypertension was defined as a 
BP ≥160/95mmHg in South Africa [Steyn et al., 2001], but the defining level has 
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been decreased to ≥140/90mmHg; in accordance with the European and American 
Guidelines [Lemogoum et al., 2003].  
 
Determining the presence of hypertension in an individual is further complicated by 
the presence of a phenomenon called white coat hypertension. This is defined as the 
presence of a raised BP in a clinical setting but normal BP during the normal daily 
activities. It can only be diagnosed with home or ambulatory BP monitoring but is a 
risk factor for developing EHT [Ugajin et al., 2005].  
 
The difficulty of determining the phenotype is highlighted when trying to associate 
genetic polymorphisms with hypertension. Many mutations described are associated 
with a minor difference in BP of questionable clinical application. Detecting these 
small changes can be difficult due to the natural variability of BP within an 
individual, the effect of BP measurement on BP  (i.e. white coat phenomenon), and 
the poor reproducibility of single BP measurements. This problem is further 
compounded when comparisons are made between subjects.   
 
There is clearly a strong inherited component to hypertension but the genetic causes 
remain elusive. This has lead to many different techniques employed by geneticists to 
determine the genotypes associated with hypertension.  
 
One of the methods employed is genome-wide linkage analysis [Gong et al., 2003] 
which uses microarrays and chip-based technology to analyse up to 500,000 SNPs in 
a single sample. With the Human Genome Project it is now possible to pinpoint the 
potential candidate genes but in some cases associations have been found in areas of 
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the genome where there are no known genes. However the potential for false positive 
results is high due to the sheer number of associations. 
 
Another method employed by geneticists to determine if there is an association with 
hypertension and a gene is the candidate gene approach. This method looks at specific 
genes (such as the β-ENaC) and determines if there are different haplotypes of the 
gene that are associated with hypertension. Once the presence of an associated 
haplotype is determined then it is possible to sequence the gene to define the 
mutation. Further association studies can then increase the information on the 
mutation. 
 
However, these methods often fail to show a pure association with the phenotype 
being assessed. In which case, it is possible to determine if the mutation is associated 
with a difference in an intermediate phenotype that is known to result in the pathology 
that is being studied. For hypertension, one such intermediate phenotype is salt 
sensitivity. 
 
Salt Sensitivity 
Salt sensitivity is defined as a more than expected rise in BP after sodium chloride 
loading and a more than expected decrease with sodium restriction. The kidney is a 
finely tuned organ that filters large volumes of sodium every day (about 
25560mEq/day); 99.4% (25410mEq/day) of which is reabsorbed [Guyton and Hall 
1996]. Sodium reabsorption in each segment is dependent on the amount delivered to 
that segment (glomerulotubular balance). A defect in any of the channels responsible 
for sodium reabsorption is thus likely to have a major effect on sodium balance. 
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Examples of defects in sodium reabsorption are Bartter‟s, Gitelman‟s [Feehally et al., 
2007] and Liddle‟s syndromes. 
 
Bartter‟s syndrome is the result of an inactivating mutation in one of the genes 
encoding the major transport proteins in the thick ascending limb of the Loop of 
Henle. The major transport proteins are the sodium-potassium-chloride cotransporter, 
renal outer medullary potassium channel, the chloride channel and the Barrtin 
accessory protein to the chloride channel. Defects in these proteins result in sodium 
and chloride wasting associated with severe hypotension and hypokalaemia and often 
result in early death. Gitelman‟s syndrome is an autosomal recessive disorder and is 
less severe, presenting in early adulthood. It is due to a defect in the sodium-chloride 
cotransporter in the distal tubule. The syndrome is characterised by hypokalaemic 
metabolic alkalosis and hypotension with hypocalcuria and hypomagnesaemia. These 
disorders represent extreme situations resulting from mutations that completely 
disrupt the function of channels responsible for sodium reabsorption. It is possible 
that different genetic coding of these same channels will have a smaller effect and 
create situations like salt sensitivity. The kidney reabsorbs 99.4% of the sodium load 
thus, even mild to moderate perturbations in function can result in severe clinical 
syndromes. Milder defects in reabsorbtive function in these channels may be 
protective against hypertension in the face of high sodium diet; conversely, defects 
resulting in hyperfunction may favour survival in the face of sodium scarcity or cause 
salt-sensitive hypertension in environments of sodium excess. 
 
Salt sensitivity is known to be more common in Black African people [Luft et al., 
1991]. The original „hunter-gatherer‟ people lived in an environment where sodium 
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was an extremely scarce commodity and had a total daily intake of about 0.3g to 3g a 
day [Carvalho et al., 1989]. Salt can be lost in the sweat (about 3-5g/day) and the 
stool (about 175mg sodium) [Guyton and Hall, 1996]. The loss of fluid and sodium in 
sweat would also tend to be larger in the heat of Africa compared with the losses 
observed in the cold European climate. Thus hunter-gatherers were in a precarious 
sodium balance. The ability to retain sodium by the kidneys was critical to survival 
and thus the ability to conserve sodium may have played a crucial role in genetic 
selection. This may be a reason why salt sensitivity is associated with population 
groups originating in Africa. 
  
The descendants of these African people are now being exposed to the lifestyle that 
westerners have been living over many centuries. This includes a diet rich in sodium. 
Increased dietary sodium intake was been found to be associated with the risk of 
cardiovascular disease and mortality [He et al., 1999]. Two studies were initiated in 
an attempt to prevent hypertension with dietary sodium reduction. The interventions 
were education and counselling for periods of up to 48 months. In a 15 year follow up 
of those who had had the interventional advice the cardiovascular events were 
significantly lower than those who had had standard dietary advice [Cook et al., 
2007]. 
 
Luft et al. [1991] showed that salt sensitivity developed as people got older and was 
due to a delay in sodium excretion. Falkner and Kushner [1990] studied normotensive 
young blacks and whites and also found that blacks were more salt sensitive than 
whites. They found that within these normotensive subjects those that were classified 
as salt sensitive had significantly higher BP than those that were salt resistant.  
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Salt sensitivity has been poorly defined, but is characterised by an increase in BP with 
higher sodium intake and a decrease in BP with sodium restriction. Sullivan et al. 
[1987] were one of the first teams to define salt sensitivity. They assessed subjects on 
their normal diet with added high (200mEq) and low (10mEq) sodium intake. They 
defined salt sensitivity as an increase in mean arterial pressure (MAP) by 5% on 
chronic dietary sodium loading. Salt sensitivity was present in 39% of the 
hypertensive subjects and 22% of the normotensive subjects. BP changes (outside of 
the normal range of 75-160mmHg) normally result in an alteration of sodium and 
water excretion which controls the BP [Guyton and Hall, 1996]. This pressure 
natriuresis and diuresis response may be defective in salt sensitivity. 
 
Since then many attempts have been made to try and define salt sensitivity. Overlack 
et al. [1993] defined salt sensitivity as an increase in MAP by 5mmHg on a high 
sodium diet when compared with a low sodium diet. A difference of less than 5mmHg 
was defined as salt resistant and those in whom their BP decreased were labelled 
counter-regulators. They tested for salt sensitivity in a group of normotensive non-
obese subjects and found that subjects that were older, female, had a lower body 
weight or a family history of hypertension were more likely to be salt sensitive. 
 
Weinberger et al. [2001] defined salt sensitivity in the acute setting. Their definition 
of salt sensitivity was a decrease in BP of 10mmHg or more when given furosemide 
after a saline challenge of 2L 0.9% saline. A decrease in BP of less than 6mmHg was 
defined as salt resistant. This definition was applied to 708 subjects and their medical 
history and cause of death was followed up almost 30 years later. Salt sensitivity was 
found to be associated with mortality in both normotensive and hypertensive subjects. 
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Another team [Gill et al., 1991] described salt sensitivity as an increase in MAP by 
8mmHg, between a week of a low (9mmol/day) sodium diet and a week of a high 
(249mmol/d) sodium diet. This dietary analysis was an in-hospital study to ensure 
strict compliance. They found that the salt sensitive group had a significantly higher 
urinary 3,4-dihydroxyphenylalanine (dopa) excretion which had a marked increase 
when the sodium was increased initially.  
 
Although there are many definitions that are used for salt sensitivity, an indirect 
indicator is low plasma renin activity, plasma aldosterone and urinary aldosterone 
excretion that are suppressed by negative feedback in response to innate sodium 
reabsorption by the kidney 
 
Racial differences in sodium homeostasis were well described by Ambrosius et al. 
[1999]. The Black group that was studied in America had lower urinary aldosterone-
potassium ratios, increased sodium retention, decreased aldosterone excretion and 
increased potassium excretion, suggesting an underlying predisposition to salt 
sensitivity in African Americans. Furthermore, these results indirectly suggest that 
overactivity of the ENaC may be the underlying difference between Black African 
and Caucasian populations. Pratt et al. [1989] showed that even African American 
children under 12 years had lower aldosterone levels suggesting this may be a genetic 
difference. Furthermore, they [Pratt et al., 1993] showed the urinary aldosterone 
excretion in Black children did not increase with time and was persistently about 35% 
lower than in White children. These differences in aldosterone and renin levels are 
also described in South Africa. Rayner et al. [2001] showed that Black African 
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normotensives had significantly lower renin and aldosterone levels than the Caucasian 
normotensives, despite a similar sodium intake. 
 
There is contrasting evidence for a racial difference in ENaC activity. Pratt et al. 
[2002] found that Blacks excreted less potassium and had higher serum potassium 
levels, and amiloride was shown to be a more effective antihypertensive in White than 
in Black individuals, indicating that Blacks have intrinsically lower ENaC activity. In 
contrast, Baker et al. [2001] showed that the ENaC was upregulated in Black people 
in London. Using a technique where they assessed nasal potential difference (which 
had been used to show a higher sodium channel activity in patients with Liddle‟s 
disease [Baker et al., 1998b]) they found that the maximum nasal potential difference 
was higher in Black subjects. Black hypertensives and normotensives did not have a 
difference in nasal potential difference.  
 
Low renin, low aldosterone hypertension (LRHT) is a well described clinical entity. 
Pratt et al. [1999] showed that it is caused by sodium retention by the kidney rather 
than the result of increased mineralocorticoid activity. Fisher et al. [2002] 
demonstrated a familial association for low renin levels, possibly implicating genetic 
factors. As the RAAS is the major system controlling sodium homeostasis and BP 
[Guyton, 1990] it warrants further discussion. 
 
Renin Angiotensin Aldosterone Syndrome 
Renin is secreted by the juxtaglomerular cells of the kidney in response to a drop in 
BP, decreased glomerular filtration rate (GFR) and increased sympathetic activity. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 46 
Renin converts angiotensinogen (AGT) to angiotensin I which in turn is converted to 
angiotensin II, by ACE (Figure 2.4). 
 
 
Figure 2.4. The renin angiotensin aldosterone system and its ability to control BP. 
(ACE- Angiotensin converting enzyme, AT1 and AT2 – Angiotensin receptors 1 and 
2, ENaC- epithelial sodium channel) 
 
Angiotensin II decreases renal blood flow, increases tubular reabsorption of sodium 
and water and stimulates the production of aldosterone. Angiotensin II is a potent 
vasoconstrictor, stimulates thirst, and via its receptors in the brain, stimulates 
sympathetic output and antidiuretic hormone secretion [Guyton and Hall, 1996]. 
Aldosterone stimulates sodium retention through stimulation of the mineralocorticoid 
receptor and the ENaC. All these effects act in concert to restore BP and sodium 
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balance. Thus the entire RAAS is a fertile source for the investigation of candidate 
genes for hypertension, particularly of the salt sensitive type. 
 
Aldosterone is produced from the adrenal glands in response to angiotensin II or a 
decrease in potassium but is inhibited by a rise in osmolarity (increased sodium). It 
acts on the principal cells in the kidneys to increase sodium retention and increase 
potassium excretion. It stimulates and increases the apical sodium channels and the 
basal sodium-potassium adenosine triphosphatase (Na/K-ATPase) pump. Sodium 
absorption is increased, along with water, increasing the extracellular fluid volume 
and BP.  
 
The activity of aldosterone on the ENaC is the final and rate limiting step in sodium 
reabsorption. However the aldosterone stimulus on BP is not as potent as angiotensin 
II [Guyton and Hall, 1996] which may account for the directed search for genetic 
polymorphisms in the renin and AGT genes. The genes that code for the proteins in 
the RAAS are candidate genes for hypertension. There have been many studies 
searching for polymorphisms in these genes to determine an association with 
hypertension.  
 
Hasimu et al. [2003a] screened the renin gene for polymorphisms in Japan and then 
assessed for phenotypic differences. A missense mutation (G1051A) in the coding 
region of the renin gene was found and was associated with EHT. The GG genotype 
had significantly higher plasma renin activity. The same group [Hasimu et al., 2003b] 
also found a variable number of tandem repeat (VNTR) polymorphism in intron 7, 
18bp upstream of exon 8, but this was not associated with hypertension. Niu et al. 
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[1999] found no evidence that the renin gene (or any other gene in the RAAS) 
influenced the pathogenesis of hypertension in the Chinese. 
 
Nagy et al. [1999] showed that there was significant linkage between the renin gene 
and higher systolic BP (SBP) in the Hungarian population, using twin studies. They 
also showed that the β- and γ-ENaC genes were linked to increased SBP. Zhu et al. 
[2003] showed that a number of polymorphisms in the renin, AGT and angiotensin 2 
receptor genes were linked to hypertension using family based studies and analysing 
the data using transmission disequilibrium testing (TDT) analysis. (For a description 
of the TDT analysis, see Appendix I.) These findings were particularly evident in the 
African American population that they studied. 
 
The AGT gene is well researched as a candidate gene. This gene was found to have a 
high frequency of the M235T variant in many different populations. The T allele has 
been significantly associated with hypertension but Jeunemaitre et al. [1997b] showed 
that a SNP (G-6A) in the pretranscription region of the gene was in complete linkage 
disequilibrium (LD) with the M235T variant and when associated with the T allele 
was significantly associated with hypertension. However, Brand et al. [1998] 
observed that there needs to be a large number of families in a study for a significant 
linkage of hypertension to an AGT candidate gene. Tiago et al. [2002] found a 
significant relationship of the M235T AGT polymorphism with the influence of body 
size on SBP in South Africans.  
 
ACE mutations were found that involved insertions and deletions. A Spanish study 
[Poch et al., 2001] found that an insertion mutation was associated with salt 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 49 
sensitivity and a higher incidence of hypertension. Another study [Kosachunhanun et 
al., 2003] in the USA found that the ACE DD genotype, when co-expressed with the 
AGT 235 TT genotype, was associated with non-modulating salt response and thus a 
higher risk of hypertension. This study also found that subjects with the AGT 235 TT 
genotype had significantly lower plasma aldosterone levels and a higher SBP.  
 
Other angiotensin gene polymorphisms have been described that are associated with 
EHT. Two studies [Caulfield et al., 1994; Atwood et al., 1997], in different 
populations confirmed the association of AGT gene GT dinucleotide repeat 
polymorphism with hypertension. Neither of these studies found a significant 
association with the M235T variant.  
 
The angiotensin receptors have been contentious with regard to their influence on BP. 
The effects of the two receptors (AT1R and AT2R) on BP were characterised by 
Munzenmeier and Greene [1996]. They found that stimulation of AT1R causes 
vasoconstriction and angiogenesis and stimulation of AT2R inhibits this response. The 
AT1R gene is found on the X chromosome. Jones et al. [2003] found that the 
AT1R11166CC genotype was found more frequently in hypertensives than in 
normotensives, and that, independent of BP, it was associated with cardiovascular 
risk. In the same study two polymorphisms were found in the AT2R gene; 
AT2R1675A>G and AT2R3123C>A. The 1675G polymorphism was found to be 
protective against the effects of hypertension and if the 1675A genotype was co-
expressed with the 3123A genotype there was a significant risk of hypertension and 
its complications. Jin et al. [2003] screened a Japanese population for polymorphisms 
of the AT2R gene and discovered a polymorphism (C4599A in exon 3) that was 
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significantly associated with hypertension in women, particularly post-menopausal 
women.  
 
These studies illustrate the difficulties of determining the effects of differing 
genotypes on multifactorial disorders. Associating a single mutation with a disease, 
independent of the remainder of the genetic make-up, excludes the additive effects of 
multiple polymorphisms.  
 
Epithelial Sodium Channel 
The ENaC is the final step in sodium reabsorption and thus of sodium balance. It is 
highly selective for sodium over potassium (>100x) and is inhibited by amiloride 
[Zhou and Bubien, 2001]. Mutations in the genes encoding the sodium channel 
subunits have been found to cause Liddle‟s disease (autosomal dominant hypertension 
with potassium wasting and hypoaldosteronism). Finding this disorder in the rate-
limiting step for sodium reabsorption has made the ENaC genes attractive candidate 
genes for EHT. 
 
The sodium channel is a ligand gated (i.e. opens or closes in response to a chemical 
messenger) transmembranous channel. The sodium channel is traditionally thought to 
be a tetramer made up of 2α, 1β and 1γ subunit as seen in Figure 2.5. However, recent 
evidence suggests that the channel is made up of equal numbers of each subunit: 
1α:1β:1γ [Staruschenko et al., 2005a] being the most likely but two or three of each 
subunit also being a possibility. This team used a fluorescence based approach to 
illustrate the relative subunit stoichiometry and subunit titration experiments to show 
that the channels were more likely to be found with equal numbers of each subunit. 
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They also illustrated that the channels are preferentially found in the heteromer form 
as opposed to the homomer.  
 
 
Figure 2.5. The ENaC is a transmembranous tetramer, composed of two α, one β 
and one γ subunit, influenced by many proteins. (Image taken from Rotin [2000]) 
ENaC, epithelial sodium channel; PDK1, 3-phosphoinositide-dependent protein; 
PI3K, PI3 kinase; CAP1, channel activating protease 1; CFTR, cystic fibrosis 
transmembrane conductance receptor; sgk, serum glucocorticoid induced kinase 
 
These findings were supported by Jasti et al. [2007] who crystallised the acid-sensing-
ion channel (ASIC). This channel has a similar amino acid sequence to the ENaC and 
is thought to have a similar evolutionary history. This team used crystallography and 
electrophysiological studies to determine the architecture and molecular properties of 
the ASIC. They found that the ASIC was expressed as a trimer but were unable to 
crystallise the intracytoplasmic region of the ASIC which influenced the ability to 
determine the function. This strongly suggests that the ENaC is also expressed as a 
trimer. 
 
Rotin [2000] 
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The ENaC was found in the apical plasma membrane of the principal cells in the 
collecting duct by Loffing et al. [2000] and has a high affinity for sodium [Babini et 
al., 2003]. Loffing et al. [2000] showed that dietary intake of sodium influenced the 
availability of the subunits and expression at the cell membrane. On a diet rich in 
sodium, mice had no detectable renal cell α-ENaC. The β and γ subunits were present 
in the cytoplasm but not at the apical surface. When the mice were on a low sodium 
diet all three subunits were found in the plasma membrane and in the subapical 
cytoplasm. The insertion of β- and γ-ENaC into the membrane coincided with 
detectable levels of α-ENaC. This regulatory feedback was replicated by Babini et al. 
[2003]. They found that upon exposure to high sodium concentrations the ENaC 
became inactive. Other factors were found to influence ENaC activity: activity is 
increased by aldosterone and vasopressin and inhibited by amiloride [Zhou and 
Bubien, 2001].  
 
Upregulation 
Insulin and aldosterone increase the number of sodium channels at the cell surface 
[Blazer-Yost et al., 1998]. The individual hormones stimulate the sodium current but 
together they act synergistically with the rate of decline of current being much slower 
when acting together. This effect was shown to be phosphatidylinositol 3 kinase (PI3 
kinase) dependant [Blazer-Yost et al., 2003], suggesting a transcellular signalling 
pathway for ENaC insertion into the apical membrane.  
 
Serum insulin acts on receptors at the basolateral membrane which then increases the 
sodium channel activity. Blazer-Yost et al. [2004] confirmed this pathway as a 
mechanism of insulin control of ENaC activity by showing that insulin increased PI3 
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kinase, which in turn resulted in phosphorylation of the ENaC with 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) causing insertion of the ENaC (from 
apical pools) into the apical membrane. Tong et al. [2004] showed that the PIP3 and 
phosphatidylinositol 3,4-bisphosphate (PIP2) had a direct stimulatory effect on the 
sodium channel by increasing open probability (Po) and confirmed that PI3 kinase 
mediated this pathway.  
 
Tallini and Stoner [2002] also showed that insulin increased the open probability (Po) 
which increased the sodium channel conductance. Serum and glucocorticoid induced 
kinase 1 (SGK1) also increased sodium current. SGK1 was phosphorylated by PIP3 
and had an additive effect with aldosterone but abolished the insulin response 
[Arteaga and Canessa, 2005]. 
 
PIP3 was shown [Pochynyuk et al., 2005] to interact with the γ-ENaC at the conserved 
positive amino acids just distal to the second transmembranous domain. This then 
regulates the signalling cascades of the γ-ENaC. The resulting alteration in channel 
function is thought to be the result of a difference in channel gating as Po is affected 
the most.  
Aldosterone stimulates the sodium channel genes to increase production of the 
subunits that make up the channel [Zhou and Bubien, 2001]. The subunits are made in 
the endoplasmic reticulum. In the endoplasmic reticulum the subunits form an 
immature channel which enters the cytoplasm on acquisition of oligosaccharides 
before insertion into the cell membrane. This maturation process is the rate limiting 
step in the production of active channels [Valentijn et al., 1998]. 
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Zhou and Bubien [2001] showed that aldosterone also activates the channel directly 
and that this process is adenosine triphosphate (ATP) dependent. This could also be 
how insulin and protein kinases A (PKA) and C (PKC) alter function with 
phosphorylation of the channel [Shimkets et al., 1998]. Cyclic adenosine 
monophosphate (cAMP) could assist in this process by increasing translocation of the 
channels into the cell membrane [Snyder, 2000].  
 
Staruschenko et al. [2005b] showed that conserved threonines and serines within the 
cytoplasmic carboxy termini of the β-ENaC and γ-ENaC are required for interaction 
with epsin, dynamin and Nedd 4-2. The state of phosphorylation of the serine and 
threonine residues determined the interaction with these proteins which in turn 
influenced the channel activity. (For a description of Nedd 4, see glossary.) 
Aldosterone also stimulates the production of protein 14-3-3β. This group of 
intracellular proteins binds to phosphorylated motifs on their target protein to control 
function. In the cortical colleting duct cells this protein binds to phosphorylated Nedd 
4-2 inhibiting its interaction with ENaC, thereby decreasing ENaC internalisation 
[Liang et al., 2006].  
 
Butterworth et al. [2005a] showed that the sodium channel is found in a subapical 
pool. This explained their earlier findings that activation of PKA results in insertion of 
channels (from a subapical storage pool of channels) into the membrane and a cAMP-
induced increase in current [Butterworth et al., 2001]. This current could be G-protein 
dependant. Using B lymphocytes, Bubien et al. [1994] found that the ENaC is 
regulated by cAMP and guanidine triphosphate- (GTP)-binding proteins, which act on 
G proteins. 
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Hill et al. [2007] showed that the sodium channel inserts into the membrane with the 
aid of lipid domains (rafts). Many different proteins also use these lipid rafts to aid in 
their function, e.g. syntaxin 1A (S1A) which acts as a transporter for the sodium 
channel. As the lipid rafts are made up of cholesterol this makes the channels 
dependant on cholesterol. The interaction of lipid rafts and the sodium channel was 
found to be important for ENaC delivery to the apical membrane, but not for retrieval. 
This paper also showed that aldosterone did not alter the interaction between the 
ENaC and these lipid rafts suggesting that this means of delivery into the cell 
membrane is an independent pathway for increasing sodium channel activity. 
 
Downregulation 
The intracellular domains of the ENaC are available to interact with intracellular 
proteins to internalise the channels. The carboxy termini of the subunits each have a 
PY motif which has been found to be important in downregulation of the channels 
[Schild et al., 1996]. The PY motif is a proline-rich sequence which has a tyrosine 
within the motif. In the human β-ENaC this motif starts at amino acid 613 and ends 
with the tyrosine in position 618. The motif is TPPPxY, where T stands for threonine, 
P for proline, Y for tyrosine and x for any amino acid. Schild et al. [1996] showed that 
changing any P, the T or the Y within the motif increased the sodium channel activity 
to a level similar to that of the R566X mutation. 
 
Nedd 4-2 is an ubiquitin-protein ligase that is involved in the ubiquitination of ENaC. 
Nedd 4-2 has multiple WW (tryptophan rich) domains that interact with the PY motif 
on the ENaC carboxy terminal allowing internalisation of the channel. (The evidence 
for this interaction was supported when Fouladkou et al. [2004] found a Nedd 4-2 
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variant (P355L) which decreased ENaC inhibition.) Once ubiquitinated, the channel is 
degraded by proteosomes or lysosomes [Staub et al., 1997]. WW domain containing 
protein 2 (WWP2) is another ubiquitin protein ligase (E3 protein) which has been 
found to internalise the ENaC, but not to the same degree as Nedd 4-2 [McDonald et 
al., 2002].  
 
Nedd 4-2 is phosphorylated by SGK1 with the aid of 14-3-3 proteins, which inhibits 
the interaction between Nedd 4-2 and the ENaC [Bhalla et al., 2005]. In this way 
SGK1 increases ENaC activity by decreasing internalisation of the channel, 
increasing the number at the cell surface. SGK1 also increases the Po (chance of the 
channel being open) of the channel and may increase the synthesis of the channels 
[Alvarez de la Rosa et al., 2004]. 
 
Another mechanism of down regulating the transmembranous ENaC is by clathrin-
mediated endocytosis. This is a process whereby channels are internalised into 
vesicles by the contractile protein clathrin. Shimkets et al. [1997] showed that the 
ENaC underwent endocytosis using clathrin which interacted with the β and γ 
subunits of the channel. Truncation of the carboxy termini of the β and γ subunits 
increased the half life of the channels, as did inhibition of clathrin. Linkage of clathrin 
lattices to the ENaC was found to be dependant on epsin [Wang et al., 2006], via an 
ubiquitin interaction motif in epsin. (The epsin family of proteins are important for 
protein-protein interactions, and interact with clathrin to allow clathrin-coated vesicle 
budding [Chen et al., 1998].) 
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Soluble N-ethyl-maleimide-sensitive factor attachment protein receptors (SNARE‟s) 
allow fusion of vesicles and membranes to transfer channels into the membrane. S1A 
is a target (t) membrane SNARE that interacts with the ENaC. S1A was found to 
increase the closed time of the channel within the membrane [Condliffe et al., 2004] 
and to decrease channel insertion into the membrane [Berdiev et al., 2004]. Accessory 
proteins stabilise the SNARE complex regulating vesicle insertion. Complexin binds 
to assembled SNARE complexes that consist of syntaxin and a vesicle-associated (v) 
SNARE and was found to inhibit ENaC activity by decreasing the number of channels 
(N) in the cell membrane [Butterworth et al., 2005b] 
 
This indicates that S1A has more than one binding site onto the sodium channel. The 
variant S518K of the β-ENaC in the transmembrane domain leaves the channel in the 
open state which is insensitive to the initial action of S1A. However, after about an 
hour S1A decreases channel activity as a result of decrease in number of channels (N) 
at the cell surface [Condliffe et al., 2003]. The position where S1A, SGK, epsin and 
the protein kinases interact has not been determined. Any intracellular protein that 
interacts directly with the β-ENaC could potentially be influenced by the R563Q 
mutation. Alteration in the binding motif for any one of these, or other unknown 
proteins, could diminish the protein-protein interaction.  
 
Internalisation of the sodium channel is described above but this does not encompass 
degradation of the channel. These pathways remove the channel from the apical 
membrane into intracellular vesicles. This then undergoes degradation or recycling. 
One method of degradation is the lysosomal pathway and another is the proteosomal 
pathway. The proteosomal pathway involves breaking down proteins by destroying 
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peptide bonds (proteolysis). This pathway involves tagging by ubiquitin and is 
catalysed by ubiquitin ligases (Nedd 4-2 is an ubiquitin ligase). Nedd 4-2 is a protein 
that is highly important for sodium channel control and so there is strong evidence 
that the proteosomal pathway is important for degradation of the channel. Malik et al. 
[2001] showed this but found no evidence suggesting the lysosomal pathway is 
involved in the degradation of the channel as others have [Staub et al., 1997]. 
 
In vivo Physical and Cellular Differences 
Baker et al. [1998b] showed that a family with Liddles‟s syndrome had increased 
nasal ENaC activity suggesting increased renal ENaC activity. They [Baker et al., 
1999] later found no difference in nasal potential difference in White normotensives 
and hypertensives, suggesting that White hypertensives are unlikely to have an 
increase in ENaC activity. This was not supported by Pratt et al. [2002], who found 
that Black American subjects with hypertension did not respond as well as the Whites 
to amiloride. 
 
Zhou and Bubien [2001] showed that the ENaC is found in B lymphocytes. This team 
[Bubien et al., 2001] also found that lymphocyte ENaC activity accurately reflects 
renal ENaC activity. Carter et al. [2001] suggested that the B lymphocytes can be 
used to identify individuals who will respond to amiloride.  
 
Genetics of the ENaC 
The ENaC is the rate limiting step in sodium reabsorption, which prompted the need 
to clone the ENaC gene in the search for candidate genes for hypertension. The α-
subunit gene is found on the short arm of chromosome 12 and the β and γ-subunit 
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genes are found close together on the short arm of chromosome 16. The β and γ 
subunit genes are found at 16p13-p12, within a 400kb fragment [Shimkets et al., 
1994]. Voilley et al. [1995] reported the cloning and sequencing of the β- and γ-
subunits. The genetic sequences for the two genes were highly similar, suggesting a 
common ancestor, possibly by gene duplication. Saxena et al. [1998] reported the 
exon-intron organisation of the β-ENaC. The last exon (13) contains the sequence for 
the second transmembrane domain and the PY motif.  
 
Linkage analysis of chromosome 16p12 revealed linkage of the β- and γ-ENaC genes 
and SBP variation within families [Wong et al., 1999]. Pseudohypoaldosteronism 
Type 1 (PHA1) is an autosomal recessive [Pujo et al., 2007] disorder that presents 
with sodium wasting and hypotension. It is a disorder that presents in neonates and is 
incompatible with a prolonged life. The genetic defect is a mutation in the ENaC and 
prevents the sodium channel from reabsorbing sodium due to lack of response to 
aldosterone. Mutations are found from exons 2 to 13. Mutations of the 
mineralocorticoid receptors can also cause PHA1. 
Liddle‟s Syndrome is a hypertensive disorder that results from mutations in the last 
exon (13) of the gene. Mutations that affect the intracytoplasmic tail of the channel 
are implicated in Liddle‟s. To cause the full Liddle‟s syndrome, disruption of the PY 
motif is required. This proline rich motif is the binding area for the intracytoplasmic 
ubiquitin protein ligase Nedd4-2. Nedd4-2 binds to the ENaC to internalise the 
channel, so decreasing the activity of the channel [McDonald et al., 2002]. 
 
PHA1 and Liddle‟s disease are two extreme disorders associated with genetic defects 
in the sodium channel genes. These two disorders indicate the level of importance of 
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the genes and many research teams have been analysing the effects of mutations 
within the genes encoding the three subunits. 
 
The α-ENaC 
The α-subunit of the sodium channel has, as yet, not been described with a mutation 
that causes full blown Liddle‟s syndrome, despite having a PY motif. This subunit 
also is the only subunit that can create a current for sodium when expressed alone in 
Xenopus oocytes. The gene encoding the α-subunit is found on chromosome 12p13.1 
and chromosome 12p was found to have linkage for EHT [Gong et al., 2003]. 
Truncation of the α-ENaC (removing the PY motif) has been found to increase the 
sodium current in vitro [Schild et al., 1996], but truncating mutations have not been 
described in vivo.  
 
A few point mutations of the α-ENaC have been described. The T663A missense 
mutation has been found more frequently in Caucasian subjects and has been found to 
be protective against hypertension [Ambrosius et al., 1999]. It did not have an effect 
on sodium current and did not show any association with the parameters that alter 
sodium balance. They found two other mutations (C618F and A334T) which did not 
differ between hypertensives and normotensives but were significantly more frequent 
in Black African subjects. Tong at al. [2006] described the effects of these three 
mutations. In Chinese hamster ovary cells the sodium current was assessed using 
patch clamping. They found that C618F and A663T increased and A334T didn‟t alter 
the current. This was achieved by an increase in number of active channels at the cell 
surface. 
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The β-ENaC 
Shimkets et al. [1994] described four other kindreds with Liddle‟s syndrome (other 
than the original family). One of these families had the same mutation as that found in 
the original family, both families were in England. This mutation has been found in 
other countries: Sweden [Melander et al., 1998] and Japan [Kyuma et al., 2001]. All 
these mutations disrupted the PY motif. They were either mutations that introduced a 
stop codon, resulting in truncation of the carboxy terminal; or caused a frameshift of 
the gene, altering the encoded proteins of the carboxy terminal of the ENaC. (A 
frameshift mutation is the result of an insertion or deletion of one or more nucleotides 
resulting in a different amino acid sequence.)  
 
Multiple point mutations of the β-ENaC have been described in association with 
hypertension. Many of these mutations cause an amino acid substitution. The T594M 
mutation has been found more frequently in individuals with hypertension [Baker et 
al., 1998a; Dong et al., 2001] who found that there was increasing frequency with 
increasing BP. Baker et al. [2002] found that amiloride alone controlled BP in those 
with this variant. There is no physiological evidence for over activity of the sodium 
channel with this mutation [Persu et al., 1998] and the association with hypertension 
was not replicated by Nkeh et al. [2003] or Ambrosius et al. [1999]. They did 
however find that the T594M mutation occurs more frequently in Black African 
individuals than in Caucasians. There was no significant difference in allele frequency 
between cases and controls in a South African study by Pegoraro et al. [2004] of pre-
eclamptics and eclamptics compared with normotensive pregnant women. The 
expected two dimensional configuration of the sodium channel is shown in Figure 2.6. 
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Figure 2.6. A 2D representation of the structure of the β-subunit of the ENaC. 
 
Possible reasons for the T594M variant not to be an activating mutation are that it is 
found in a region of the sodium channel β-subunit gene that is poorly conserved 
across species and it is not near the vital PY motif. A further reason is that methionine 
and threonine are both non-charged amino acids. 
 
The G442V mutation of the β-ENaC in exon 8 was also found more frequently in 
African individuals and is more frequent than the T594M variant [Persu et al., 1998]. 
There was no difference in allele frequency in three BP categories in a population 
screened by Dong et al. [2001]. The G442V variant also did not alter the sodium 
current when expressed in Xenopus oocytes [Ambrosius et al., 1999] but subjects with 
the G442V mutation had biochemical changes suggesting higher intrinsic activity of 
the ENaC.  
 
Persu et al. [1998] screened the β-ENaC gene and found seven polymorphisms; five 
were found in exon 13. Melander et al. [1998] also sequenced the gene and found one 
point mutation in exon 13: βGly587Ser. This mutation was found in an individual 
who had early onset of hypertension and a positive family history of hypertension. 
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The mutations found by Persu et al. [1998] were more common in African Americans 
and some (G589S and R624C) altered sodium sensitivity when expressed in Xenopus 
oocytes, especially the amiloride-sensitive sodium uptake. R597S had a suppressed 
renin level and G589S tended toward hypokalaemia.  
 
Hannila-Handelberg et al. [2005] also found one of the variants that Persu et al. 
[1998] found (G589S), when he screened the β-ENaC gene for mutations in Finland. 
However, this mutation was not significantly more frequent in hypertensives than in 
the controls and there was no difference in clinical characteristics or biochemical 
parameters. There was a non-significant blunted renin response to a captopril 
challenge and an increased excretion of potassium in relation to plasma renin and 
aldosterone. This mutation did not affect sodium current when expressed in Xenopus 
oocytes either. This team also found a variant in the intron, 17 nucleotides before the 
13
th
 exon, which did not affect the ribonucleic acid (RNA) sequence. It was however 
more frequently found in hypertensives than in normotensives.  
 
Mutations that disrupt the PY motif are more likely to cause differences in the 
biochemical parameters of the subjects and to alter the sodium current significantly 
when expressed in Xenopus oocytes. Shimkets et al. [1994] described four mutations 
that interfered with the PY motif. Two mutations introduced premature stop codons: 
R564X and Q589X, which removed the PY motif. Two other mutations resulted in a 
frameshift: a deletion of a cytosine in the six cytosine sequence from 593-595 
resulting in altered protein sequence until the new stop codon at 673 and an insertion 
of cytosine at T-592 altering the encoded proteins till the new stop codon at 605. This 
kindred is described in more detail by Findling et al. [1997].  
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The R566X mutation was the mutation found in the kindred who originally presented 
to Dr Liddle, who described the syndrome. This mutation was expressed in Xenopus 
oocytes by Schild et al. [1995] and was found to increase sodium current 
significantly. The same team [Firsov et al., 1996], showed that the means of 
increasing the current was by increasing the N at the cell surface and by increasing the 
Po of the channel. Jeunemaitre et al. [1997a] described the deletion of 32 nucleotides 
starting at 579 which then introduced a new stop codon at position 582. Inoue et al. 
[1998b] described a cytosine insertion at Arg-597 also causing a frameshift and loss 
of the last 34 amino acids of the carboxy terminal.  
 
All of these mutations were found in individuals or kindreds who had presented with 
full blown Liddle‟s syndrome and they all removed the complete PY motif. Schild et 
al. [1996] tried to determine the exact impact of the carboxy terminal by sequentially 
deleting portions of the carboxy tail. They found that deletions of the terminal amino 
acids, up to the last 10, increased sodium current in vitro. The increase in current was 
attenuated as the number of amino acids deleted decreased.  
 
Subsequently it has been found that point mutations of the PY motif interfere with 
sodium current and can cause full blown Liddle‟s disease. The P616L missense 
mutation has been described as a de novo mutation in China [Yamashita et al., 2001], 
and in an unrelated family, also in China [Gao et al., 2001]. This mutation had been 
previously described in the USA [Hanssen et al., 1995b] and in Japan [Uehara et al., 
1998] as a de novo mutation. Hanssen et al. [1995b] described the physiological 
characteristics of this mutation and found that the mutation caused a significant 8.8-
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fold increase in sodium current and it altered the biochemical parameters of the 
individuals. (Some of the described mutations are shown in Figure 2.7.) 
 
 ATC GTC TGG CTG CTC TCG AAT CTG GGT GGC CAG TTT GGC  
511 I V W L L S N L G G Q F G 525 
 TTC TGG ATG GGG GGC TCT GTG CTG TGC CTC ATC GAG TTT  
526 F W M G G S V L C L I E F 539 
 GGG GAG ATC ATC ATC GAC TTT GTG TGG ATC ACC ATC ATC  
540 G E I I I D F V W I T I I 552 
 AAG CTG GTG GCC TTG GCC AAG AGC CTA CGG CAG CGG CGA  
553 K L V A L A K S L R Q R R 566 
 GCC CAA GCC AGC TAC GCT GGC CCA CCG CCC ACC GTG GCC  
567 A Q A S Y A G P P P T V A 579 
 GAG CTG GTG GAG GCC CAC ACC AAC TTT GGC TTC CAG CCT  
580 E L V E A H T N F G F Q P 592 
 GAC ACG GCC CCC CGC AGC CCC AAC ACT GGG CCC TAC CCC  
593 D T A P R S P N T G P Y P 603 
 AGT GAG CAG GCC CTG CCC ATC CCA GGC ACC CCG CCC CCC  
604 S E Q A L P I P G T P P P 616 
 AAC TAT GAC TCC CTG CGT CTG CAG CCG CTG GAC GTC ATC  
617 N Y D S L R L Q P L D V I 629 
 GAG TCT GAC AGT GAG GGT GAT GCC ATC TAA      
630 E S D S E G D A I STOP       639 
Figure 2.7. Exon 13 of the β-ENaC gene. The amino acid numbers are shown on the 
sides. Yellow shading shows the transmembranous domain, green shading shows 
the PY motif, some published mutations that have been shown to cause to Liddle’s 
syndrome are shaded in purple and non-Liddle’s-causing mutations are shaded in 
blue. The arginine at position 563 is shaded in dark blue. Poorly conserved amino 
acids are shown in red writing. 
 
Other point mutations of the PY motif have been found to cause Liddle‟s disease. 
P616R was described by Furuhashi et al. [2005] as a de novo mutation in a family 
who presented with Liddle‟s disease. Another proline in the motif has been 
implicated. P615S was found in a family who presented with Liddle‟s in Japan [Inoue 
et al., 1998a]. The substitution of tyrosine to histidine (Y618H) in the motif was also 
found to cause Liddle‟s [Tamura et al., 1996]. 
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The R563Q mutation of the β-ENaC 
The R563Q mutation of the β-ENaC is a SNP of the β-ENaC gene. The mutation is 
found in the exon of the carboxy-terminal cytoplasmic tail of the β-ENaC (Figure 
2.8). It is a transition of guanine to adenine (CGG to CAG) in codon 563, resulting in 
a missense mutation from arginine to glutamine. The mutation was found to be 
associated with low renin, low aldosterone hypertensives in Black African and 
Coloured groups [Rayner et al., 2003]. 
 
 
Figure 2.8. Exon 13 of the β-ENaC showing the close proximity of the R563Q 
mutation to the original Liddle’s mutation (R566X), the transmembranous domain 
(yellow) and the PY motif (green), with the stop codon at position 639. 
 
This polymorphism was found by sequencing of the carboxy terminal domains of the 
β- and γ-ENaC genes. Polymerase chain reaction (PCR) with restriction digest 
confirmed the presence of this mutation in a heterozygous form in 18 unrelated 
individuals. Fourteen of these individuals were tested for plasma renin and 
aldosterone levels. Nine had low renin and aldosterone levels and two had low 
aldosterone without a fully suppressed renin but one of these patients had renal 
impairment. Two patients had unprovoked hypokalaemia, one of them was severely 
hypokalaemic (2.1mmol/l). Eleven had severe hypertension with target organ damage.   
 
Recently the R563Q mutation has been shown to be associated with pre-eclampsia by 
Dhanjal et al. [2006]. A racial difference in frequency of the mutation was evident; 
there was a higher incidence in Black African people than in Coloureds. Renin levels 
X V L C L I E F G E I I I D F V W I T I I TPPPNYDSL 
R563Q 
R566X 
552 
613-621 
639 
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were lower in individuals with the mutation, but there was no difference in plasma 
aldosterone and potassium levels. All subjects that have been found to have the 
mutation were heterozygous for the R563Q mutation. 
 
The γ-ENaC 
The γ-ENaC has also been implicated in Liddle‟s syndrome. Truncations of the 
carboxyterminal of the γ-ENaC have been found to cause full blown Liddle‟s 
syndrome. Yamashita et al. [2001] found a de novo truncating mutation (W576X) of 
the γ-ENaC in a patient who presented with Liddle‟s syndrome. This mutation 
truncates the carboxy terminal before the PY motif which starts at position 624 on the 
γ-ENaC gene. Another Liddle‟s mutation was found by Hansson et al. [1995a]. This 
mutation, K574X, is also a truncating mutation of the γ-ENaC and was found to alter 
the activity of the channel when expressed in oocytes. 
Schild et al. [1996] also tested sequential deletions of the γ-ENaC. They found that 
there was significant gain in function if the PY motif was deleted. The last 21 amino 
acids, when deleted, did not alter the sodium current and there was not the sequential 
increase in current with increase in number of amino acids deleted as with the β-
ENaC. 
 
No point mutations found in the γ-ENaC have yet been found to cause full blown 
Liddle‟s disease. However, a few have been described in association with 
hypertension. Two variants (A531L and C582R) were found in one patient with 
diabetic nephropathy [Melander et al., 1998]. Neither was found in any of the control 
subjects and no functional analyses were implemented. They also detected a common 
mutation in codon 650: CTC to CTG. It did not alter the amino acid sequence and was 
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not found to associate with BP differences. An extra proline was also found, in one 
patient, after codon 594 due to the insertion of 3bp (CCT). 594insP was also found by 
Persu et al. [1999] but did not alter the sodium current in Xenopus oocytes. Neither 
did another mutation (R631H). Both these mutations were only found in one patient 
each.  
 
Persu et al. [1999] found four other common mutations: three missense mutations 
(T387C, T474C and C549T) and a point mutation in the complementary DNA 
(C1990G). None of these mutations was more frequent in hypertensives but they were 
more commonly found in African Americans. Hannila-Handelberg et al. [2005] also 
found a common mutation in the γ-ENaC: V546I. This mutation did not alter sodium 
current in Xenopus oocytes or change the renin response and was not significantly 
more frequent in hypertensives. Ambrosius at al. [1999] also found three nucleotide 
variants which did not alter the amino acid sequence and were silent mutations. Poch 
et al. [2000] described a C to G transversion in codon 649 which did not associate 
with hypertension or salt sensitivity. 
 
Summary  
The ENaC is the rate limiting step in sodium reabsorption and is implicated in salt 
sensitive hypertension of genetic origin. It has been found to cause autosomal 
dominant forms of hypertension along with only a few other Mendelian forms of 
hypertension. There have been many mutations described, some of which have been 
associated with hypertension. Most of these mutations have been found in only a few 
individuals, but a few have been described at higher frequencies: T594M and G442V. 
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The R563Q mutation has been associated with hypertension and pre-eclampsia but 
further data are lacking. This study was designed to gather more information on this 
mutation from an in vivo physiological perspective and to study the prevalence in the 
South African multiethnic populations.  
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HYPOTHESIS AND AIMS 
Hypothesis 
The R563Q mutation of the ENaC is an activating variant found in the multiethnic 
populations in South Africa causing salt sensitivity and hypertension. The mutation 
originated in Southern Africa and has become a common variant as a result of scarce 
sodium supplies in traditional diets. 
 
Aims 
1. To demonstrate that the R563Q mutation associates with hypertension in 
family analyses by studying index cases and their families. 
2. To investigate the geographical representation of the mutation across South 
Africa and its association with hypertension by collecting samples 
representing the Black African and Coloured groups living in Johannesburg, 
Cape Town and the Northern Cape. 
3. To investigate the origin of the mutation. Specifically, to determine if the 
mutation in the South African Black African and Coloured groups might have 
originated in the Khoisan, who lived a hunter-gatherer lifestyle with scarce 
sodium supplies and a diet rich in potassium. 
4. To document the clinical characteristics of the index patients heterozygous for 
the R563Q mutation compared with age and sex matched controls attending 
the Hypertension Clinic at GSH. 
5. To examine the functional phenotype of subjects heterozygous for the R563Q 
mutation. Specifically, to investigate these subjects for impaired salt excretion 
and a greater BP response to an acute saline load compared with age matched 
normal controls. 
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6. To determine the effect of the R563Q mutation on sodium current when 
expressed in the Xenopus laevis oocytes compared with wild-type sodium 
channels 
 
This study was approved by the Research Ethics Committee of the University of 
Cape Town. Reference Number: 269/2006 (see Appendix III) 
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CHAPTER 3 
General Methods, Procedures and Equipment 
 
This chapter describes the procedures and methods applied that were common to 
many sections of this thesis. Further details are described in each chapter, where 
relevant.  
 
SUBJECTS 
All subjects were counselled and gave signed informed consent for all clinical 
procedures and genetic testing. Subjects were selected for each section of the thesis as 
described in the methods for each section. 
Consent forms are available in Appendix III. 
 
CLINICAL METHODS 
Blood pressure (BP) was measured in the sitting position after five minutes rest with a 
calibrated Accouson® mercury sphygmomanometer or a calibrated Omron® 
automatic sphygmomanometer (validated auscultatory BP monitors). The cuff size 
used was suitable for the arm circumference.  
 
The mean of two stable readings was used. Hypertension was defined by a SBP ≥140 
and/or diastolic BP (DBP)≥90 mmHg, or the use of antihypertensive medication. The 
MAP was calculated for each patient as one third of the pulse pressure plus DBP. 
MAP = (SBP-DBP)/3 + DBP 
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BLOOD MEASUREMENTS 
Renin, aldosterone, sodium, potassium and creatinine were measured by the National 
Health Laboratory Services (NHLS) at GSH. This is a South African National 
Accreditation System (SANAS) accredited laboratory and all the tests performed are 
accredited. The equipment used is calibrated regularly and standards and external 
quality control samples are run according to SANAS requirements. 
 
Renin: 5ml blood was collected in an EDTA tube from subjects sitting for 10 minutes 
and kept at room temperature until delivery to the laboratory, within four hours. Renin 
was measured using RENIN III Generation® (a commercially available kit from CIS 
bio international, France). The renin level was determined by an immunoradiometric 
technique that used a pair of antirenin monoclonal antibodies which recognise the 
active and inactive forms of renin. 
 
The serum was incubated in a polystyrene test tube with an insoluble monoclonal 
antibody on the wall of the tube that recognised both the inactive and the active form 
renin. A second monoclonal antibody labelled with 125-iodine was added to the tube 
which binds only the active renin. The solution was incubated at room temperature for 
three hours. The solution was washed to remove free reagent. Radioactivity was 
measured with a gamma counter for two minutes and compared with a standard serum 
sample. The technique and kit are internationally recognised as an accurate means of 
determining the active renin in human plasma. 
 
Aldosterone: 5ml of blood was collected in a serum separator tube after the patient 
had been seated for ten minutes. Aldosterone was measured using radiolabelled 
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antibodies that bind to plasma aldosterone from a commercially available kit (Coat-a 
count Aldosterone Radioimmunologie®, Behring). This kit is an internationally 
accepted means of determining plasma aldosterone levels and the technique used was 
in accordance with the manufacturer‟s instructions.  
 
Antibodies to aldosterone are coated onto test tubes. The sample was placed into the 
test tube. Radiolabelled (I
125
) aldosterone was added to each tube which was then 
vortexed and incubated at room temperature for 18 hours. All residual fluid was 
removed and a gamma counter recorded the amount of radiation over one minute.  
 
Sodium, potassium and creatinine: 5ml of blood was collected in a serum separator 
tube that allows the blood to clot. The tube was then spun and the serum undergoes 
analysis with an ion-specific electrode. This method uses an ion-exchange membrane 
to determine the difference in electromotive force between the sample and a reference 
solution. The activity across the membrane is directly proportional to the 
concentration of the electrolyte. This is a standard and accredited means of 
determining plasma electrolyte concentrations. 
 
CALCULATIONS 
Glomerular filtration rate (GFR) is an indicator of renal function as it is an estimate of 
the flow rate of filtered fluid through the kidney. The estimated GFR is calculated 
using the equation:  
GFR = 32788 x (PCr)
-1.154
 x (age)
-0.203
 x (0.742 if female) x (1.210 if Black African) 
A GFR of less than 60ml/min/1.73m
2
 is an indicator of chronic kidney disease 
(CKD). (PCr, plasma creatinine) 
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Urinary sodium-creatinine ratio (Na/Cr) was calculated from the measured urinary 
sodium and creatinine levels. It is an indicator of sodium intake. 
 
Fractional excretion of sodium (FENa) was calculated from the measured plasma and 
urinary sodium and creatinine levels. 
FENa = (UNa
+
/PNa
+
)*(PCr/UCr)*100 
(U, urine; P, plasma; Na
+
, sodium; Cr, creatinine) 
 
Total urinary sodium-potassium ratio (UNa/K) was calculated as a ratio of the 
measured urinary sodium and potassium levels.  
 
Total potassium excretion (TUK) was calculated using the equation:  
UK+*Volume excreted 
1000 
[U, urine; K
+
, potassium (mmol/l); Volume (ml)]    
 
MOLECULAR METHODS 
The laboratory is maintained according to SANAS. Equipment is calibrated regularly 
and space is divided to ensure accuracy of results without the risk of contamination. 
Products used are stored according to the manufacturer‟s recommendations.  
 
DNA Extraction: DNA from the Western Cape was extracted from whole blood 
collected in ethylene diamine tetra-acetic acid (EDTA) tubes. A minimum of 200µl 
whole blood was required. A commercially available extraction kit (Invisorb Spin 
Blood Mini Kit®) was used to extract the DNA. 
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200µl Lysis buffer A was added to the blood with 20µl Proteinase K, vortexed and 
incubated at 56
o
C for 10 minutes. A receiver tube was then prepared with a spin filter. 
400μl Binding Buffer B6 was added and the solution vortexed. The sample was 
loaded onto the Spin Filter and incubated for one minute then centrifuged at 12,000 
rpm for two minutes. The receiver tube with the filtrate was discarded and the spin 
filter was placed into a new 2ml receiver tube.  
 
500μl Wash Buffer I was added and the sample was centrifuged at 12 000 rpm for one 
minute. The filtrate was discarded and the spin filter returned to the 2ml receiver tube. 
800μl Wash Buffer II was added and the sample was centrifuged at 12 000 rpm for 
one minute. The filtrate was discarded and the spin filter returned to the receiver tube. 
The washing step was repeated and the filtrate discarded. The spin filter was placed 
back into the 2ml receiver tube and finally centrifuged for four minutes at 13 000 rpm, 
completely removing the ethanol. The spin filter was placed into a new 1.5ml receiver 
tube and 200μl of Elution Buffer D at 56oC was added to the centre of the spin filter 
then incubated for one minute. Then the product was centrifuged for one minute at 10 
000 rpm. This step was repeated to improve the yield of genomic DNA. DNA was 
stored at -20
0
C until further analysis. 
 
The Khomani San DNA was extracted in Johannesburg at the South African Institute 
for Medical Research by C. Schlebusch. DNA was extracted from EDTA-blood or 
buccal swabs. Extracted DNA in both cases was dissolved in TE buffer (10mM Tris 
and 1mM EDTA, pH 8.0.) DNA was quantified using the NanoDrop ND-1000 
Spectrophotometer (Coleman Technologies Inc., LabVIEW®) and diluted to 50ng/ul 
using double distilled water. DNA was extracted using the salting-out method [Miller 
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et al., 1988]. The PureGene® Genomic DNA Purification Kit (Gentra Systems) was 
used for extraction of DNA from buccal swabs, according to the manufacturer's 
instructions.   
 
DNA from a group of Black Africans from Johannesburg was donated by Professors 
Woodiwiss and Norton from the University of the Witwatersrand. The DNA was 
collected as part of another study [Nkeh et al., 2003] involving hypertensive patients 
attending a referral hypertension clinic in Johannesburg and matched controls. 
Consent was given for DNA analysis for hypertensive studies.   
 
Polymerase Chain Reaction 
Determination of the R563Q mutation in exon 13 of the ENaC: Exon 13 of the ENaC 
underwent amplification by PCR. Primers were designed using readily available 
software, Oligo®. Primer pairs were checked for length, compatible melting 
temperatures and possible primer dimers. The primer pair used for the analysis is 
shown in Figure 3.1. 
 
Figure 3.1. Primer positions on the β-ENaC 
 
 
ctctgtgctgtgcctcatcgagtttggggagatcatcatcgactttgtgtggatcaccatcatcaagc
tggtggccttggccaagagcctacggcagcggcgagcccaagccagctacgctggcccaccg 
 
cccaccgtggccgagctggtggaggcccacaccaactttggcttccagcctgacacggccccc
cgcagccccaacactgggccctaccccagtgagcaggccctgcccatcccaggcaccccgcc
ccccaactatgactccctgcgtctgcagccgctggacgtcatcgagtctgacagtgagggtgatg
ccatctaaccctgcccctgcccaccccgggcggctgaaactcactgagcagccaagactgttgc
ccgaggcctcactgt  
Forward Primer  
Reverse Primer  
bp1688 g>a = R563Q 
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The PCR reagent contained: (for each 40µl PCR reaction) 
 Premixed master mix consisting of:   
2.4µl MgCl2 5mM with a final concentration of 1.5mM MgCl2 
1.6µl dNTP 5mM with a final concentration of 0.2mM dNTP 
8µl 5x Green GoTaq® (Promega) Flexi Buffer -pH8.5 with a final 
concentration of 1x buffer 
26.8µl Nuclease free distilled water 
 0.4µl Forward Primer 50pmol/l (5‟ atcgagtttggggagatcatc 3‟) in 1x TE buffer 
with a final concentration of 0.5µM 
 0.4µl Reverse Primer 50pmol/l (5‟ caacagtcttggctgctcagt 3‟) in 1x TE buffer 
with a final concentration of 0.5µM 
 0.2µl GoTaq® Flexi DNA polymerase 5U/µl with a final concentration of 1U 
(TE buffer protects the nucleotides from degradation. MgCl2 magnesium chloride, 
dNTP, deoxyribonucleotide triphosphate consisting of equal concentrations of dATP, 
dTTP, dGTP and dCTP) 
 
The β-ENaC gene was amplified by adding 1µl DNA from each specimen to the PCR 
reagent. The DNA was denatured at 98
o
C for three minutes, then underwent 35 cycles 
of 94
o
C for 30s, 56.5
o
C for 30s then 72
o
C for 50s. After the cycles, the reaction was 
completed with eight minutes at 72
o
C. The product was stored at 4
o
C until restriction 
enzyme digestion. 
 
The presence of PCR product was checked with a 2% agarose gel run for 20 minutes 
at 120V and 250mA. The agarose gel was made up using a commercially available 
agarose (LE, analytical grade, Promega) mixed in 1x Tris-acetate-EDTA [TAE -
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40mM Tris, 20mM acetic acid, 1mM EDTA, ph 8.3 (Bio-Rad)] buffer to make up a 
2% gel solution. The agarose was dissolved and 5µl of 10µg/ml ethidium bromide 
was added before being set. After electrophoresis the gel was viewed under ultraviolet 
light to detect the presence of PCR product (Figure 3.2). 
 
 
Figure 3.2. Gel confirming PCR product of the carboxy terminal of the β-ENaC. The 
presence of PCR product is confirmed by the dark bands. A control (blank) before the 
1Kb ladder confirmed that there were no contaminants in the reagents or primers. 
 
Restriction Enzyme Digestion: The R563Q mutation creates a Sfc1 restriction enzyme 
recognition site (CTACGG > CTACAG). The PCR product was digested for 16 hours 
at 25
o
C, 1 hour at 30
o
C and 1 hour at 37
o
C with Sfc1 restriction enzyme (New 
England Biolabs). Each 30µl PCR product was mixed with 1.8µl digestion buffer 4, 
0.35µl albumin and 0.85µl Sfc1 restriction enzyme. (Buffer 4 contains 20 mM Tris-
acetate, 50 mM potassium acetate, 10 mM Magnesium Acetate, 1 mM Dithiothreitol 
at a pH of 7.9 at 25°C.) 
 
Restriction enzyme digestion involves detecting differences in DNA sequences by 
using restriction enzymes that recognise specific DNA sequences (usually about 4-
6bp in length). These enzymes are produced by bacteria and cleave the DNA at 
Blank  
control 
1Kb  
ladder 
250bp 
500bp 
750bp 
1000bp 
2000bp 
1500bp 
367bp 
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specific recognition sites. Restriction fragment length polymorphisms (RFLP) are the 
product of restriction enzyme digestion. 
 
The Sfc1 restriction enzyme is produced by Streptococcus faecium and recognises 
these DNA sequences (see Figure 3.3 for positions in exon 13 of the β-ENaC): 
5‟…C^TRYAG…3‟ 
3‟…GAYRT^C…5‟ 
Where: T= Thymine 
A= Adenine 
C= Cytosine 
G= Guanine 
R= either purine 
Y= either pyramidine 
 
 
Figure 3.3. Restriction Enzyme Recognition Sites in exon 13. A shows the 
recognition site (underlined) created by the R563Q mutation and B shows the normal 
recognition site that is present towards the end of exon 13. The position where Sfc1 
cleaves the DNA is shown by arrows. 
 
The post digest product was run on a 2% agarose gel for 40 minutes at 120mV to 
detect the presence of the mutation. The normal β-ENaC cuts into two bands, 
consisting of 264 and 103bp bands; and the mutated gene cuts into bands of 189, 103 
and 75bp (Figure 3.3). 
A 
B 
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Figure 3.4. Restriction digest gel after the PCR product was digested with Sfc1 
restriction enzyme. The normal sodium channel cuts into bands of 103 and 264bp 
and the allele with the mutation cuts into bands of 189, 103 and 75bp (not shown) 
long. 
 
Sequencing: The PCR product was cleaned of dNTP‟s, buffers and primers before 
preparing for sequencing. 
Purification: A commercially available kit (QIAquick® PCR purification Kit - 
Qiagen) was used for purification of the DNA, according to the manufacturer‟s 
instructions. 175µl binding buffer was added to 30µl PCR product and mixed, added 
to a spin column then centrifuged at 13 000rpm for one minute. The solution was 
discarded and the wash step repeated. To remove all fluid the column was centrifuged 
at 13 000rpm for one minute before being placed in an eppendorf tube and 30µl 
elution buffer was added to the column. The column was left standing for 60 seconds 
then centrifuged at 13 000rpm for one minute. The cleaned PCR product was stored at 
-20
o
C until further analysis 
 
Sequencing: A commercially available kit (ABI Prism BigDye Terminator Cycle 
Sequencing Ready Reaction Kit
®
, PE Biosystems) was used for sequencing of the 
purified DNA. The PCR product came to 200-500bp which requires a 3ng template. 
103bp 
264bp 
189bp 
100bp  
Ladder 
Heterozygous  
Positive Control 
Heterozygous  
Positive 
100bp 
Normal 
300bp 
200bp 
500bp 
400bp 
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The solution included 1µl BigDye®, 0.6µl sequencing buffer and 6.4µl sterile water, 
1µl reverse (4R) primer and 1µl PCR product. The solution was mixed and placed in 
the thermocycler for 15s at 96
o
C; 30 cycles of 15s at 96
o
C, 15s at 50
o
C, 4 minutes at 
60
o
C; then completed with 10 minutes at 60
o
C.  
 
The product was sent to the Central DNA Sequencer at the University of Stellenbosch 
where it was analysed on an ABI sequencer to determine the sequence. (The 
sequencer is used for determining the sequence for diagnostic purposes and thus 
complies with NHLS accreditation standards.) The sequences were read manually 
using Chromas lite® and confirmed with Bioedit®. Figures 3.5 and 3.6 show the 
normal and heterozygous sequences, respectively. 
 
 
Figure 3.5. Normal Sequence 
 
Figure 3.6. Sequence from a heterozygous patient 
Presence of  
Guanine only 
Nucleotides 
563 R 564 Q 562 L Amino Acids 
   
C T T G G C C A A G A G C C T A C G G C A G C 
Presence of  
Adenosine and  
Guanine 
   C T T G G C C A A G A G C C T A C R G C A G C 
563 RQ 
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All samples that were homozygous for R563Q were checked with a second set of 
primers to exclude mutations or deletions that may have occurred in the location of 
the initial primers. Such a mutation could cause only one allele to amplify resulting in 
a false positive homozygous mutation rather than a heterozygous mutation. The 
alternative forward primer was 5‟-GTC TGG CTG CTC TCG AAT CTG-3‟ and the 
reverse primer 5‟-GTG AGT CCT CGG GCA ACA GT-3‟ (Figure 3.7). 
 
 
Figure 3.7. Alternative primer positions 
 
The PCR using the alternate primers were amplified under the same conditions. 
However, the PCR product was larger (445bp), and after restriction enzyme digestion 
the normal alleles were 118bp and 327bp long and the mutant alleles were digested 
into fragments 118bp, 189bp and 138bp long. 
 
STATISTICS 
Results were analysed using SPSS
®
 statistical software (SPSS
®
 version 11.0, Chicago, 
USA). Categorical variables were analysed using Chi squared (Χ2) analysis and, 
where the numbers analysed were less than five, Fisher‟s Exact Test. Continuous 
variables were analysed using Student‟s t test. Where the distribution deviated 
significantly from the normal distribution, as assessed by a significant Schapiro-
Reverse Primer  
Forward Primer  
ctgttccccacagatcgtctggctgctctcgaatctgggtggccagtttggcttctggatggggggctctgtg
ctgtgcctcatcggtttggggagatcatcatcgactttgtgtggatcaccatcatcaagctggtggccttggc
caagagcctacggcagcggcgagcccaagccagctacgctggcccaccgcccaccgtggccgagct
ggtggaggcccacaccaactttggcttccagcctgacacggccccccgcagccccaacactgggccct
accccagtgagcaggccctgcccatcccaggcaccccgccccccaactatgactccctgcgtctgcag
ccgctggacgtcatcgagtctgacagtgagggtgatgccatctaaccctgcccctgcccaccccgggcg
gctgaaactcactgagcagccaagactgttgcccgaggcctcactgtatggtgccctctc 
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Wilk‟s test, data were log transformed before analysis. P values of less than 0.05 were 
considered significant. (Specific sections requiring further statistical analyses are 
discussed in the relevant section.) 
 
MISSING DATA 
There are missing variables in each section. This was due to inability to collect the 
data, inability to analyse the sample or lost samples. All results were included in the 
analysis and no results were excluded on the basis of inability to explain the result. 
Further information is given in each section as to the reasons why data were missing. 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
PART 2 
A HIGHLY PREVALENT MUTATION 
ASSOCIATED WITH HYPERTENSION 
 
 
 
Hypertension: 
A disorder with a familial association 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 86 
CHAPTER 4 
The R563Q Mutation is Associated with Hypertension in 
Kindreds 
 
INTRODUCTION 
Studies involving close relations have long been used to show linkage of genetic 
polymorphisms with phenotypes. Twin studies were the initial form of analysis. Wietz 
[1954] compared the difference between dizygotic and monozygotic twins as 
comparisons if there was an association between hypertension and inheritance. Platt 
[1963] used the fact that twins exhibited almost identical phenotypes to support his 
single gene hypothesis.  
 
Family studies have progressed from twin studies to studies involving siblings [Allan, 
1933; Platt, 1947] through to studies of parents and one or two children [Spielman, 
1993] and large families [Abecasis et al., 2000b]. These studies often involve 
complicated statistical analyses [Luft, 2001; Abecasis et al. 2000a]. 
 
The aim of the present study was to investigate the phenotype of the R563Q mutation 
within affected kindreds, which provide a more uniform genetic and environmental 
background against which the phenotypic effects of the mutation can be assessed. 
 
METHODS 
Subjects were counselled and gave signed informed consent to join the study, 
including for DNA analysis. (See appendix III for consent forms.) 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 87 
Individuals heterozygous for the R563Q mutation attending the Groote Schuur 
Hypertension Clinic and one heterozygous normotensive case (who was identified in 
the previous study [Rayner et al., 2003]) and their kindred were approached to 
participate in the study. Forty five index cases and 93 family members agreed. BP was 
measured as described in Chapter 3. Blood was then drawn for potassium (K
+
), renin 
and aldosterone and DNA analysis. Antihypertensive medication was not withdrawn 
prior to BP measurement or blood sampling. DNA extraction, PCR amplification of 
the β-ENaC gene and restriction enzyme digestion for detection of the R563Q 
mutation are described in Chapter 3.  
 
The variables were summarised as medians with interquartile ranges (IQR) due to 
extremes in the R563Q heterozygous group.  Quantitative transmission disequilibrium 
testing (QTDT) [Abecasis et al., 2000a; Abecasis et al., 2000b]
 
was used to estimate 
heritability and to test for association between transformed numerical variables and 
R563Q mutation status.  Observations within families are more similar (correlated) 
than between families and QTDT takes the degree of relatedness into account in the 
analysis. The QTDT analysis assesses subjects within families, protecting the results 
from population stratification. The QTDT is unable to determine the mode of 
inheritance and does not estimate separate between and within family effects but 
rather calculates a single overall effect size, using all available information. Quantile 
normalisation [Pilia et al., 2006] was used to transform all to a normal distribution, 
before analysing them, because the distributions of some of the variables were highly 
skewed. The tests were adjusted for sex, race and age.  (For further discussion of the 
QTDT analysis, see Appendix I.) Mixed-effects models were used to analyse 
measurements that did not undergo QTDT analysis, in order to control for the fact that 
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observations within families will be more similar than between families.  This was 
used for variables that could be influenced by the presence of hypertension or 
antihypertensives (renin, aldosterone, potassium and creatinine). Numerical variables 
were log transformed to symmetry, where necessary.   
 
RESULTS 
Overall, 138 individuals (45 index cases and 93 family members) were studied, of 
whom 89 were heterozygous for the R563Q mutation and 49 normal. The 
demographics of the heterozygous and normal subjects are shown in Table 4.1. All 
patients and subjects were from either Coloured or Xhosa origins, and 49% (67) were 
male. No evidence of population stratification was found in the groups when they 
were assessed by the QTDT analysis. 
 
Table 4.1. Demographics of the R563Q heterozygous and normal subjects 
  R563Q heterozygous R563Q normal 
  Index cases (45) Relatives (44) Relatives (49) 
  Number Percentage Number Percentage Number Percentage 
Male 19 42 24 55 24 49 
Xhosa 14 31 8 18 9 18 
Coloured 31 69 36 82 40 82 
Hypertensive 44 98 27 61 17 35 
 
Forty-four index cases had hypertension and one was a normotensive control 
identified in a previous study [Rayner et al., 2003]. Twenty two index cases had at 
least one relative willing to participate in the study. Of the relatives, 74 were first 
degree relatives (brother, sister, son, daughter, mother or father), 11 were nephew or 
niece, two half brothers, two half sisters and four were grandchildren, in relation to 
the index cases.   
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The main characteristics of the individuals heterozygous or normal for the R563Q 
mutation are summarised in Table 4.2. The p-values in Table 4.2 are for a test of 
association with mutation status, after adjusting for race, age and kindred-membership 
(except for age, which was only adjusted for kindred-membership). There was a 
significant association between age and R563Q mutation status (p<0.001), confirming 
the necessity of adjusting for age in all models.  The subjects heterozygous for the 
R563Q mutation were older than the normal group, with a median difference of nine 
years. 
 
Table 4.2. Characteristics of the R563Q heterozygous and normal groups 
  R563Q heterozygous (91) R563Q normal (47)   
  n Median IQR n Median IQR p-value* 
Age, years 89 43 35, 57 46 34 26, 44   
SBP, mmHg 89 150 135, 175 47 132 123, 149 0.003 
DBP, mmHg 89 92 80, 103 47 84 73, 91 0.010 
MAP, mmHg 89 113 99, 129 47 101 90, 110 0.005 
Potassium, mmol l-1 84 4.2 3.8, 4.4 45 4.2 4.0, 4.4 0.224 
*P values are for tests of association with R563Q mutation status, after adjusting for 
race, age and kindred membership, using QTDT. IQR, interquartile range 
 
Of the R563Q heterozygous subjects, 71 (80%) had hypertension, while 17 (35%) of 
the normal subjects were hypertensive, p<0.0005. Mean SBP, DBP and MAP 
(p=0.005) were significantly higher in the heterozygous subjects (Table 4.2). This 
difference was present despite antihypertensive treatment not being removed prior to 
examination. More heterozygous subjects, compared with the normal group, were 
receiving antihypertensive therapy (65/89 (73%) vs. 14/49 (29%) respectively). Of the 
71 heterozygous subjects with hypertension only 65 knew they were hypertensive 
before the study. Of these 65 only 10 (15%) had controlled BP (<140/90mmHg). Of 
the 17 hypertensive normal subjects 2 (12%) had controlled BP. There is no 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 90 
significant difference between heterozygous and normal subjects with controlled BP. 
Χ2 analysis of the relatives, excluding the index cases, to decrease ascertainment bias, 
revealed a significant association of the R563Q mutation with the presence of 
hypertension (p=0.008). 
 
Six heterozygous subjects had hypokalaemia. Two displayed the full Liddle’s 
syndrome phenotype during pregnancy. (These will be discussed in Chapter 10 as 
case studies.) Three patients had hypertension and hypokalaemia associated with the 
use of diuretics, and another was normotensive with unprovoked hypokalaemia (K
+
 
3.3mmol/l). A R563Q normal family member had mild unprovoked hypokalaemia 
(3.4mmol/L) and a normal BP. However, the observed difference in the mean serum 
potassium between the heterozygous and normal groups was not significant 
(p=0.225). 
 
A pedigree is shown in Figure 4.1 which demonstrates the autosomal dominant 
pattern of inheritance. All positive subjects in this study were heterozygous for the 
R563Q mutation. The pedigree also demonstrates the difficulty of associating a SNP 
with a common phenotype like hypertension in a single pedigree. In this pedigree 
there were no heterozygous normotensive subjects but in the entire group there were 
18 normotensive individuals heterozygous for the mutation suggesting incomplete 
penetrance or added environmental factors, as some of these normotensive subjects 
were over 40 years old. Index cases were selected from the Hypertension Clinic, 
because this is where the mutation was originally identified. Patients attending the 
clinic have a severe uncontrolled form of hypertension making it unethical to stop 
their antihypertensive medication. Thus, blood was taken while the hypertensive 
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subjects were on medication. Renin and aldosterone levels did not undergo the QTDT 
analysis because the results would be affected by the presence of antihypertensive 
medication, invalidating the results in 60% of the subjects. As the renin and 
aldosterone levels were measured they were analysed to determine if a trend was 
observed, and the results were adjusted for age and family relationship. 
 
 
Figure 4.1. A pedigree showing the distribution of the mutation across two 
generations. (The arrow points to the index case. Subject ages are shown in years 
below identities.) 
 
The observed differences in plasma renin (p=0.935) and aldosterone (p=0.326) levels 
between the two groups were not significant (Table 4.3). Suppressed aldosterone 
(<225 pmol/L) was present in 47% of R563Q-heterozygous subjects and in 56% of 
R563Q-normal subjects. Suppressed renin (<20 mU/L) was seen in 43 (48%) of 
R563Q-heterozygous and in 26 (52%) of R563Q-normal subjects. The serum 
creatinine levels were not significantly different between the heterozygous and normal 
groups (p=0.786). In the subjects who were not on treatment there was no difference 
between any of the parameters assessed (Table 4.4). Basic statistical methods were 
used for this analysis as there were very few related subjects. 
II:5 
61 II:6 
I:1 I:2 
II:3 
67 II:4 II:2 
III:1 
46 III:2 40 
II:7 
III:5 
43 III:4 45 III:7 35 III:8 33 III:3 47 III:6 40 
N 
III:9 
34 
N 
III:10 
23 
  
Mutation Negative Normotensive 
Mutation Negative Hypertensive 
Not tested 
Mutation Positive Hypertensive 
Deceased 
N N 
II:1 
73 
N N 
U
ive
rsi
ty 
of 
Ca
pe
 To
wn
 92 
Table 4.3. Renin, aldosterone and creatinine levels in the family analysis 
 R563Q heterozygous R563Q normal  
 n Median IQR n Median IQR p-value 
Creatinine, µmol l-1 88 76 67, 93 46 78 68, 87 0.786 
Aldosterone, pmol l-1 85 222 139, 390 47 206 142, 303 0.326 
Renin, mmol l-1 85 18 9, 33 47 18 12, 25 0.935 
 
 
Table 4.4. Means for untreated subjects 
 Heterozygous (24) Normal (35)  
 
Mean ±SD / 
Median (IQR)* 
Mean ±SD / 
Median (IQR)* P value 
Age, y 35.4±13.1 30.8±13.5 0.197 
SBP, mmHg 133±26 122±18 0.077 
DBP, mmHg 80 (73;87) 80 (69;87) 0.121** 
MAP, mmHg 96 (87;105) 94 (84;102) 0.092** 
Renin, mmol l-1 22.5 (11.5;27.6) 18 (12;22.8) 0.884** 
Aldosterone, pmol l-1 189 (125.3;301.3) 193 (144.5;292) 0.617** 
Potassium, mmol l-1 4.3±0.4 4.3±0.4 0.806 
Creatinine, µmol l-1 75.2±13.6 76.2±18.2 0.868 
*Medians with IQR are displayed for log transformed variables; SD, standard 
deviation. ** P values for log transformed measurements 
 
P values were calculated for the family analysis, excluding the index cases without 
families and excluding founders of the families (Table 4.5). This decreased the 
numbers analysed but also decreased the risk of bias toward associating the mutation 
with hypertension caused by selecting the families of hypertensive patients with the 
mutation. After excluding founders, only the SBP remained significant and after 
excluding index cases none of the variables were significantly different between the 
heterozygous and normal subjects. 
 
Table 4.5. P values calculated with QTDT after excluding founders and index cases 
 
Original 
p-value 
Excluding 
founders 
Excluding 
index cases 
SBP, mmHg 0.003 0.041 0.064 
DBP, mmHg 0.01 0.064 0.175 
MAP, mmHg 0.005 0.053 0.110 
Serum Potassium, mmol l-1 0.224 0.426 0.262 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 93 
DISCUSSION 
This family analysis examined the prevalence of hypertension and levels of BP in 
R563Q heterozygous and normal family members of index cases, and supports the 
suggestion that the R563Q mutation is a dominantly transmitted cause of hypertension 
in the Cape Town population forming the basis of this study.  Table 4.1 gives the 
demographics of the groups. In the full group of 138 subjects the R563Q mutation 
was strongly associated with hypertension: 71 (80%) of the heterozygous subjects had 
hypertension, while 17 (35%) normal subjects were hypertensive, p<0.0001. 
 
Further support for the dominant nature of the R563Q mutation was demonstrated in 
the clinically significant differences in SBP, DBP and MAP (Table 4.2). The 
differences in the medians for the heterozygous and normal groups (after adjusting for 
the effects of race, age and kindred membership) were 21mmHg, 8mmHg, and 
14mmHg for SBP, DBP and MAP respectively. This was despite the difference 
between the groups in those on antihypertensive medication. 73% of heterozygous 
patients were on antihypertensive treatment compared with 29% in the normal group. 
If those on antihypertensives had been able to stop their medication it is expected that 
their BP would increase, increasing the differences between the heterozygous and 
normal groups. 
 
The presence of antihypertensive medication also confounds the biochemical results. 
Most of the hypertensive subjects in this study are patients attending the Hypertension 
Clinic at GSH who have resistant hypertension requiring multiple medications to 
control the BP. The majority of the patients on antihypertensives would be taking an 
ACE inhibitor or a thiazide diuretic as part of their treatment. Both these drugs affect 
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the biochemical parameters that control BP. ACE inhibitors interrupt the renin 
angiotensin system and would tend to increase the renin level and decrease the 
aldosterone level. ACE inhibitors tend to cause hyperkalaemia whereas thiazide 
diuretics tend to decrease the potassium levels. 
 
The subjects that had not been on treatment for hypertension were analysed as 
unrelated individuals. In this analysis there was no statistical difference between the 
groups with and without the mutation. The trends observed were as expected. Those 
with the mutation had higher BP and a lower aldosterone level, but the heterozygous 
group had a median age of nine years greater than the normal group. 
 
The analyses could have been adjusted for the use of antihypertensive medication, as 
the results are confounded by these medications. However, if the SBP and DBP had 
been adjusted for the use of antihypertensive medication it would be tantamount to 
adjusting for the presence of hypertension, as the majority of the hypertensive 
subjects were on treatment. This would essentially remove the difference in BP. A 
further limitation of this analysis is that index cases are from the Hypertension Clinic, 
i.e. they are all hypertensive. For this reason the index cases were excluded from the 
analysis to exclude ascertainment bias. In the family based analysis the numbers were 
small so the association with a difference in BP was not significant, but the 
association with hypertension was significant when assessing the relatives by X
2
 
analysis. 
 
The BPs in the family analysis support the hypothesis that the R563Q substitution is 
an activating ENaC mutation. However, lower renin and aldosterone levels in the 
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heterozygotes compared with the normal group were not found, as previously 
described [Rayner et al., 2003]. This is likely to be due to a combination of factors. 
Antihypertensive therapy was not withdrawn prior to testing, and renin and 
aldosterone may increase due to renal and vascular changes secondary to longstanding 
hypertension [Williams and Hollenberg, 1991]. Rayner et al. [2001] previously 
reported low renin and aldosterone in the normotensive population groups from which 
these families were drawn. This suggests that other genetic and environmental factors 
are present in these population groups, which also lead to suppression of renin and 
aldosterone. The serum creatinine level was not different between the heterozygous 
and normal groups, unlike the results in the Hypertension Clinic patient comparison 
(see Chapter 7). This is probably because there were fewer subjects involved in the 
family study with hypertension, which causes CKD. 
 
Two of the index cases presented with the full Liddle’s phenotype; they developed 
hypertension and severe persistent hypokalaemia during pregnancy. They are 
discussed further in Chapter 10. Only one relative of the hypokalaemic patients was 
available for study and she did not carry the mutation and was normotensive. The 
presence of hypokalaemia in only a minority of the heterozygous subjects is 
consistent with the low penetrance of hypokalaemia reported in kindreds with other 
Liddle’s syndrome mutations [Findling et al., 1997], and suggests that other genetic or 
environmental factors are critical in determining the extent to which the full Liddle’s 
syndrome phenotype is expressed. 
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CONCLUSION 
The R563Q β-ENaC mutation associates with hypertension within kindreds. This 
finding strengthens the case for a causative role for the R563Q mutation in 
hypertension because the genetic background is more homogeneous within kindreds 
than in the general population.  
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CHAPTER 5 
The Prevalence of the R563Q Mutation in South Africa 
 
INTRODUCTION 
As previously discussed, the R563Q mutation has been found to be common amongst 
people of Coloured or Xhosa descent (but not in people of European descent) with 
resistant hypertension in the Cape Town area [Rayner et al., 2003]. It has not been 
detected in other studies which included subjects of African descent [Dong et al.; 
2001; Ambrosius et al., 1999] and it is possible that these findings are isolated to 
Southern Africa. The purpose of this chapter was, firstly, to determine the prevalence 
of the R563Q mutation in the ethnic groups living in the Johannesburg area compared 
with Cape Town and, secondly, to determine if the previously reported association 
with hypertension remains in other population groups. 
 
METHODS 
Cape Town 
Records since 2002 of patients attending the referral Hypertension Clinic at Groote 
Schuur Hospital were examined for hypertension, gender, age, ethnic group and 
screening of the R563Q mutation. Normotensive controls from previous studies 
[Rayner et al., 2003] were included in the analysis but relatives were excluded 
because they would distort the prevalence of the mutation in the South African 
population. 
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Johannesburg 
In Johannesburg patients are not routinely screened for the presence of the R563Q 
mutation but DNA has been obtained for research purposes from other hypertension 
studies. DNA from hypertensives referred to the tertiary hypertension clinics in 
Johannesburg and controls without a family history of hypertension were accessed 
from a data base at the University of the Witwatersrand, Department of Physiology, 
which is in the care of Professor Woodiwiss and Professor Norton. The subjects were 
defined as hypertensive if their clinical and daytime ambulatory DBP was greater than 
89mmHg or their SBP was greater than 139mmHg. The control subjects had a mean 
DBP of less than 90mmHg after five minutes in the seated position. Controls were 
required to have been urban residents for at least two years and not to have a family 
history of hypertension. Secondary hypertension was excluded as described by Nkeh 
et al. [2003]. (At the time of sample collection hypertension was defined as a BP 
≥160/95.) 
 
All subjects gave consent for DNA analysis for research purposes. A history was 
taken and records were kept on subject age, gender and the presence of smoking and 
alcohol intake. Their height and weight were recorded, from which their body mass 
index (BMI) was calculated. The samples had been collected over many years and the 
DNA was stored at -20
o
C until being prepared for PCR. Statistical analysis has been 
described (Chapter 3). Power was calculated using a freely available online calculator: 
Statistical Calculators. 
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RESULTS 
Cape Town  
1382 unrelated subjects were analysed in Cape Town. 1177 were hypertensive and 
205 normotensive. 753 were of Coloured, 407 of Black African and 177 of Caucasian 
origin, with no significant difference between the groups with and without the R563Q 
mutation in the Coloured and Black African groups. Forty five subjects were not 
allocated into an ethnic group. 523 were male and 208 subjects had no record of 
gender. Forty nine subjects were heterozygous for the mutation; one of these subjects 
was normotensive. No homozygous subjects were found. 4.2% of the Coloured and 
Black African subjects were heterozygous for the mutation (p=0.002 for association 
of the mutation with hypertension). Table 5.1 summarises the data analysis.  
 
Table 5.1. Cape Town subjects (and % of total) assessed for the R563Q mutation 
    Heterozygous Normal  P value* 
    Number Percentage Number Percentage   
Ethnicity Coloured 28 2 725 52.5   
  Caucasian 0 0 177 12.8   
  Black African 21 1.5 386 27.9   
  Unknown   45   3.3   
Gender Male 22 1.6 501 36.3   
  Female 27 2 623 45.1   
  Unknown   208 15.1   
Disorder Hypertensive 48 3.5 1129 81.7 0.002 
  Normotensive 1 0.07 204 14.7   
*P value is for comparison between hypertensives and normotensives. 
 
The mean age of the individuals with the mutation was 54.1±14.9 years and those 
without 52.8±13.9 years. (Caucasian subjects were not included.) 21/307 (6.8%) 
Black African subjects and 28/648 (4.3%) Coloured subjects with hypertension had 
the mutation. The hypertensive group heterozygous for the mutation had lower renin 
and aldosterone levels but these did not reach statistical significance (Table 5.2). 
Figure 5.1 shows the ranges of age for the groups with and without the mutation. One 
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normotensive Coloured subject was heterozygous for the R563Q mutation and none 
of the Black African normotensives had the mutation.  
 
Table 5.2. Renin and aldosterone levels in Cape Town hypertensives 
  Heterozygous Normal   
  Number Median (IQR) Number Median (IQR) P value* 
Aldosterone, pmol l-1 46 220 (132;354) 230 291 (202;431) 0.100 
Renin, mmol l-1 46 24 (10;37) 233 18 (8;54) 0.173 
*P values for log transformed measurements 
 
 
Figure 5.1. Mean ± standard deviation (SD) with extremes of age in the groups 
heterozygous and normal from Cape Town 
 
Johannesburg 
The DNA was available from three different ethnic groups: Nguni, Sotho and Venda. 
The subjects from Johannesburg were represented by 519 (66%) individuals of Nguni 
ethnicity, of which 333 (64%) were hypertensive, and 261 (34%) Sotho individuals, 
of which 184 (70%) were hypertensive. None of the Venda individuals tested had the 
mutation. There were very few people from this ethnic group (17 in total, 10 of whom 
were hypertensive) so they were excluded from the combined prevalence analyses. 
There were 527 (66%) subjects with hypertension and 270 (34%) normotensives in 
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total. In the entire group 7.4% of the hypertensives were heterozygous for the R563Q 
mutation and 2.6% of the normotensives (p=0.006). The hypertensive group was over 
represented by females (p<0.0005) but there were fewer smokers and alcohol drinkers 
(Figure 5.2). The hypertensives had significantly higher BP, BMI and weight but were 
shorter. The difference in age was not statistically significant (Table 5.3). 
 
Figure 5.2. Percentages in the hypertensives and normotensives from Johannesburg 
 
Table 5.3. Differences between hypertensives and normotensives from 
Johannesburg 
 
Hypertensives 
(527) 
Normotensives 
(270) P value 
 Mean ±SD Mean ±SD  
Age, y 53.6±10.3 52.3±9.7   0.088 
Height, cm 159.7±8.5 164.1±8.5 <0.005 
Weight, kg 75.3±16.2 71.3±16.6   0.001 
BMI, kg m
-2
 29.7±6.9 26.7±6.9 <0.005 
SBP, mmHg 150.9±13.4 122.9±12.4 <0.005 
DBP, mmHg 93.2±9.1 76.4±8.8 <0.005 
 
Table 5.4 summarises the results of the DNA analyses. There were 333 hypertensive 
Nguni of which 28 (8.4%) were heterozygous for the R563Q mutation. 186 were 
normotensive of which 5 (2.7%) were heterozygous for the R563Q mutation. In the 
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Sotho population there were 184 hypertensives with 11 (6.0%) heterozygotes and of 
the 77 normotensives 2 (2.6%) were heterozygous for the R563Q mutation.  
 
 
Table 5.4. Summary of Johannesburg DNA results 
 Analysed R563Q Heterozygous 
 Group Number Number Percentage 
Hypertensives Total 527 39 7.4 
 Nguni 333 28** 8.4 
 Sotho 184 11* 6.0 
 Venda 10 0 0 
Normotensives Total 270 7 2.6 
 Nguni 186 5** 2.7 
 Sotho 77 2* 2.6 
 Venda 7 0 0 
Footnote: The frequency of the R563Q mutation was different between the 
hypertensive and normotensive groups, *p=0.242 for the Sotho group, **p=0.01 for 
the Nguni group and p=0.006 for the combined results, excluding the Venda. 
 
Table 5.5 summarises the parameters of each of the ethnic groups divided into 
hypertensives and normotensives and into those with and without the mutation. This 
table highlights the differences between hypertensives and normotensives. The 
hypertensives have higher BP but the age and BMI are similar. 
 
Table 5.5. Summary of Nguni and Sotho physical characteristics 
  Nguni Sotho 
  Hypertensive Normotensive Hypertensive Normotensive 
R563Q Hetero Normal Hetero Normal Hetero Normal Hetero Normal 
Number 28 305 5 181 11 173 2 75 
Age, y 54±12 53±10 55±6 52±8 57±6 54±10 56±5 52±10 
Height, cm 159±7 160±9 158±11 164±8 159±9 160±8 172±6 164±9 
Weight, kg 77±16 75±16 76±18 73±17 73±18 76±17 69±5 67±15 
BSA, m2 1.79±0.17 1.76±0.18 1.77±0.17 1.78±0.18 1.75±0.2 1.79±0.18 1.81±0.1 1.72±0.18 
BMI, kg m-2 31±7 30±7 31±10 27±7 29±7 30±7 23±0 25±6 
SBP, 
mmHg 151±14 152±13 129±17 123±12 155±17 150±14 131±9 122±14 
DBP, 
mmHg 95±10 93±9 73±10 77±8 96±12 93±9 84±1 76±11 
Footnote: Means ± SD. Within the hypertensive and normotensive groups the 
difference between the means of those with and without the mutation was not 
significant for any of the variables. BSA, body surface area; BMI, body mass index; 
Hetero, heterozygous 
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Table 5.6 shows the differences between the groups with and without the mutation. 
There was no significant difference in mean age or BMI between the groups with and 
without the R563Q mutation. Overall those with the mutation had significantly higher 
BP (p=0.003 for SBP and p=0.004 for DBP). The presence of hypertension was not 
significantly different between the Sotho heterozygous and normal groups despite the 
T test for blood pressures being adequately powered (observed power for SBP 0.996, 
and for DBP 0.990). 
 
Table 5.6. Differences between combined Nguni and Sotho groups with and without 
the mutation. 
 Heterozygous (46) Normal (734) P value 
 Mean SD Mean SD  
Age, y 55 10 53 10 0.296 
SBP, mmHg 149 17 141 19 0.003 
DBP, mmHg 92 13 87 12 0.004 
BMI, kg m-2 30 7 29 7 0.175 
 
The normotensive subjects with the mutation tended to have higher SBP than those 
without the mutation (Table 5.7) but this difference was not significant (p=0.161). 
The DBP was not different between the groups. The groups with and without the 
mutation were represented by similar percentages of smokers, drinkers, males and 
females (Figure 5.5). 
 
Table 5.7. BP in the normotensive Nguni and Sotho subjects from Johannesburg 
  R563Q N Mean SD 
SBP Heterozygous 7 129 14 
  Normal 256 123 12 
DBP Heterozygous 7 76 10 
  Normal 256 76 9 
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Figure 5.3. Percentage of males, females, smokers and those that drink alcohol in 
the Johannesburg subjects 
 
Combined Results for Johannesburg and Cape Town 
The Sotho and Nguni groups both belong to the Black African group (speaking a 
Bantu language) inhabiting South Africa. The Xhosa, which is the Black African 
group in Cape Town, also belong to the Nguni tribe but have lived separately from the 
Zulu (the major Nguni group in Johannesburg) for many centuries. The Coloured 
subjects from Cape Town are known as the Cape Coloured and have a mixture of 
Khoisan, Southeast Asian, western European and African Black genes [Rousseau et 
al., 2003]. Both the Coloured and Black African subjects analysed here have genetic 
input from the Bantu groups that migrated into southern Africa. 
 
The samples in this thesis were collected from people in these groups attending two of 
the major referral hypertension clinics in South Africa. The control subjects were age 
matched normotensives. The Cape Town data set does not have records of the 
presence of smoking and alcohol intake, nor are there records of height, weight and 
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body surface area. The mean age of the Cape Town and Johannesburg subjects was 
very close; 52.8±13.9y and 53.1±10.1y respectively. The data sets were represented 
by similar frequencies of males, females and R563Q heterozygous individuals (Figure 
5.6). 
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Figure 5.4. Frequency of males and subjects with the R563Q mutation and mean 
age of subjects in Johannesburg and Cape Town 
 
In total, 2179 unrelated subjects were analysed for the mutation. 1704 (78%) were 
hypertensive and 475 were normotensive. 753 (35%) were of Coloured, 1204 (56%) 
of Black African origin and 177 (8%) were Caucasians. Forty five did not have an 
allocated ethnic group. The gender and race were not significantly different between 
the R563Q heterozygous and normal groups.  In the combined group of Coloured, 
Nguni and Sotho people there were 95 (4.9% of the total) subjects who had the 
mutation; 87 (5.7%) of the hypertensives and 8 (1.7%) of the normotensives 
(p=0.0002 for association with hypertension) (Figure 5.5). The difference in mean age 
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between those with the mutation and those without was not significant, 54.4± 12.6 
years vs. 52.9±12.5 years respectively.  
 
Figure 5.5. Percentages of subjects analysed in South Africa 
 
DISCUSSION 
The R563Q mutation of the β-ENaC has previously been found in subjects in the 
Cape Town area but has not been determined in other areas in South Africa. These 
results show that the R563Q mutation is prevalent and strongly associated with 
hypertension in three of the major ethnic groups in South Africa.  
 
The frequency of the R563Q mutation in the GSH Hypertension Clinic referral clinic 
was found to be 6.8% in the Xhosa patients and 4.3% in the Coloured patients. It was 
not found in Caucasian hypertensive subjects and only one (0.5%) normotensive 
subject had the mutation. The R563Q mutation was found in 7.4% of the hypertensive 
group studied in Johannesburg and only in 2.6% of ethnically matched normotensive 
H ypertensive
R 563Q  N orm al
74.3%
N orm otensive
R 563Q  N orm al
21.2%
N orm otensive
R 563Q  H eterozygous
0.5%
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controls. This difference was statistically significant as was the association with 
higher BP in the entire group. 
 
In the search for candidate genes for hypertension many studies have found that 
mutations in the ENaC genes do not have a substantial role in EHT, [Munroe et al., 
1998; Chang and Fujita, 1996]. There are a few studies that have found mutations at 
high frequencies, but their association with hypertension has been queried. The 
G442V mutation of the β-ENaC is found in exon 8 of the gene and was not associated 
with hypertension [Ambrosius et al., 1999]. It was associated with an increase in 
potassium excretion and a decrease in aldosterone excretion and aldosterone-
potassium ratio suggesting an increase in ENaC activity. However, when expressed in 
Xenopus oocytes there was no difference in sodium current. The frequency of the 
G442V mutation in the Black African subjects of this study was 8.3%, but only 0.2% 
in the Caucasian subjects. This is in keeping with other reports of sodium channel 
mutations being found more commonly in Black Africans than in Caucasians [Persu 
et al., 1998]. A mutation in the α-ENaC (T663A) that was more common in a 
Caucasian population [Ambrosius et al., 1999], with a significant difference between 
the hypertensives and normotensives, was found to be protective against hypertension.  
 
The T594M mutation appears to be the only other mutation of the sodium channel that 
has data published for South Africa and if the association of the T594M mutation with 
hypertension is spurious then there are no published mutations found at high 
frequencies definitively associated with hypertension in the ENaC genes of South 
Africans. The R563Q mutation has a strong association with hypertension in this 
study and is found at high frequencies in Johannesburg. In the data for this thesis there 
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was no difference in BMI (which has been shown to have an affect on the interaction 
between genotype and blood pressure in the same population groups [Tiago et al., 
2002]) between those with and without the R563Q mutation (Table 5.4) but there was 
a consistent association of the R563Q mutation with higher BP. 
 
The R563Q mutation is significantly associated with hypertension and BP differences. 
In subjects from Johannesburg there was an average difference of 8/5 mmHg between 
the heterozygous and normal individuals (p=0.006 for SBP and p=0.005 for DBP). 
This sample (780 Nguni and Sotho) represents two of the major Black African groups 
living in South Africa [Lehohla, 2001]. When the ethnic groups were separated, the 
presence of the mutation in the Sotho group did not significantly associate with 
hypertension. This could be due to the smaller numbers. However, the numbers were 
adequately powered. There was half the number of Sotho’s sampled, with almost two 
thirds having hypertension.  
 
In the combined Johannesburg and Cape Town sample analysed the association 
between the R563Q mutation and hypertension was still present (p=0.001). There was 
no difference between the R563Q heterozygous and normal groups with respect to 
smoking, alcohol intake, age, gender or BMI so they were not used as covariates in 
the analysis. This does not exclude the possibility that environmental factors 
contribute to the influence this mutation has on channel activity. It is thought that the 
R563Q mutation increases sodium channel activity and would thus be influenced by 
sodium intake of the individual. There were no data reflecting sodium intake for this 
sample (e.g. spot urinary sodium-creatinine ratio which is a reliable and easy indicator 
of sodium intake and is shown to have a direct correlation with BP in infants 
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[Pomeranz et al., 2002]). Thus, it was not possible to determine if the sodium intake 
was different between those with the mutation who were hypertensive or 
normotensive. 
 
The R563Q mutation has not been found in a group of Black African people that has 
been analysed in London [Hartmann, 2007]. The Nguni and Sotho groups are Bantu-
speaking people who originated from Central Africa. (This is also likely to be the 
place of origin of the individuals sampled in London.) The Nguni and Sotho come 
from the south-eastern Bantu migration into southern Africa, see Figure 5.6. At the 
time of this immigration southern Africa was populated by a hunter-gatherer 
population known today as the Khoisan who lived in the extreme and harsh 
environment of the Kalahari Desert but had migrated east and south, inhabiting most 
of southern Africa [Pereira et al., 2001; 2002; Soodyall et al., 1992].  
 
Figure 5.6. Bantu Migration [Encarta, 2008] 
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The Nguni in South Africa mostly consist of the Xhosa and Zulu tribes, who have a 
very high genetic correlation [Soodyall, 1993]. The Xhosa are the major group 
populating the Eastern and Western Cape whereas the Zulu traditionally lived in 
KwaZulu Natal. The Sotho inhabited the mountainous area Lesotho which lies inland 
and between the Eastern and Western Cape [Lehohla, 2001]. These groups have all 
been living in southern Africa for 2000 to 3000 years and the geographical boundaries 
have all but disappeared resulting in extensive genetic admixture between them [Salas 
et al., 2002; Soodyall, 1993]. 
 
The prevalence estimates in this chapter are not a true reflection of the prevalence 
within South Africans. These samples were selected according to blood pressures and 
thus show prevalences in these groups rather than the general population. Further 
studies are required to determine population prevalences.  
 
CONCLUSION 
The above data show that there is a strong association of the R563Q mutation with 
hypertension in areas other than the Western Cape. This association is independent of 
the patient’s BMI and age. The mutation has a high prevalence in the hypertensive 
Black African and Coloured people of South Africa suggesting it may be the 
commonest clinically relevant cause of EHT described to date. 
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CHAPTER 6 
The Khoisan: An Investigation into the Possible Origin of 
the R563Q Mutation in South Africans 
 
INTRODUCTION 
South Africa is a country with people of diverse origins. The aboriginal groups to 
southern Africa are the Khoikhoi and the San. These two groups became known 
together as the Khoisan and are found in the highlighted are in Figure 6.1. The 
Khoisan are thought to be direct descendents of the original Homo sapiens who 
inhabited Africa, as they have been found to have the oldest clades in mitochondrial 
DNA and the Y chromosome [Chen et al., 2000; Semino et al., 2002; Underhill et al., 
2000].  
 
 
Figure 6.1. The Khoisan groups inhabit south western sub-Saharan Africa, including 
the Kalahari Desert. [Encyclopaedia Britannica, 2004] 
Khoisan Homeland 
Khomani San 
South Africa 
Zambia 
Angola 
Botswana 
Namibia 
Zimbabwe 
Mozambique 
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The hunter-gatherer existence of the San included a diet rich in potassium and very 
low in sodium. The Khoikhoi were a pastoral group who have mostly been either 
incorporated into the San or the Black African groups that migrated into southern 
Africa. The Black African groups are the major groups that currently inhabit most of 
sub-Saharan Africa. These groups originated in central Africa at the confluence of the 
Niger and Benue rivers, and all speak Bantu languages. The groups migrated 
throughout sub-Saharan Africa, mingling with the aboriginal groups, as they 
expanded. This led to genetic admixture and the Zulu and Xhosa in South Africa have 
considerable genetic similarities with the Khoisan [Soodyall, 1993].  
 
The R563Q mutation has been found in the Nguni and Sotho groups in South Africa 
at a high frequency, especially in hypertensives (see Chapter 5), but not in the Black 
African groups in the United Kingdom [Hartmann, 2007]. This chapter examines the 
frequency of the R563Q mutation in the Khoisan groups that are living in southern 
Africa and examines the following questions.  
 Is the presence of this mutation in the Black African groups of South 
Africa a reflection of genetic admixture from the Khoisan?  
 If the mutation is found in this group at what frequency and is it in Hardy 
Weinberg Equilibrium (HWE)?  
 If present, does this mutation alter BP in this group, or the electrolytes and 
aldosterone levels in the Khoisan? 
 
As discussed in Chapter 7, in order to determine if the R563Q mutation alters the 
parameters that determine the BP it is important to measure these parameters in 
individuals who are not taking any antihypertensive medication. Most of the subjects 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 113 
with the R563Q mutation have severe resistant hypertension. This makes it impossible 
to get a true reflection of these parameters. The Khoisan are known to have normal to 
low BP [Nurse and Jenkins, 1977]. Thus, investigation of Khoisan subjects created 
the opportunity to determine the effects of the R563Q mutation in treatment naïve 
individuals. 
 
METHODS 
In collaboration with the University of the Witwatersrand, samples were collected 
from a group of Khoisan from the Northern Cape known as the Khomani San. An 
ongoing project to determine mitochondrial DNA and Y chromosome diversity has 
been approved by the University of the Witwatersrand provided it is accepted by the 
various Khoisan communities. The University of Cape Town Ethics Committee gave 
approval for association studies. The author was invited as the team medical officer 
in order to collect the blood samples and record the BP from the subjects in the 
Northern Cape. 
 
DNA was available from a small cohort of Khoisan from Namibia [Rousseau et al., 
2003] courtesy of Dr J. Rousseau. These subjects were judged to be unrelated on the 
basis of interviews but more distant inbreeding could not be excluded as the 
community was small. The DNA underwent PCR followed by restriction enzyme 
digestion to determine the presence of the R563Q mutation, as described in Chapter 3.  
 
A random sample of DNA from the Khomani San was collected by driving into the 
communities and requesting people to be involved in the study. Subjects were self 
identified as Khomani San and gave the ethnicity and place of birth for each parent, to 
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the best of their knowledge. Close relatives were excluded in order to prevent over- or 
under-representation of the prevalence of the mutation.  
 
BP was measured as previously described. Blood was taken for aldosterone, sodium, 
potassium and creatinine and DNA analysis. The blood was spun at 6000rpm for three 
minutes and the serum was stored in a different tube in an insulated container with 
ice-blocks (but was not directly placed on the block in order not to freeze them) until 
the samples could be placed in a refrigerator at 4
o
C. The samples were then 
transported to the laboratory at GSH in an insulated container. This was to prevent 
haemolysis causing falsely raised potassium levels. Subjects receiving 
antihypertensive medication did not undergo biochemical analysis due to the 
influence of antihypertensives on electrolytes and aldosterone. DNA was extracted at 
the University of the Witwatersrand. The presence of the mutation was determined 
with PCR and sequencing as described in Chapter 3. All homozygous results were 
checked with different primers and sequenced, as previously described. HWE was 
calculated and, to determine if the deviation form equilibrium was significant, the 
Hardy Weinberg calculator was accessed from a website. The SPSS package was used 
for further statistical analyses. Student’s t test was used for continuous variables and 
Χ2 was used for categorical variables. Power was calculated from a freely available 
online calculator: Statistics calculators. 
 
RESULTS 
Namibian Khoisan 
Eighty two samples from Namibia were analysed for the mutation. Fifteen (18%) 
subjects were heterozygous for the mutation, and one (1%) subject was homozygous. 
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The results were used to determine if the Namibian sample was in HWE (Figure 6.2). 
HWE is explained in the glossary (Appendix II). Briefly, the equation is used to 
determine if the actual number of heterozygous and homozygous individuals is 
similar to the expected frequencies. Significant deviation from the expected 
frequencies needs to be explained.  
 
 
Figure 6.2. Hardy Weinberg calculations for the Namibian Khoisan  
 
This small random sample with a high prevalence of subjects heterozygous for the 
R563Q mutation and one homozygote did not have data on BP or any other 
phenotypic data. The Hardy Weinberg calculations suggested that the mutation may 
be in equilibrium in this population, but as it is a small sample additional subjects 
would be required before it is possible to determine if this population is truly in 
equilibrium. 
 
 
 
• Total number of samples: 82 
• Heterozygous: 15 
• Normal (RR): 66 
• Homozygous for the Q allele: 1 
•  p2 = 66/82 = 0.804878 
•  p = 0.8971499 
• And q=1-p = 0.1028501 
•  q2 = 0.0105781 =~ 1/100 
• And q2 = 1/82 = 0.0121951 from the 
samples 
• 2pq = 0.1845438 using calculated figures 
• 15/82 = 0.1829268 from the samples 
• Approximately equal at ~18% each 
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Northern Cape Khomani San  
85 Khomani San from the Northern Cape were analysed for the presence of the 
R563Q mutation. 51 (60%) were male, and 55 (65%) were normotensive (Table 6.1). 
13 (15%) were heterozygous for the R563Q mutation and 3 (4%) were homozygous. 
The prevalence of hypertension in the normal group (negative) was similar to the 
combined homozygous and heterozygous (positive) group (Table 6.1).  
 
Table 6.1. Frequency of hypertension in each group 
  R563Q     
  Positive (%) Negative Total Χ2 
Normotensive 12 (24) 37 49   
Hypertensive   4 (11) 32 36   
Total 16 (19) 69 85 0.129 
 
Table 6.2 shows the results from the measurements that were taken form the Khomani 
San people from the Northern Cape. The positive group had a median age of seven 
years greater than the negative group. The serum potassium was not different between 
the groups, neither was the urinary excretion of sodium or potassium or the urinary 
sodium-creatinine ratio. The aldosterone levels were significantly lower in the 
positive group: the median was 52.3pmol/l vs. 96.2pmol/l (p=0.035 for the logarithm 
of the mean). However, the analysis is shown to be underpowered and more subjects 
will be required in order to be sure there is no difference. Figure 6.3 shows the 
calculations for the Hardy Weinberg equation for the frequency of the mutation in the 
Northern Cape Khomani San.  
 
The observed frequencies of the genotypes in the Northern Cape Khomani San were 
different to the expected frequencies. In a sample of 85 with three homozygotes more 
than 13 heterozygotes were expected. The deviation from HWE was calculated and 
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the Χ2 analysis is shown in Table 6.3. The small sample of Namibian Khoisan did not 
deviate significantly from the expected frequencies but the Northern Cape Khomani 
San deviated significantly (p=0.034). 
 
Table 6.2. Variables in the positive and negative groups 
  R563Q Positive R563Q Negative    
  N 
Mean / 
(Median**) 
SD / 
N 
Mean / 
(Median**) 
SD / P value 
(Power) (IQR) (IQR) 
Age 16 45 36;61 67 38 33;56 0.129*  
SBP, mmHg 16 129 121;147 69 129 126;139 0.303* (0.325) 
DBP, mmHg 16 76 10 69 81 11 0.075  (0.616) 
Sodium, mmol l-1 12 134 5 44 133 5 0.221  (0.256) 
Potassium, mmol l-1 10 3.9 0.4 43 3.9 0.4 0.431  (0.070) 
Creatinine, µmol l-1 12 65.9 13.2 44 69.9 16.3 0.221  (0.257) 
Aldosterone, pmol l
-1
 12 96.2 54.5;191.7 44 52.3 31;118.1 0.035* (0.079) 
Urinary Sodium, mmol l-1 8 54 29.5;146.0 27 52 40.5;125.8 0.372* (0.199) 
Urinary Potassium, mmol l-1 8 25 12.5;48.9 27 21.3 18.3;32.5 0.209* (0.256) 
Urinary Creatinine, mmol l-1 8 11 3;18 27 7 3.8;9.3 0.274* (0.517) 
Sodium-Creatinine ratio 8 7.3 5.1;12.9 27 9.6 5.3;14.4 0.183* (0.233) 
BP, blood pressure; N, number; SD, standard deviation; * P values for log 
transformed values, ** Medians and IQR are shown for data that required log 
transformation before analysis. 
 
 
Figure 6.3. Hardy Weinberg Calculations for the Northern Cape Khomani San 
 
 
 
 
• Total number of samples: 85 
• Homozygotes (QQ): 3 
• Heterozygotes: 13 
• Normal (RR): 69 
•  q2 = 3/85 = 0.03529  
•  q = 0.18786 
• And p=1-q = 0.81213 
• But in these data p2= 69/85 = 0.81176  
•  p=0.90098 
•  Expected frequency for heterozygotes:  
• 2pq= 2*0.18786*0.81213 = 0.30513 
• Actual frequency in this sample: 13/85 = 0.15294 
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Table 6.3. Chi Squared Calculation for Deviation from HWE 
 Genotype Number Expected Frequency Statistic 
Namibian RR 66 65.881 p=0.8963  
Sample RQ 15 15.2378 q=0.1036  
 QQ 1 0.881  Χ2 = 0.0199 
 Total 82   P=0.888 
Khomani RR 69 67.0617 p=0.8882  
San RQ 13 16.8764 q=0.1117  
 QQ 3 1.0617  Χ2 = 4.4846 
 Total 85   P=0.034 
Total RR 136 133.9285 p=0.8928  
 RQ 28 32.1428 q=0.1071  
 QQ 4 1.9285  Χ2 = 2.7908 
 Total 168   P=0.095 
 
Comparison with Cape Town Normotensives  
The Northern Cape Khomani San live a rural lifestyle, with the men going out to farm 
in the concessions that have been granted to the communities. The food that they do 
not produce on the farms they get from small shops that stock standard produce. Most 
of this produce was preserved food as the electricity supply to many of the areas was 
inadequate [Jones, personal observations]. Thus, the traditional diet that the Khoisan 
had has largely fallen away. The Khoisan that were sampled in the Northern Cape 
were compared with a group of normotensive subjects from the Western Cape in 
order to determine if there were any differences between the rural Khomani San 
normotensives and the urbanised Cape Town normotensives (Table 6.4). The R563Q 
status of the Cape Town normotensives was not known and the Khomani San was a 
group combining all the normotensives irrespective of the R563Q status. The subjects 
from Cape Town were included in a previous study requiring normotensive controls 
[Rayner et al., 2001]. These 87 normotensive subjects from Cape Town were a 
mixture of Black African (41) and Coloured (46) individuals and consisted of 26% 
males. The Khoisan were represented by a larger percentage of males (61%).  
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Table 6.4. Comparison of Northern Cape Khomani San and Cape Town 
normotensives 
 Khomani San Cape Town subjects  
  Number Mean SD Number Mean SD P value 
          
  Physical Parameters 
Age, y 48 41 16 87 55 10 <0.005 
SBP, mmHg 49 127 120;137 87 130 120;140    0.200* 
DBP, mmHg 49 75 72;83 87 80 75;90    0.010* 
          
  Blood Measurements 
Potassium, mmol l
-1
 46 3.9 0.4 86 4.4 0.4 <0.005 
Creatinine, µmol l
-1
 49 65 56;78 86 76 69;83    0.001* 
Aldosterone, pmol l
-1
 49 91.4 53.2;191.2 86 310 221.2;426.0 <0.001* 
          
  Urine Measurements 
Sodium-Creatinine 31 7.3 4.6;13.0 86 12.2 7.5;18.1 0.016* 
Sodium, mmol l
-1
 31 53 26;130 86 116 70;153 0.001* 
Creatinine, mmol l-1 31 8 3;16 87 10 6;15 0.127* 
* P values for log transformed data for which medians and IQR are displayed 
 
The SBP was not different between these two groups, despite the thirteen year 
difference in age between them. The difference in DBP reached statistical significance 
but after adjusting for age this difference was attenuated (Table 6.5). An interesting 
observation was the lower potassium and aldosterone levels in the Northern Cape 
Khomani San suggesting innate overactivity of the sodium channels. The sodium-
creatinine ratio was significantly higher in the Cape Town normotensives indicating 
that the sodium intake was higher in urbanised individuals. Despite the low sodium 
intake, the aldosterone level was lower in the Khomani San supporting innate ability 
to retain sodium. This has a long term impact on BP and aldosterone levels in the 
urbanised group. Adjusting for the difference in age did not alter the difference 
between potassium and sodium-creatinine ratio (Table 6.5). The aldosterone level was 
significantly different between the groups but this did not influence the differences in 
potassium level and sodium-creatinine ratio. 
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Table 6.5. Adjusting for age and aldosterone 
  Age Aldosterone 
  P value P value 
DBP*, mmHg 0.09   
Aldosterone*, pmol l-1  <0.005   
Potassium, mmol l-1  <0.005 <0.005 
Sodium-Creatinine* 0.016 <0.005 
Footnote: This table shows the p values that were calculated after the variables were 
adjusted for age or aldosterone levels as these were significantly different between 
the groups. * Log transformed variables 
 
Untreated Subjects 
Many of the subjects (including the Khoisan, subjects from the family study and 
subjects from Johannesburg) that were assessed in this thesis were not on treatment 
for hypertension, either because they were normotensive or because they had not 
previously been assessed for hypertension. This created the opportunity to determine 
if there was a difference in biochemical characteristics and BP between those with 
and without the R563Q mutation. This analysis consisted of subjects from each of the 
chapters analysed in this thesis. The only excluding criterion for this analysis was the 
current use of antihypertensive medication. Despite the differences between the 
groups (such as the Khomani San and the Cape Town normotensives) all subjects 
were placed together and divided into two groups: a group with two copies of the 
normal β-ENaC (negative) and a group consisting of subjects either heterozygous or 
homozygous for the R563Q mutation. 
 
There was a larger percentage of subjects with the mutation who were hypertensive 
(31% vs. 20%) but this was not significant until adjusted for the age difference (Table 
6.6). The mean SBP, MAP and DBP were significantly higher in the subjects with the 
mutation; 134±19mmHg vs. 128±15mmHg (p=0.001); 99±13mmHg vs.95±9mmHg 
(p=0.013); and 81±11mmHg vs. 78±8mmHg (p=0.025) respectively. This difference 
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was present despite the eight year difference between the groups, the negative group 
was older (p<0.0005). The difference in BP was exacerbated by adjusting for age. 
Table 6.7 shows that there was no significant biochemical difference between the 
groups. 
 
Table 6.6. BP for all untreated subjects 
  Positive (55) Negative (456) P value P value* 
  Number Percent Number Percent    
Hypertensive 17 31 93 20 0.072 0.012 
  Mean  SD Mean  SD    
Age 43 15 51 13 <0.0005   
SBP, mmHg 134 19 128 15 0.001 <0.0005 
DBP, mmHg 81 11 78 8 0.025 0.001 
MAP, mmHg 99 13 95 9 0.013 <0.0005 
*P values after adjusting for age 
 
Table 6.7. Biochemical parameters in the untreated subjects  
  Positives Negatives   
  N 
Mean / 
Median* 
SD / 
IQR* N 
Mean / 
Median* 
SD / 
IQR* P value 
Potassium, mmol l-1 36 4.1 0.4 75 4.1 0.4 0.436 
Sodium, mmol l-1 15 136 4.8 49 134 5.4 0.120 
Creatinine, µmol l-1 39 72 14 84 72 17 0.931 
Aldosterone, pmol l-1 39 142.0 106.9;233.0 84 156.3 81.4;247.3 0.490* 
Urinary Sodium, mmol l-1 8 52.0 40.5;125.8 28 46.5 27.5;131.0 0.432* 
Urinary potassium, mmol l-1 8 21.3 18.3;32.7 28 24.2 12.1;46.6 0.273* 
Urinary sodium/creatinine 8 9.6 5.3;14.4 27 7.4 5.1;12.5 0.281* 
FENa 8 4.3 2.4;6.1 27 4.0 2.9;6.6 0.458* 
FENa, fractional excretion of sodium; *p values for log transformed variables and 
median and IQR are given. 
 
DISCUSSION 
A Common Mutation 
The R563Q mutation was found at a high frequency in the two Khoisan groups that 
were sampled. Almost 20% of the subjects had the R563Q mutation in either the 
homozygous or heterozygous form. The fact that the R563Q mutation was found at 
such a high frequency in the Khoisan population supports the hypothesis that the 
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mutation in the Black and Coloured South Africans originates from the Khoisan. The 
Khoisan traditionally lived a sodium depleted lifestyle [Nurse and Jenkins, 1977], so 
if this mutation does increase sodium retention it would be expected to improve the 
chance of survival. This could explain the high frequency in this population. Another 
reason the frequency of this mutation could be high in this population is due to 
inbreeding. They are a small community and tend to be confined to small areas. This 
increases the risk of consanguineous mating which would increase the frequency of 
mutations.  
 
Although the Hardy Weinberg calculation could be questionable with these small 
numbers it was considered worthwhile as they were random samples and represent 
small communities. The calculation could indicate if the samples were in the expected 
equilibrium. However, deviation may not be significant. It is known that the Khoisan 
live in small communities and thus the risk of non-random mating is high. There may 
have been very little migration in and out of the communities, but the fact that this 
mutation was not in equilibrium in a sample this size does not mean that there has 
been positive selection for this mutation. In a larger sample, deviation from HWE 
suggests that there is a selection pressure on a mutation. In this case it would be in 
favour of the mutation. Despite the small size of these samples the frequency of this 
mutation is important. These figures are in two random samples and are similar which 
support each other as true reflections of the frequency of the mutation in the Khoisan.   
 
An excess of homozygotes (as was the case in the Northern Cape Khomani San) 
suggests that there could have been inbreeding, a selection pressure for the mutation 
or null alleles (i.e. deletions). The risk of another SNP that may have affected primer 
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annealing and extension was excluded by sequencing and using different primers to 
check the homozygous results. There is still debate as to whether or not the high 
frequency of the homozygotes is due to inbreeding or due to a selection pressure. 
Cannings and Edwards [1969] showed that, in small samples, the Hardy-Weinberg 
law did not correctly predict the actual genotypic frequencies. This suggests that the 
appearance of selection pressure in this sample could be a reflection of the sample 
size.  
 
Functional Analysis in the San 
The differences detected between the Northern Cape Khomani San with and without 
the R563Q mutation are shown in Table 6.2. The mutation did not associate with 
higher BP. The negative group was older than the positive group by a median of seven 
years but this was not significant. The DBP was higher in the negative group by a 
mean of 5mmHg which could be explained by the difference in age. The SBP did not 
display a similar trend. The lack of association with hypertension in this group could 
also be the result of other external factors, such as low sodium diet, and may not be 
relevant due to the small size of the sample. It is of interest that the aldosterone level 
was significantly lower in the group with the mutation, suggesting sodium channel 
over-activity. There was no difference in serum and urinary electrolytes between the 
groups. 
 
When compared with a group of urbanised normotensives from Cape Town, the 
Northern Cape Khomani San normotensives had lower DBP but they were also 
younger (Table 6.5). The difference in DBP was attenuated by adjusting for age. The 
urbanised group were selected as age matched normotensive controls to compare with 
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a group of hypertensives, so would tend to be older to middle aged and have lower 
BP. The Khomani San were randomly selected for analysis and the hypertensives 
were excluded from this part of the analysis. This could explain the difference in age 
between the groups. The normotensive Khomani San had a significantly lower sodium 
intake than the urbanised group, as seen by the lower urinary sodium-creatinine ratio. 
They also had significantly lower potassium levels which may explain the low 
aldosterone levels, which are counterintuitive to the lower sodium intake. The low 
sodium intake with lower potassium levels and lower aldosterone levels could all be 
explained by an innately overactive sodium channel in the Khomani San. 
 
The traditional Khoisan diet consisted of foraged and hunted foods which were high 
in potassium, lean protein, fibre and a balance of minerals [O’Keefe and Cordain, 
2004]. This healthy lifestyle led to a low prevalence of hypertension, diabetes and 
hypercholesterolemia [Nurse and Jenkins, 1977]. The Northern Cape Khomani San 
live in communities which are made up of Khoisan people who have been relocated 
into farms. These communities do not live the traditional active hunter-gatherer 
lifestyle but eat a Westernised-type diet. In fact, it is not permitted to hunt without a 
permit and there are only permits for guns; none for bows and arrows. This means that 
those without guns may not hunt, and, as guns are expensive, many of these poverty-
stricken people do not have access to food. This, within the arid African landscape, 
has created a community that struggles to survive. 
 
Many families do not have access to electricity so fresh produce is not easily 
available. This means that they require food that is possible to store without a 
refrigerator. Most of these food products are in tin cans or are dried. These products 
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usually have added sodium chloride to preserve the foods and for flavour. This 
automatically increases the daily sodium intake which has been shown to increase the 
long term risk of hypertension and cardiovascular events [Tuomilehto et al., 2001].  
 
This pseudo-westernised lifestyle has led to the presence of hypertension and, in a few 
cases, diabetes. Instead of the thin lithe bodies there is a fair amount of obesity [Jones, 
personal observations]. This has increased the incidence of the lifestyle disorders. The 
observed BP was higher than expected in this community, as was the incidence of 
hypertension. However, there was no difference in BP between the positive and 
negative groups. Those subjects that were on antihypertensives had their BP recorded 
and blood was taken for DNA but electrolytes, creatinine and aldosterone were not 
measured as these are influenced by antihypertensive medication which would 
invalidate the results. 
 
In a group that was expected to have innately increased sodium reabsorption it would 
be expected that the aldosterone levels would be lower than the average ranges found 
in urbanised communities. This was the case, with 10 (17%) out of the 58 measured 
aldosterone levels being less than 31pmol/l. Thirty-one pmol/l is the level below 
which the laboratory does not report. The sodium and potassium levels were not 
different which reflects good compensation; as is expected in individuals that are 
clinically stable. However, there were many sodium levels that were lower than the 
normal clinical range (135-147mmol/l). There were 11 subjects who had a sodium 
level below 130mmol/l (the lowest was 117mmol/l) but only one of these subjects had 
the mutation. This subject had a sodium level of 128mmol/l and was heterozygous. 
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There were three homozygous subjects. Two of them were known hypertensives on 
treatment. They were both female. One was 67 years old and had a BP of 
130/61mmHg and the other was 47 with a BP of 143/95mmHg. The third 
homozygous subject was 28 and was not known to have hypertension but her BP was 
143/94mmHg. Her aldosterone was less than 31pmol/l, sodium was 132mmol/l and 
her potassium was 3.6mmol/l. Thus, all three homozygotes had raised BP in a 
community where this is not a common phenotype. 
 
It was not possible to test renin levels as this test requires that the blood is stored 
frozen and is not defrosted until testing. This was not possible in the field. Field work 
in the Northern Cape involves being in the car for most of the daylight hours with no 
fridge or freezer so the samples were stored in an insulated container with ice-blocks. 
(The samples were not directly placed on the ice-blocks in order not to freeze them.) 
Furthermore, there was no dry ice for transport purposes. The samples were spun 
when there was access to electricity and stored until they could be placed in the 
refrigerator where they were stored at 4
o
C until being transported back to Cape Town. 
A further complication of collecting samples in the field was the lack of ablution 
facilities at close range. Many of the subjects were found on the side of the road and 
refused to give urine samples, hence the small number of urine samples analysed. 
 
The aldosterone and renin levels were previously found to be lower in Black African 
and Coloured normotensive subjects from Cape Town when compared with their 
White counterparts [Rayner et al., 2001]. The aldosterone was even lower in the 
Khomani San group, as was the potassium level. Sodium suppresses aldosterone and 
as the sodium intake is lower in the Northern Cape Khomani San the aldosterone level 
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was expected to be higher. A lower aldosterone in this group indicates an innately 
increased activity of the sodium channel. This is supported by the significantly lower 
potassium in the Northern Cape Khomani San. Pratt’s team have repeatedly found 
that aldosterone levels are lower in Black African subjects when compared with 
Caucasians [Pratt et al., 1989; 1993; 1999]. The aldosterone appears to be even more 
suppressed in the Khomani San population in southern Africa.  
 
Pratt et al. [2002] found that the lower aldosterone levels were not likely to be the 
result of higher ENaC function, as the subjects were not sensitive to amiloride. This 
group of young Black Americans had high levels of sodium retention resulting in 
aldosterone suppression. In The Northern Cape Khomani San the sodium intake was 
lower than the average urbanised individual and the serum aldosterone was lower, 
which would be explained if the ENaC activity was innately increased due to 
activating mutations. The R563Q mutation is a possible mutation and it is possible 
that this mutation hasn’t altered the biochemical characteristics enough to reach 
statistical significance in a small sample. This supports the hypothesis that the R563Q 
mutation originates in the Khoisan. A mutation that completely alters the biochemical 
characteristics may not be sustainable but one that slightly alters the ability to survive 
is more likely to have a selection advantage. 
 
It will be interesting to compare the mtDNA and Y chromosome clades and 
mutations. These data may show an association of the R563Q mutation with either the 
Khoikhoi or the San. The San, being a more hunter-gatherer group, may have had a 
higher prevalence of mutations in the sodium channel genes.  
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An interesting opportunity arose during this analysis. With so many subjects that were 
found to have the mutation and who were not taking antihypertensives it was possible 
to assess the difference in measurements between the groups with and without the 
R563Q mutation in an uninfluenced environment. The BP was significantly higher in 
the group with the mutation, with a mean difference of 6/3mmHg, despite the eight 
year age difference (positives: 43y and negatives: 51y). Adjusting for age increased 
the significance of the difference in BP. The biochemical parameters were not 
different between the groups but this could be due to the different results from the 
different groups, especially the Khomani San with their different sodium intake, i.e. 
population stratification. Thus, in all the untreated subjects analysed in this thesis the 
association of the R563Q mutation with hypertension remained significant. 
 
CONCLUSION 
The aboriginal group in southern Africa, the Khoisan, are most likely to be direct 
descendants of the original Homo sapiens that initially populated Africa. This group 
has been shown to have a high frequency of the R563Q mutation, which did not 
associate with hypertension in a small sample from this population. In one group 
analysed the mutation was in HWE but the equilibrium was not replicated in the 
second group analysed. However, the Hardy Weinberg Law may not apply to these 
small samples. Within the Khomani San there was no significant difference in the 
biochemical parameters that are affected by sodium channel activity, except the 
aldosterone level which was lower in those with the mutation. The lack of association 
with BP within this group could be related to the low sodium intake, when compared 
with the urbanised group. The high frequency of the R563Q mutation in the Khoisan 
groups, the history of intermingling between the Khoisan and the Black African 
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groups of Southern African and the lack of the mutation in other Black African groups 
previously studied suggest that the origin of the R563Q mutation in the South African 
Black population is the Khoisan. However, it needs to be acknowledged that 
alternative explanations as to the origins of the mutation are plausible and further data 
are required. 
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PART 3 
THE R563Q MUTATION AND FUNCTION OF 
THE SODIUM CHANNEL 
 
The Khoisan of Africa 
 A people requiring a sodium retentive genome 
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CHAPTER 7: 
The R563Q Mutation Alters Phenotype in the Setting of 
Chronic Hypertension 
 
INTRODUCTION 
Patients that come to the GSH Hypertension Clinic are refractory to the standard 
levels of care in the primary and secondary health care systems. As a result of 
uncontrolled hypertension there is a high prevalence of target organ damage in these 
patients. Assessing the clinical characteristics of patients attending the Hypertension 
Clinic may determine whether the presence of the R563Q mutation of the β-ENaC is 
likely to predict a difference in levels of target organ damage and so may differentiate 
patients with the R563Q mutation from patients with EHT. 
 
Intra- and inter-individual phenotypic variation increases the difficulty of assessing 
genetic polymorphisms. The index case with Liddle’s syndrome was described by 
Liddle [1963], who also examined family members. Each subject presented slightly 
differently, despite having the same mutation. The index case had severe hypertension 
and hypokalaemia with alkalosis at 16 when she presented with symptomatic 
hypokalaemia. Her brother was asymptomatic but at the age of 16 was examined by 
Liddle as part of a follow up on the index cases and her family. He was found to have 
similar BP and potassium levels as his sister did at presentation. Liddle also listed the 
BP and potassium levels of close relatives, illustrating considerable variation between 
individuals, within a family, heterozygous for the same mutation (R566X). This 
phenotypic variation has been seen in other families [Melander et al., 1998].  
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The original index case with Liddle’s disease developed chronic renal failure which 
responded well to renal transplantation [Botero-Velez, 1994]. After the 
transplantation her BP improved significantly, her aldosterone and renin levels 
returned to normal and she was normokalaemic. However, a biopsy of her kidneys did 
not reveal any major pathology and none of her family members developed renal 
failure. This case was a particularly severe presentation. Missense mutations outside 
the PY motif present with more subtle differences which, bearing in mind the 
differences in individuals with the R566X mutation, could be more difficult to 
illustrate.  
 
This inherited hypertensive disorder illustrated the variation in blood pressure and 
target organ damage. Hypertension is a vascular disorder resulting from disrupted 
homeostasis of vascular resistance, volume and, occasionally, viscosity. The effects of 
an increase in BP are global as the vascular system is an integral part of every organ. 
However, there are a few organs that are particularly affected by hypertension. The 
heart muscle pumps against the pressure within the vasculature and so muscle mass 
and dilatation of the heart are influenced by BP. The kidneys are the major control 
organ for BP as they excrete sodium and water depending on the volumes and 
concentrations within the nephron. The nephron is highly sensitive to BP variation 
excreting renin when the BP decreases, resulting in an increase in BP (described 
previously). 
 
In humans it is not possible to visualise the vasculature of the kidneys without an 
invasive procedure. It is however possible to see the vessels in the retina which give 
an indication of the effects of BP on the microvasculature. Thus, a clinical 
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examination detailing the retinal appearance of the microvasculature, the renal 
function (urea, creatinine and microalbumin-creatinine ratio) and the cardiac function 
(cardiothoracic ratio (CTR) and cardiac muscle hypertrophy) are considered good 
indicators of the effects of BP on microvasculature.  
 
Each patient that is referred to the Hypertension Clinic undergoes an initial 
biochemical assessment which created the opportunity to determine if there was a 
difference in these parameters. Alderman et al. [1995] showed that renin levels are 
directly proportional to myocardial events in hypertensive patients. An overactive 
sodium channel would tend to decrease the renin and aldosterone levels and increase 
the potassium levels possibly resulting in fewer coronary vascular events. Thus, 
analysing the differences between these biochemical parameters and the 
macrovascular complications of hypertension (IHD, cerebrovascular disease and 
peripheral vascular disease) in the patients attending the Hypertension Clinic may 
illustrate the effects of the mutation and help to predict the chronic effects of the 
mutation.  
 
Patients attending the Hypertension Clinic at GSH have access to amiloride, which is 
generally not available in South Africa as it is not registered in this country. 
Amiloride is brought into South Africa under section 21 of the Medicine Control Act. 
If a patient is confirmed to carry the R563Q mutation amiloride is added to their 
antihypertensive regimen. Amiloride is a potassium sparing diuretic which blocks the 
ENaC, decreasing sodium and water reabsorption [Rang et al., 1999]. 
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Thus, as part of this study, the aims were to determine the levels of target organ 
damage in chronic hypertensives heterozygous for the R563Q mutation and compare 
with hypertensives without the mutation. Additionally, the opportunity arose to 
determine if there was a difference in biochemical parameters in the groups and to 
determine if there was a significant response to amiloride. However, this assessment 
was in the presence of multiple antihypertensives. 
 
PATIENTS 
All the patients known to GSH that were heterozygous for the R563Q mutation were 
selected to be part of this retrospective analysis. Age matched controls were selected 
from the GSH Hypertension Clinic where all Coloured and Black African patients are 
routinely screened for the R563Q mutation. 
 
METHODS 
A retrospective analysis of the clinical characteristics of the index cases known to 
GSH Hypertension Clinic, compared with age- and sexed-matched patients without 
the mutation, was performed. Folders of the index cases were accessed and the 
clinical characteristics at the time of presentation were recorded. Age and sex 
matched R563Q normal controls were selected from the Hypertension Clinic and their 
clinical presentation was compared with those with the mutation. The concentrations 
of potassium, urea, creatinine, aldosterone and renin were determined from serum 
taken on referral. The aldosterone-renin ratio (ARR) was calculated from the 
measured values. Urine was analysed for albumin and creatinine concentrations and 
the microalbumin-creatinine ratio was calculated. 
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Sokolow-Lyon (SL) criteria were calculated from the electrocardiogram (ECG) as the 
amplitude of the S wave in millimetres in lead V1 plus the amplitude of the R wave in 
millimetres in either lead V5 or V6 (depending on which is the larger). The CTR was 
determined from the chest X ray as a ratio of the largest transverse diameter of the 
heart on the erect posteroanterior film compared with the inner diameter of the 
thoracic cage on the same film. BPs were recorded from the folders and MAP was 
calculated as one third of the pulse pressure plus the DBP. 
 
Results were converted to categorical variables. Left ventricular hypertrophy was 
determined by a Sokolow-Lyon value of greater than 35 and left ventricular 
enlargement is present if the CTR is greater than 0.5. Microalbuminuria was defined 
as a microalbumin-creatinine ratio between 3mg/mmol and 30mg/mmol and a ratio 
greater than 30mg/mmol was considered macroalbuminuria. A raised urea level was 
7mmol/l or more and a raised creatinine level was greater than 100µmol/l for females 
and greater than 120µmol/l for males. An aldosterone concentration of less than 
255pmol/l was defined as suppressed [Rayner et al., 2003].  
 
IHD was present if the patient reported having had an ischaemic event or if there were 
signs of IHD on the ECG (ST segment changes or q waves). The patient was defined 
as having had a cerebrovascular event if the patient reported an event or if clinical 
examination revealed neurological deficit suggestive of such an event. A history of 
peripheral vascular disease was present if the patient reported claudication, if they had 
had peripheral vascular surgery or the peripheral vasculature was compromised on 
examination. Signs of congestive heart disease were present if the patient had class 2 
or more dyspnoea according to the New York Heart Association classification, if 
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there were signs on physical examination or if there was evidence of pulmonary 
oedema on the chest X ray. Hypertensive retinopathy was present if there were signs 
of hypertensive vascular changes on fundoscopy. The GFR was calculated using the 
formula described in the Chapter 3. A GFR of less than 60ml/min/1.73m
2
 was 
classified as CKD. 
 
The response to amiloride was determined by recording the BP and potassium level 
from the first visit to the Hypertension Clinic and the latest recordings while taking 
amiloride. The mean change for all patients on amiloride was calculated.  
 
Continuous results that were not normally distributed were log transformed before 
analysis in order to allow analysis with the student’s t test. The groups were divided 
into those with and without pathology or abnormal criteria. This highlighted the 
difference between the groups.  
 
RESULTS 
Initially, 136 Caucasian hypertensive subjects were tested for the presence of the 
R563Q mutation but none were found to have the mutation [Rayner et al., 2003] so 
the presence of the mutation is not routinely determined in this population group. In 
total, 855 non-Caucasian patients have been tested for the mutation; 561 Coloureds, 
278 Black Africans and 16 of other ancestry. 44 patients attending the Hypertension 
Clinic were known to be heterozygous for the R563Q mutation; 18 (6.5%) Black 
African and 26 (4.6%) Coloureds. All these patients were selected for this analysis. 
Out of those known not to carry the mutation, 52 age matched control patients (563Q 
normal) were selected to compare with those carrying the mutation. Figure 7.1 shows 
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the percentages of patients who were receiving the various antihypertensives on 
referral to the Hypertension Clinic. The antihypertensives represent the treatment 
available for hypertension in the primary and secondary hospitals and could either be 
as a single agent or a fixed combination medication. Table 7.1 lists the quantitative 
variables that were assessed with the median and IQR as they deviated significantly 
from the normal distribution. The P values are means of the log transformed variables.  
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Figure 7.1. Percentages of patients taking the different antihypertensives on referral 
to the Hypertension Clinic 
(P=0.032 for loop diuretics and p=0.007 for central acting antihypertensives.) 
 
There was no significant difference between those with and without the mutation in 
the GSH Hypertension Clinic in age, renin, aldosterone and electrolytes; although, the 
potassium was slightly lower in the group with the R563Q mutation, and approached 
statistical significance (p=0.054). The urea and creatinine were significantly higher in 
the group with the mutation (p=0.016 and p=0.024 respectively) (Table 7.1). These 
two groups displayed a similar clinical picture. There was no significant difference in 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
 138 
BP between the two groups which is supported by the minimal difference in ECG 
Sokolow-Lyon criteria (showing cardiac hypertrophy) and CTR (showing 
enlargement). 
 
Table 7.1. Quantitative variables assessed 
  R563Q Heterozygous (44) R563Q Normal (52) P value* 
  N 
Median / 
Mean 
IQR / 
SD N 
Median /  
Mean 
IQR /  
SD   
Age**, y 44 53 14 52 52 14 0.385** 
Years on treatment 35 10 3;23  44 5 2;15 0.087 
Age at onset of HPT, y 36 39 31;45  44 38 30;44 0.617 
Aldosterone, pmol l-1 41 219 140;466 52 256 201;365 0.160 
Renin, mmol l-1 41 19 7;39 49 16 6;36 0.327 
Potassium**, mmol l
-1
 44 4.1 0.6 52 4.3 0.5 0.054** 
ARR 41 17.9 6.2;32.0 49 15.2 5.0;42.6 0.442 
ECG SL criteria, mm 36 28 25;40 50 34 23;41 0.405 
CTR 38 0.51 0.49;0.58 48 0.53 0.50;0.57 0.202 
albuminuria, mg mmol-1 35 3.0 0.9;26.5 47 4.4 0.8;12.5 0.167 
urea, mmol l
-1
 44 6.2 4.4;8.4 52 5.3 3.8;6.3 0.016 
creatinine, µmol l
-1
 44 101 74;118 52 82 74;98 0.024 
SBP, mmHg 44 160 150;192 52 170 150;191 0.324 
DBP**, mmHg 44 102 23 52 101 19 0.423** 
MAP**, mmHg 44 125 24 52 125 20 0.436** 
Footnote: N, number of individuals assessed for each variable; ARR, aldosterone 
renin ratio; SL, Sokolow Lyon criteria; ECG, electrocardiogram; CTR, cardiothoracic 
ratio; BP, blood pressure; MAP, mean arterial pressure; HPT, hypertension. *P 
values were calculated after log transformation. **Normally distributed variables with 
means ±SD and p values calculated from original data. 
 
Table 7.2 shows the presence of pathology in the heterozygous and normal groups. 
The markers of renal function (urea, creatinine and GFR) all indicate that the renal 
function in those patients with the mutation was worse than those without the 
mutation. There was a difference in small vessel damage, as seen by the larger 
numbers of those with hypertensive retinopathy, in the normal group, but this did not 
reach statistical significance (p=0.063) for presence of hypertensive retinopathy of 
any grade. The trend across grades of hypertensive retinopathy was different 
(p=0.007) (Figure 7.2). 
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Table 7.2. The frequency of pathology in relation to the R563Q mutation 
 Total Heterozygous (%) Normal (%) P value 
ECG LVH 34 13 (36) 21 (42) 0.582 
Left Ventricular Enlargement 49 19 (50) 30 (63) 0.245 
Albuminuria (>3.5mg/mmol) 44 17 (53) 27 (57) 0.425 
Microalbuminuria 33 11 (32) 22 (48) 0.241 
Macroalbuminuria 11   6 (18)   5 (11) 0.347 
Urea (>7mmol/l) 27 18 (41)   9 (17) 0.010 
Elevated Creatinine 23 14 (32)   9 (17) 0.045 
Ischaemic Heart Disease 23   7 (17) 16 (31) 0.089 
Cerebrovascular Event   9   4 (10)   5 (10) 0.635 
History of Peripheral Vascular Disease   3 0 3 (6) 0.165 
Hypoaldosteronism (<255pmol/l) 53 27 (66) 26 (50) 0.125 
Hypertensive Retinopathy 61 26 (70) 35 (88) 0.063 
Signs of Congestive Cardiac Failure 18 10 (24)   8 (15) 0.204 
GFR<60ml/min/1.73m
2
 24 15 (34)   9 (17) 0.029 
Footnote: GFR, glomerular filtration rate 
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Figure 7.2. Grade of hypertensive retinopathy between heterozygous (blue) and 
normal (red) patients. The p value is for the difference in trend between the groups. 
 
Microvascular disease was present in a large portion of the entire group (70% of the 
heterozygotes and 86% of the normal) suggesting long standing hypertension. There 
were two patients heterozygous for the R563Q mutation who underwent a renal 
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transplant as a result of CKD. These two patients were excluded and the analysis 
repeated to determine if this altered the results (Table 7.3). Removing these two 
patients decreased the differences in GFR but the heterozygous group had persistently 
elevated urea levels and less overall retinopathy. 
 
Table 7.3. Variables without the patients who received a renal transplant 
  Heterozygous Normal P value 
  Median (IQR) Median (IQR)   
Potassium, mmol l
-1
 4.2 (3.7;4.3) 4.3 (3.9;4.6) 0.025* 
Urea, mmol l
-1
 6.0 (4.3;8.1) 5.3 (3.8;6.2) 0.045* 
      
  Number (%) Number (%)   
Elevated Urea 16 (38) 9 (17) 0.023 
Decreased GFR 13 (31) 9 (17) 0.120 
Retinopathy 24 (69) 35 (88) 0.046 
*P values for log transformed data 
 
Twenty two heterozygous patients were taking amiloride as part of their 
antihypertensive regimen. The average decrease in BP (Table 7.4) for all the patients 
on amiloride was 36/17mmHg, (p<0.0001 for SBP and DBP). Nine of these patients 
reached the target blood pressure on this treatment regimen. Furthermore, the patients 
with measured potassium levels increased while on amiloride (0.6mmol/l, p=0.002) as 
was expected of an agent that inhibits sodium channel activity. 
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Table 7.4. Summary of BP and potassium levels at presentation and on amiloride 
treatment 
 Initial Latest Change 
Patient 
BP, 
mmHg 
Potassium, BP, 
mmHg 
Potassium, BP, 
mmHg 
Potassium 
mmol l-1 mmol l-1 mmol l-1 
1 172/86 4.9 126/60 5.3 46/26 0.4 
2 160/100 3.7 148/80  12/20   
3 169/91 3.0 135/82 3.8 34/9 0.8 
4 180/130 4.2 138/110  42/20   
5 160/90 3.7 118/85 4.1 42/9 0.4 
6 154/96 4.7 114/80  40/16   
7 176/100 3.9 139/82 4.6 37/18 0.6 
8 222/100 4.2 153/85 4.4 69/15 0.2 
9 210/92 2.9 152/75 3.5 58/17 0.6 
10 142/90 4.2 140/95 5.0 2/+5 0.8 
11 180/110 3.6 148/85 3.9 32/25 0.3 
12 190/90 3.9 110/69 4.1 80/21 0.2 
13 210/90 4.2 162/65 5.2 48/25 1.0 
14 137/94 4.4 132/90 4.5 5/4 0.1 
15 162/100 4.1 128/78 6.6 34/22 2.5 
16 208/130 3.7 149/101 4.4 59/29 0.7 
17 153/95  133/84  20/11 0.0 
18 142/99 3.8 146/80 4.1 +4/19 0.3 
19 144/94 4.3 104/70 5.3 40/24 1.0 
20 180/115 3.7 142/94 4.8 38/21 1.1 
21 169/90  140/68  29/22 0.0 
22 190/104 4.1 140/85 4.3 50/19 0.2 
Mean 172/99 4.0 136/82 4.6 37/17 0.6 
 
DISCUSSION 
This thesis has analysed the differences in clinical and laboratory characteristics 
between the heterozygous and normal patients presenting to the Groote Schuur 
Hypertension Clinic. Patients that attend the clinic are likely to have a similar history 
of prolonged hypertension resistant to the standard secondary level care for high 
blood pressure. This was found to be true. The patients heterozygous for the R563Q 
mutation had been hypertensive for a median of ten years and the normal patients for 
five years, but this difference was not significant. All the medications were being 
taken by similar percentages in the normal and heterozygous patients except for the 
central acting antihypertensives (more for normal patients) and loop diuretics (more 
for heterozygous patients). Resistant hypertension and the presence of multiple 
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antihypertensive medications provide a similar environment in which to compare 
subjects with and without the R563Q mutation. The two groups were well matched 
for age and gender. 
 
These data suggest that individuals heterozygous for the R563Q mutation with 
hypertension are more susceptible to CKD. The mean BP for the patients in this 
analysis did not reach target levels and inadequately treated hypertension has been 
shown to be associated with elevated creatinine levels and a decrease in renal function 
[Coresh et al., [2001]. The heterozygous patients did not have mean BP significantly 
different from those patients without the R563Q mutation but more heterozygous 
patients had an estimated GFR suggestive of CKD than those without (34% vs. 17%, 
p=0.029). The urea supported the difference in GFR but there was no difference in the 
presence of albuminuria (Table 7.3). Thus, despite similar degrees of hypertension, 
the patients attending the hypertension clinic that were heterozygous for the R563Q 
mutation had an increased prevalence of CKD.  
 
Heterozygous patients had higher urea and creatinine levels than those without the 
mutation, but this could be due to the selection criteria. All heterozygous patients that 
are known to GSH were assessed. The patients that were selected for comparison 
were hypertensive patients attending the Hypertension Clinic who had been tested for 
the mutation. None of the comparative patients had been through other units whereas 
two patients with the mutation had had kidney transplants and others had been 
referred to the clinic for investigation for Liddle’s syndrome. Selecting all the patients 
with the mutation may have lead to bias. When the two transplant patients were 
excluded from the analysis the difference in renal function decreased between the two 
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groups. The GFR indicating CKD was no longer different between the groups but the 
presence of a raised urea was still significantly higher in the heterozygous group. 
Interestingly, the difference in potassium levels became significant when the two 
transplant patients were excluded: the heterozygous group had a lower potassium 
level than those without the mutation. CKD requiring a transplant is likely to increase 
the potassium level. The potassium in the transplant patients was in the upper range of 
the normal levels, which could account for the difference when they were excluded.  
 
Saydah et al. [2007] reported the prevalence of CKD, from the NHANES data, to be 
16.8% of the adults in the United States, between 1999 and 2004. CKD was higher in 
the Black African population (19.9%) and cardiovascular disease and diabetes were 
the major contributing factors. Afshar et al. [2007] reported that hypertension was the 
cause of CKD in 13.5% of cases in Iran and that hypertension, for more than five 
years, was associated with smaller kidneys. Data for South Africa [Naicker, 2003] are 
lacking but the higher prevalence in the Black Americans suggests that chronic renal 
disease could be linked to different population groups. The prevalence of the R563Q 
mutation, and its association with hypertension, may explain some of the CKD in the 
South African population. The mutation appears to be associated with renal disease in 
this cohort. Further support for this is that two patients with the mutation required 
renal transplantation for end stage renal disease.  
 
Rayner and Becker [2006] found that microalbuminuria was present in 25.4% of 
hypertensives in private practices in Cape Town which is lower than the 41% present 
in the group of hypertensive patients analysed here. Patients referred to GSH all 
present with severe resistant forms of hypertension which could explain this 
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difference. The presence of CKD would tend to increase the potassium level in these 
patients. Despite this the potassium level was lower in the heterozygous group, 
possibly supporting the hypothesis that the mutation influences sodium channel 
activity. 
 
Renin and aldosterone levels and the presence of hypoaldosteronism were not 
significantly different between the groups. However, these serum levels were 
determined while patients were taking their antihypertensive treatment which 
influences the levels. Traditionally, increased plasma renin activity has been 
associated with deteriorating renal function [Baldoncini et al., 1999] and inhibition of 
the RAAS has been shown to improve renal function [Furumatsu et al., 2008]. In 
some subjects treated with RAAS inhibitors a phenomenon was observed where 
aldosterone levels increased after the initial suppression. This ‘aldosterone escape’ 
was associated with a decline in GFR [Schjoedt et al., 2004]. In this data set there is 
no evidence to suggest that heterozygous subjects are more likely to exhibit this 
phenomenon; both groups had similar levels of aldosterone and renin after similar 
periods on treatment. Despite the similarities the heterozygous group presented with 
more renal impairment and lower potassium levels which would support an increase 
in ENaC activity. However, the increased use of loop diuretics in the heterozygous 
group distorts the effects the mutation could have on the potassium level. 
 
It is interesting that the heterozygous subjects were prescribed more loop diuretics as 
a group. This could be a reflection of the poorer renal function in this group. As the 
renal function decreases thiazide diuretics are less effective and patients are changed 
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to loop diuretics. It could also be the result of fluid retention but there was no 
difference between the groups in prevalence of signs for congestive cardiac failure. 
 
The heterozygous group appears to have lower levels of microvascular disease, as 
evidenced by less hypertensive retinopathy, 70% vs. 86%, but this was not 
statistically significant (p=0.063). It did become significant when the two patients 
requiring a renal transplant were removed from the analysis because they both had 
grade III hypertensive retinopathy (p=0.046). The trend for hypertensive retinopathy 
was also different between the groups (Figure 7.2) and retinopathy is an independent 
predictor of damage due to BP [Duncan et al., 2002]. In a group of Nigerian 
hypertensives [Nwankwo et al., 2007] hypertensive retinopathy was found to be a risk 
factor for the development of impaired renal function so it was predicted that the 
heterozygous group would have greater levels of hypertensive retinopathy when they 
were found to have more CKD. Unexpectedly, this was not the case. A possible 
explanation for this is a protective effect during the initiation of the disease. 
Treatment would distort the biochemical picture at the time of analysis, but before 
treatment there may have been considerable differences in the renin and aldosterone 
profiles, as suggested by the analysis in Chapter 8. 
 
Despite the microvascular differences the macrovascular events did not differ greatly 
between the two groups, but the normal group did have more events. 31% of the 
normal group had a history of IHD compared with 17% of the heterozygotes. There 
was no difference in those who had had strokes (for which hypertension is the 
commonest risk factor in South African general practice [Connor et al., 2005]) and 
very few overall reported a history of peripheral vascular disease. Overall, 40% of this 
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group had ECG criteria for left ventricular hypertrophy. Again, this is much higher 
than the group studied by Rayner and Becker [2006] (18.9%), probably for similar 
reasons. These results suggest that there is not a significant difference between the 
heterozygous and normal patients in the presence of vasculopathy. 
 
Studies assessing the differences in biochemical and physical parameters between a 
mutation and the normal variant are scarce due to the low numbers of sodium channel 
mutations found at high frequencies. Staessen at al. [1999] conducted a meta-analysis 
of the literature on the M235T variant of the AGT gene. They found that the T allele 
was associated with hypertension but not with atherosclererotic or microvascular 
disease, including renal disease. This meta-analysis illustrates the difficulties of 
associating point mutations with disease. The T594M and G442V mutations were also 
found at high frequencies in the African population in London and Dong et al. [2001] 
tried to determine if the BP and biochemical parameters between those with and 
without these mutations were different. They showed that the T594M mutation was 
associated with hypertension but there was no difference in electrolytes, creatinine 
and renin and aldosterone and the variants did not appear to interact. The association 
with hypertension of the T594M mutation was not replicated in South Africa [Nkeh et 
al., 2003]. This could indicate that the T594M mutation is in LD with another 
mutation in the sodium channel in the African population in London but not with the 
South African Black African population. 
 
This analysis was in treated hypertensive patients, which distorts the picture when 
trying to determine a difference in the biochemical parameters affected by sodium 
channel activity. However, determining the difference in biochemical parameters in 
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this environment was expected to be complicated by the presence of antihypertensive 
medications and from this additional analysis no definite conclusions were drawn. 
 
Initially, on observing the BP of the R563Q heterozygous patients in response to 
amiloride, it appeared that amiloride had a significant effect on hypertensives with the 
R563Q mutation. However, the patients at the Hypertension Clinic are referred for 
specialist opinion as the secondary hospitals have not managed to control the BP with 
the standard antihypertensives available. The secondary hospitals are inundated with 
patients and often do not have the time to give a full assessment or give the required 
lifestyle change advice. When patients arrive at GSH they are given a full 
examination and biochemical assessment. If there are any indications patients are 
investigated for secondary causes of hypertension. Lifestyle modification advice is 
given at the Hypertension Clinic and most patients are seen by a dietician. The 
patients are given optimal antihypertensive medication at the correct doses and 
schedules.  
 
Amiloride has been suggested as the specific drug treatment for subjects with 
mutations in the sodium channel [Baker et al., 2002]. Those authors found that 
subjects with the T594M mutation of the β-ENaC had similar BP on amiloride when 
compared with two drugs. When the amiloride was stopped the BP increased 
significantly (17/8±4/2mmHg) and returned to within normal ranges (140/88mmHg) 
after the amiloride was restarted. This decrease in BP is less than the observed 
decrease in BP of the subjects presented here.  
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Carter et al. [2001] studied the effects of amiloride on nine subjects with refractory 
hypertension. These subjects were given add-on therapy for two weeks of 5mg 
amiloride daily and then two weeks of 5mg amiloride twice a day. The BP was 
determined at the beginning of the trial and after the amiloride treatment. An 
independent electrophysiological analysis divided these subjects into a group of three 
subjects with a hyperactive ENaC and six subjects with normal ENaC activity. Those 
subjects with the hyperactive ENaC had a significant decrease in BP 
(24/15±7/6mmHg). Those with normal ENaC activity did not have a significant 
decrease in BP. This confirms that amiloride is specifically useful in subjects with 
increased sodium channel activity. This study, similar to the cases presented here, was 
add-on therapy but the mean decrease in BP was even greater in the cases presented 
above. 
 
Another study [Saha et al., 2005] found that amiloride, as add-on therapy (to a 
calcium channel blocker and a diuretic) for nine weeks, significantly decreased the BP 
by 9.8/3.4±1.6/1.0mmHg. This was part of a randomised double blind trial and 21 
subjects were included in this arm. The patients with the R563Q mutation had a 
decrease in BP of 36/17mmHg, but this was not a controlled analysis and other 
treatments were instituted. It is interesting that the decrease in BP in all three studies 
presented here for subjects on amiloride was less than the decrease observed in the 
subjects with the R563Q mutation. 
 
CONCLUSION 
Patients heterozygous for the R563Q mutation with severe hypertension appear to be 
more susceptible to CKD compared with age and sex matched patients with severe 
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hypertension. The R563Q mutation does not allow differentiation between EHT and 
LRHT at initial biochemical assessment while chronically treated patients are on 
medication. The presence of the mutation does not predict increased vascular or 
cardiac disease, but there may be a protective effect resulting in a lower prevalence of 
hypertensive retinopathy than expected. Furthermore, there is a clinically significant 
decline in BP for R563Q heterozygous patients on amiloride that warrants a 
controlled clinical trial to assess the true effect of amiloride on subjects with the 
mutation. 
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CHAPTER 8 
Electrolyte Excretion and Blood Pressure Response to an 
Acute Saline Challenge 
 
INTRODUCTION 
The high prevalence of the R563Q mutation in hypertensives suggests that it is an 
activating mutation. The susceptibility for hypertension is thought to be due to an 
increased propensity to reabsorb sodium. Thus, the aim was determine if there was a 
difference in response to sodium challenge between R563Q heterozygous and normal 
subjects suggesting that the sodium channel is overactive in the presence of the 
R563Q mutation. 
 
Most authors [Overlack et al., 1993; Poch et al., 2001; Gill et al., 1991] have defined 
salt sensitivity in terms of BP response to acute or chronic sodium restriction or 
loading. In other words, in salt sensitive individuals BP drops to a greater extent 
during times of restriction and rises to a greater extent during salt loading. In terms of 
feasibility of assessing salt sensitivity, chronic salt loading or restriction over two to 
four weeks will be fraught with problems in controlling sodium intake outside the 
premises of metabolic units, unless there is very strict supervision of the diet.  
 
Weinberger et al. [2001] proposed that salt sensitivity should be determined by the BP 
response to acute intravenous sodium loading followed by acute deprivation and 
diuresis. He suggested that a decrease in MAP of 10mmHg or more between the BP at 
the end of salt loading and the end of salt deprivation as salt sensitive and a difference 
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of less than 5mmHg as salt resistant. Between these values was defined as 
indeterminate. The use of BP in defining salt sensitivity (while important) is fraught 
with problems related to measurement and variability of BP requiring large numbers 
of subjects. Furthermore it is not a direct measurement of sodium channel activity. 
Rydstedt et al. [1986] used an acute saline challenge to show that individuals with 
EHT had blunted natriuresis. The saline suppression test is used to diagnose primary 
aldosteronism [Mulatero et al., 2006], suggesting that this test is a valid means of 
illustrating salt sensitivity. 
 
It is important to assess a mutation in vivo as this is where the potential effects of a 
mutation exist. In vitro analyses are important to determine how a mutation 
potentially alters protein activity but any functional effect of the mutation is within 
the cells in which the protein is expressed. Hence the importance of the saline 
challenge. The effect of a mutation can also be a long term cumulative effect which 
will not be evident in a once off functional measurement of, for example, a single 
cell’s sodium current. (This is a method used to illustrate alterations in sodium 
channel activity.) The sodium excretion, BP response, renin and aldosterone were 
assessed during an acute saline challenge in order to determine if the mutation created 
an environment sensitive to sodium. Analysing sodium excretion creates the 
opportunity to focus on the underlying pathophysiological mechanisms. The subjects 
with the R563Q mutation were expected to excrete less sodium, more potassium and 
have a decreased urinary sodium-potassium ratio due to intrinsically increased sodium 
channel activity. In addition, baseline aldosterone levels would be significantly lower 
and suppress more after the saline challenge.  
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METHODS 
Subjects over 21 years of age, whose R563Q status was known from previous studies, 
[Rayner et al., 2003; Family analysis, Chapter 4], were contacted. Patients were 
excluded if they had a known history of cardiac or renal disease; were taking 
antihypertensives to avoid the effects of these drugs on sodium excretion and the 
RAAS; or had severe hypertension with a SBP greater than 180mmHg or a DBP 
greater than 100mmHg at commencement of the challenge. All subjects gave signed 
informed consent for the procedure (Appendix III). 
 
All subjects fasted from 22.00 hours on the evening before the challenge until the end 
of the procedure, to standardise sodium intake. Ad libitum water was allowed until an 
hour before the procedure to maintain hydration. During the challenge the subjects 
remained strictly nil by mouth until completion.  
 
On arrival a brief history was taken, and subjects had their height and weight 
measured, bladders were emptied and urine was analysed with hand-held rapid tests 
(Dipstix
®
) to determine the presence of protein and blood. Subjects were then 
allocated a bed and an individual number. After 10 minutes at rest patients had their 
BP measured and the mean of three readings was recorded. Blood was taken for 
electrolytes, creatinine, renin and aldosterone. A litre of 0.9% sodium was infused 
over 60 minutes.  
 
BP was measured every hour for four hours after the start of the procedure. The mean 
of three stable readings was recorded. After one hour bladders were emptied again 
and the volume measured. Urine was taken for analysis. A second litre of 0.9% 
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sodium was infused over 60 minutes. Two hours after the start of the procedure the 
drip was removed, bladders emptied and volumes recorded. Urine was sent for 
analysis to determine sodium, potassium and creatinine levels, and blood creatinine 
and electrolyte concentrations were measured. 
 
After three hours bladders were emptied, volume measured and urine sent for 
analysis. At four hours blood was taken for renin and aldosterone levels. Again 
bladders were emptied, volume measured and urine sent for analysis. Subjects were 
discharged. A summary of the saline challenge measurements is given in Figure 8.1. 
 
 
Figure 8.1. Summary of measurements at each time interval. Arrows indicate 
initiation of each litre of normal saline and the black bar indicates when the infusion 
stopped. (U&E, urea, electrolytes and creatinine; A&R, aldosterone and renin) 
 
Continuous variables that were not normally distributed were log transformed before 
analysis with the student’s t test and assessing in the multivariate analysis. In the 
tables the medians and IQR are shown for data that were not normally distributed and 
in the graphs means and standard deviations are displayed in order to ensure 
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consistency. The differences between the variables in the heterozygous and normal 
groups were compared. Paired samples T test was used to compare the differences 
between baseline and measurements during the challenge of serum electrolytes and 
renin and aldosterone levels. General Linear Models were fitted to compare the 
response to saline in electrolytes and renin and aldosterone between the heterozygous 
and normal groups. Pillai’s Trace Test from the Repeated Measures Analysis was 
used to assess the significance of differences between groups and to indicate power. 
 
RESULTS 
The baseline characteristics of the groups with and without the R563Q mutation are 
shown in Table 8.1. Twenty four subjects completed the study and were analysed; 13 
(54%) individuals were heterozygous for the R563Q mutation and 11 (46%) were 
normal; 15 (63%) subjects were male and 23 (96%) were Coloured. Two subjects 
from each group were found to be hypertensive at initial assessment and were advised 
accordingly. 
 
Table 8.1. Baseline characteristics of the heterozygous and normal groups  
R563Q Heterozygous (13) Normal (11) P value 
 
Mean / 
Median* 
SD / 
IQR 
Mean / 
Median* 
SD / 
IQR  
Age, y 35 30;40 33 24;37 0.970* 
Height, cm 172.5 9.44 164.5 9.903 0.060 
Weight, kg 75 58;90 73 59;80 0.670* 
BMI, kg m-2 24.6 5.4 26.18 5.65 0.500 
SBP, mmHg 135 139;142 134 126;144 0.836* 
DBP, mmHg 82 77;92 81 74;88 0.580* 
MAP, mmHg 99 97;109 98 92;109 0.680* 
Pulse, b min-1 62 61;70 70 64;80 0.076* 
Potassium, mmol l-1 4.1 0.4 4.3 0.3 0.101 
Sodium, mmol l
-1
 141.5 1.8 139.6 1.8 0.017 
Aldosterone, pmol l
-1
 217.2 120.8 332.8 153.8 0.051 
Renin, mmol l-1 9.8 6.5;27.5 22.6 16.3;38.3 0.081* 
Creatinine, µmol l-1 72 14 69 14 0.606 
BMI, body mass index; *P values were calculated from log transformed data and 
medians and IQR are displayed. 
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Sodium Handling 
The serum sodium levels at the start and end of the infusion were significantly higher 
in those with the mutation (Table 8.2). This was despite the similar urinary sodium-
creatinine ratio between the groups (the means were 23.8±13mmol/l for the 
heterozygotes and 29.4±18.3mmol/l for the normal group). The change in serum 
sodium during the challenge was significantly different between those with and 
without the mutation (p=0.001). Throughout the challenge the serum sodium was 
higher in the heterozygotes (Figure 8.2 A). The difference in serum sodium was 
exacerbated by the infusion of sodium indicating that those with the mutation were 
less able to handle the sodium load. The urinary excretion of sodium at each time was 
not significantly different between the groups (Table 8.3). 
 
Table 8.2. Serum sodium at the start and completion of the saline infusion 
 R563Q Heterozygous (13) R563Q Normal (11) P Value 
Hour Mean ± SD, mmol l-1 Mean ± SD, mmol l-1  
0 142±1.81 140±1.8 0.020 
2 143±2.06 141±1.76 0.008 
 
Table 8.3. Urinary Excretion of Sodium during the saline infusion 
  R563Q Heterozygous (13) R563Q Normal (11)   
Hour Median (IQR), mmol Median (IQR), mmol P Value* 
1 19.8(6.1;32.9) 17.4(11.5;34.2) 0.305 
2 46.5(14.8;70.5) 24.0(19.6;50.1) 0.052 
3 44.0(17.1;53.2) 23.4(12.5;43.9) 0.093 
4 38.7(21.0;45.9) 23.1(17.6;26.5) 0.458 
Total** 156.4 (77.9;194.4) 83.1(70.4;151.2) 0.099 
*P values calculated from log transformed data. ** Total sodium excreted during the 
challenge. 
 
The total urinary excretion of sodium (p=0.004 for trend) was higher in the group 
with the mutation (Figure 8.2 B). Throughout the four hours the heterozygous group 
excreted more sodium and the sodium excretion plateaued when the infusion was 
stopped. In contrast the normal group had a blunted natriuretic response to the saline 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 156 
challenge, compared with the heterozygotes and sodium excretion declined in the two 
hours after the infusion was discontinued. The sodium-potassium ratio was also 
significantly higher in the heterozygotes (p<0.0005 for trend). 
 
Figure 8.2. Serum (A) and urinary (B) sodium levels during the saline challenge with 
standard deviations (SD) (Subjects heterozygous for the mutation are shown in blue 
and the normal subjects are shown in red, p values are for trend, as assessed by the 
general linear model. This will apply to all the figures in this chapter.) 
 
 
Figure 8.3. Relationship of sodium with interquartile ranges (IQR) to potassium 
excretion during the saline challenge 
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Potassium Handling  
Serum potassium levels at the start and end of the infusion were not different between 
the groups. Similarly potassium excreted at each hour during the infusion was not 
different between the two groups except for an isolated difference at four hours when 
the excreted potassium was higher in the heterozygous group (p=0.047) (Table 8.3). 
However there was no difference in the total amount of potassium excreted between 
the groups (Figure 8.4). Thus the highly significant difference in sodium-potassium 
ratio (p<0.0005) (Figure 8.3) was likely to be the result of the difference in excreted 
sodium.   
Table 8.4. Total potassium excreted during the saline infusion 
 R563Q Heterozygous (13) R563Q Normal (11)  
Hour Median (IQR), mmol Median (IQR), mmol P Value* 
1 4.1 (2.3;8.0) 4.4 (3.0;6.4) 0.756 
2 6.9 (3.7;7.8) 5.7 (3.3;6.8) 0.843 
3 5.4 (3.6;6.6) 6.8 (2.5;8.2) 0.972 
4 6.4 (4.7;7.7) 4.3 (3.1;5.5) 0.047 
Total** 26.1(16.4;29.8) 19.3(9.7;30.5) 0.176 
*P values calculated from log transformed data. ** Total potassium excreted during 
the challenge. 
Figure 8.4. Comparison of potassium handling during the saline challenge. (A) 
Measured serum potassium levels, (B) Calculated excreted potassium, with IQR. 
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 Aldosterone and Renin 
The aldosterone concentration was lower in the heterozygous group at the start of the 
saline infusion and the difference approached statistical significance (Table 8.4). The 
difference in aldosterone was less marked at the end of the study but the overall trend 
during the study between the groups was highly significant (p<0.0005) (Figure 8.5), A 
similar trend was seen with plasma renin except the control group had a greater 
suppression at 4 hours (Table 8.4 and Figure 8.5). 
Table 8.5. Aldosterone and renin levels and ratio at the start and finish of the 
challenge 
  R563Q Heterozygous (13) R563Q Normal (11)  
 Hour 
Mean ±SD / 
Median (IQR)*  
Mean ±SD / 
Median (IQR)* P value 
Renin, mmol l-1 0 9.8 (6.5;27.5) 22.6 (16.3;38.3) 0.081* 
Aldosterone, pmol l
-1
 0 217.2±120.7 332.8±153.8 0.051 
Renin, mmol l-1 4 8.9 (6.5;9.7) 6.1 (5.1;8.7) 0.321* 
Aldosterone, pmol l-1 4 59 (55;64) 70 (47;86) 0.167* 
*P value calculated from log transformed data with medians and IQR’s. 
 
 
Figure 8.5. Serum renin (A) and aldosterone (B) levels with IQR during the challenge 
 
Volumes 
Some subjects were not able to pass urine at each time point. The urine volume and 
electrolyte concentrations were recorded as zero for that time point and were excluded 
from the calculation of the mean. The volumes excreted at each time point were 
0 4
Tim e, h
0
100
200
300
400
500
A
ld
o
s
te
ro
n
e
, 
p
m
o
l 
l-
1
p<0.0005
0 4
Tim e, h
0
10
20
30
40
50
R
e
n
in
, 
m
m
o
l 
l-
1
p<0.0005A B 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 159 
similar except at 4 hours, when the heterozygous subjects excreted a significantly 
higher volume (Table 8.5). The total volume excreted as a fraction of the volume 
infused was not different between the groups. The total output for both groups was 
similar.  There was a significant difference in the way the volumes were excreted 
(p=0.001 for trend) during the four hours (Figure 8.6).  
Table 8.6. Urine volumes excreted at each hour and the fraction of infused fluid 
excreted 
 R563Q Heterozygous (13) R563Q Normal (11) P Value* 
Hour Median (IQR), ml Median (IQR), ml  
1 170 (90;310) n=12 135 (70;205) n=10 0.388 
2 330 (130;475) 338 (153;488) n=10 0.841 
3 290 (85;340) 205 (90;305) 0.499 
4 180 (110;260) 100 (88;110) 0.036 
Total 1000 (440;1405) 750 (380;1055) 0.461 
Fraction 0.5 (0.2;0.7) 0.4 (0.2;0.5) 0.398 
Footnote: Where the number of samples differs from the total number of participants 
the different ‘n’ is shown. * P values for log transformed data. 
 
 
Figure 8.6. Volumes excreted with IQR, over the four hours after the start of the 
saline infusion. 
 
The heterozygotes had a steady increase in urine output during the infusion, whereas 
the normal group were initially slower but the excretion was equal by the time the 
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infusion ceased. The normal group had a steeper response to the fluid infusion with 
greater a decline after cessation of the fluid infusion.  
 
Blood Pressure and Pulse 
Baseline BP was not different between the groups and there was no rise in BP in 
response to saline infusion in either group. There was a possible trend for higher SBP 
and DBP in the heterozygotes (figure 8.7) during the experiment. Interestingly there 
was a lower pulse rate in the R563Q heterozygous subjects at baseline and this trend 
became highly significant throughout the study. (p=0.002 for trend) (Figure 8.8). 
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Figure 8.7. BP changes with IQR at each hour during the saline challenge 
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Figure 8.8. Pulse with IQR at each hour during the saline challenge 
 
Summary 
The difference between serum concentrations in electrolytes and aldosterone and 
renin levels from the start and the second measurement between the groups are shown 
in Table 8.6. Table 8.7 summarises the results from the saline challenge and presents 
the power for each analysis. 
Table 8.7. Paired samples T test P values 
 
R563Q 
Heterozygous 
R563Q 
Normal 
Aldosterone 0,4, pmol l
-1
 <0.0005 <0.0005 
Renin 0,4, mmol l
-1
 0.031 <0.0005 
Sodium* 0,2, mmol l
-1
 0.005 0.075 
Potassium* 0,2, mmol l-1 0.195 0.578 
 
Table 8.8. Summary of saline challenge results 
Variable 
Time 
point 
R563Q 
heterozygous GLM p value 
Observed 
Power 
Serum sodium, mmol l-1 0, 2 ↑, ↑   0.001 0.946 
Excreted sodium, mmol     0.004 0.668 
Urinary sodium-potassium ratio   <0.005 0.997 
Serum potassium, mmol l-1     0.207 0.240 
Excreted potassium, mmol 4 ↑   0.945 0.087 
Serum renin, mmol l-1   <0.005 0.986 
Serum aldosterone, pmol l-1   <0.005 1.000 
Urine volumes 4 ↑   0.001 0.954 
SBP, mmHg     0.065 0.558 
DBP, mmHg     0.083 0.526 
Pulse, b min-1 1 ↓   0.002 0.968 
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Footnote: The table displays the time point at which the variable was significantly 
different between the groups and whether the subjects with the mutation had a mean 
that was significantly higher (↑) or lower (↓) at that time point. The p value is for the 
difference assessed by the general linear model (GLM) between the groups. 
 
DISCUSSION 
The patients from the Hypertension Clinic are poorly controlled hypertensives with 
target organ damage. These patients were unable to participate in the saline challenge 
due to renal failure, congestive cardiac failure or the inability to stop their 
antihypertensive medication. It was, however, possible to find members of their 
families with the R563Q mutation and other people not being treated for hypertension 
in whom it was possible to infuse two litres of a 0.9% sodium solution. The saline 
challenge described the biochemical differences in response to an acute saline 
challenge between the heterozygotes and normal subjects. The saline challenge tested 
for salt sensitivity in an out-patient setting as it only required the subjects to be in the 
hospital for four hours. It also created the opportunity to measure the physiological 
determinants of salt sensitive BP. There was a significantly different response to 
saline between those with and without the mutation, the results of which are 
summarised in Table 8.7. 
 
The salient findings in the saline challenge were: 
1. At baseline  
 The BPs were similar between the normal and heterozygous subjects 
(p=0.836 for SBP and p=0.580 for DBP). 
 The pulse rate was lower in the heterozygotes (borderline significant, 
p=0.076). 
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 Serum sodium was significantly higher in the heterozygotes (p=0.017). 
 Serum aldosterone was lower in the heterozygotes (borderline significant, 
p=0.051). 
 There was no difference in serum potassium (p=0.101). 
2. During the challenge 
 There was no rise in BP after saline challenge in either group and there 
was no significant differences in BP during the experiment (p=0.065 for 
SBP and p=0.083 for DBP). 
 The pulse was significantly different due to the infusion (p=0.002). 
 The aldosterone level was suppressed to a greater degree in the normal 
subjects during the infusion (p<0.0005). 
 The sodium excretion (p=0.004) and sodium-potassium ratio (p<0.0005) 
were higher in the heterozygotes, contrary to expectations. 
 Potassium excretion was higher four hours into the saline challenge in the 
heterozygotes (p=0.047), but overall potassium excretion was the same. 
 
The saline challenge was performed on subjects who were normotensive or never 
treated mild hypertensives as many antihypertensives interfere with the RAAS, 
altering the response to saline and renin and aldosterone concentrations. This would 
also tend to reduce the differences in BP between the groups. The mean baseline BP 
was within the normal range (138±14/85±11mmHg for the heterozygous group and 
136±21/82±13 mmHg for the normal group) and only two subjects in each group 
were found to be hypertensive. In addition vascular changes resulting from long 
standing severe hypertension were not expected to influence the response to the saline 
infusion or any baseline differences between the groups. 
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The baseline results in this experiment are very suggestive of innate overactivity of 
the ENaC and chronic sodium overload in the R563Q heterozygous group. Despite no 
difference in baseline sodium levels intake as determined by urinary sodium-
creatinine ratio the baseline serum sodium was significantly higher and the plasma 
aldosterone concentration suppressed. The significantly lower pulse rate could be 
explained by reduced sympathetic and increased vagal tone due to stimulation of 
baroreceptors in response to sodium overload. Furthermore during the challenge the 
aldosterone levels were suppressed and the serum sodium level increased to a greater 
degree in the heterozygous group. The change in serum potassium was not significant 
during the saline infusion between the two groups. Neither was there a difference 
within each group between the serum potassium levels at the beginning and the end of 
the infusion. The total excretion of potassium was not significantly different between 
the groups over the four hour period. The sodium-potassium ratio was significantly 
higher in the subjects with the mutation, which is a reflection of the higher sodium 
excretion.  
 
Contrary to our hypothesis the total sodium excretion was higher in the heterozygotes 
after saline challenge. On reflection, although the ENaC is the final determinant of 
sodium regulation by the kidney, it is important to note that only between 2-5% of 
sodium reabsorption is regulated by the ENaC. As discussed previously it appears that 
the R563Q subjects are chronically sodium overloaded and the increased sodium 
excretion in response to saline challenge could have occurred at a variety of other 
sodium regulatory sites in the kidney. For instance Gill et al. [1991] found that salt 
sensitive subjects had an increased urinary dopa (a metabolite of dopamine) excretion. 
Dopamine is known to cause natriuresis at the level of the proximal convoluted tubule 
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[Baum and Quigley, 1998]. Atrial natriuretic peptide (ANP) is also a natriuretic 
hormone than is increased in volume overloaded states [Guyton and Hall, 1996] with 
vasorelaxant effects [Bolli et al., 1987]. ANP inhibits sodium reabsorption, increases 
GFR, inhibits aldosterone and renin release, increases nitric oxide activity (another 
vasodilator) and inhibits the vasoconstrictor activity of angiotensin II [Feehally et al., 
2007]. This suggests that ANP is an alternative mechanism controlling sodium 
homeostasis in patients with chronic sodium overload [Ferri et al., 1994]. However, 
neither of these parameters was measured and further studies are required to 
determine if the R563Q mutation influences dopamine and ANP response to a saline 
infusion. The use of lithium may have also help determine the site of sodium 
excretion in this experiment. 
 
Volume or water excretion was different between the two groups. The heterozygotes 
were slower to respond to the saline infusion. The initial response in the heterozygous 
group was a steady increase in excreted volumes but by two hours the normal group 
had a similar output. When the saline infusion ceased the normal group decreased the 
volume excreted but the heterozygotes were slower to diminish the volumes excreted. 
By four hours the volumes excreted were significantly different; the heterozygotes 
had a higher volume excreted. However, the total volume excreted over the four hours 
and the fraction of the infused volume that was excreted was no different between the 
groups. These differences are of interest but remain unexplained in this experimental 
model, but may be due to an expanded intravascular volume as previously discussed 
or already increased number of sodium channels at the cell surface.  
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Heterozygous individuals had a non-significant higher mean SBP than the normal 
individuals. There was large intra- and inter-individual variation of BP which made it 
difficult to determine a significant difference in such a small sample. Furthermore, 
differences in BP in the acute setting have been difficult to determine, and has 
involved pre-loading with dietary sodium [Luft et al., 1991] or volume depleting the 
subjects with intravenous furosemide [Weinberger et al., 2001]. Higher BPs would be 
expected in an overactive sodium channel, but the BP did not increase or differ 
between the groups, with the saline infusion, but it is important to note this may not 
be the case if patients with hypertension were included in the sample. Alternatively to 
detect BP changes more extreme stressors such as sodium overload followed by 
volume depletion by furosemide may be required. In support of this it is noted that the 
analysis for blood pressure was underpowered and the differences that are observed 
may become statistically significant should there be higher numbers. It is also 
observed that all non-significant results were underpowered in this analysis.  
 
CONCLUSION 
There are several lines of evidence to support that subjects with the R563Q mutation 
have functional overactivity of the ENaC, in this experiment. Firstly, aldosterone, an 
important marker of volume status, was suppressed and, taken in conjunction with the 
significantly higher serum sodium levels and slightly lower serum potassium levels, 
supports the hypothesis that the ENaC with the R563Q mutation is inherently 
overactive but does not provide proof of this. Contrary to our expectations, urinary 
sodium excretion was higher in R563Q heterozygous subjects. This probably reflects 
that, in the face of chronic sodium overload, these subjects excreted sodium by other 
counter-regulatory mechanisms in the kidney. 
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CHAPTER 9 
The R563Q Mutation Does Not Alter the Sodium Current in 
the Xenopus Expression System 
 
INTRODUCTION 
The association of the R563Q mutation with hypertension and the differences 
exhibited in the saline challenge are not sufficient to determine the isolated 
physiological effects of a mutation. Phenotypic variation, such as that seen in the 
saline challenge, could be as the result of a mutation in LD with the discussed 
mutation. The effect seen in the saline challenge could thus be the result of a mutation 
other than the R563Q mutation that is inherited with it. Thus, despite a mutation being 
only one of the differences in each individual’s genome, it is important to determine 
whether the isolated mutation is associated with a difference in function which could 
then have an effect on phenotype.  
 
The most commonly used method to determine a difference in activity of the sodium 
channel is by expressing the protein in Xenopus oocytes. This method is currently the 
most sensitive method available and has been used by many teams to show a 
difference in sodium channel activity when a mutation causes Liddle’s syndrome 
[Schild et al., 1995; Hansson et al., 1995b; Tamura et al., 1996]. This method has not 
shown a difference in sodium channel activity for mutations that do not interfere with 
the PY motif [Ambrosius et al., 1999]. Unfortunately, this method does not illustrate 
the biochemical effects of changes to the protein and is purely a means of determining 
the change in sodium fluctuation through the channel. 
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METHODS 
The contents of this chapter represent work that was organised and completed in Dr 
Stephen J. Tucker’s Laboratory of the Oxford Centre for Gene Function, Department 
of Physiology, Anatomy and Genetics, Oxford, England. Dr Lijun Shang assisted with 
the measurements. The author was involved in the planning of the project and visited 
the Oxford Centre for Gene Function in order to observe and learn the technique, 
particularly the defolliculation and the electrophysiological measurements. 
 
The Oxford Centre for Gene Function has ethical approval to use Xenopus laevis 
for this technique. 
 
Oocyte Preparation 
An adult female Xenopus laevis underwent a laparotomy under anaesthesia to remove 
the oocytes. After surgical removal of the oocytes she was killed in a humane way. 
Oocytes were treated with collagenase type II and manually defolliculated.  
 
Mutant DNA Preparation 
The mutated DNA sequence was introduced into the rat genome via mutagenesis of 
the β-ENaC subunit cloned into the pBF oocyte expression vector. Complementary 
RNA was synthesised in vitro and 5-8ng was injected into mature oocytes which were 
then incubated overnight in Barth’s solution (88 mM NaCl, 1 mM KCl, 0.33 mM 
Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 2.40 mM NaHCO3 and 20 mM HEPES 
(N-(2 hydroxyethyl) piperazine-N-2-ethanesulfonic acid) at pH 7.2). 
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Electrophysiology 
The two electrode voltage clamp technique was used to measure the sodium current in 
a recording solution consisting of 115 mM NaCl, 2 mM KCl, 1.8 mM CaCl2 and 
10 mM HEPES(NaOH) at pH 7.2. Sodium channel activity was assessed by 
measurement of the amiloride sensitive current. The amiloride sensitive current was 
the difference in sodium current at a membrane potential of -100mV in the recording 
solution with and without 5µM amiloride. Between five and eight oocytes from the 
same animal were used for each experiment and repeated with oocytes from a 
different animal. The mean current with standard error of the mean is recorded.  
 
RESULTS 
There was no significantly recordable difference in amiloride-sensitive sodium 
channel activity between the Xenopus oocytes with the wild-type and the R563Q 
variant of the β-subunit gene. The results are shown in Table 9.1 and illustrated in 
Figure 9.1. 
 
Table 9.1. Sodium Currents in the Wild-Type and R563Q variant when expressed in 
Xenopus oocytes 
  
Wild 
type 
R563Q 
Variant 
Control 
(uninjected)   P value 
Number 18 18    
Mean, µA 12.35 11.96 <0.2 0.104 
Standard Error 0.89 0.93    
Blocked with 30µmol 
amiloride >95% >95%     
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Figure 9.1. Currents detected. A) currents for wild-type ENaC. B and C, respectively, 
show blockade with amiloride and recovery. Similarly, D, E and F show currents for 
β-ENaC-R563Q. 
  
DISCUSSION 
The most commonly used technique to determine a difference in sodium current is 
expression in Xenopus oocytes [Valentijn et al., 1998] although this method has not 
been found to be helpful in determining differences in mutations that do not alter the 
PY motif [Schild et al., 1996].  In this study, the method did not show a difference in 
sodium channel activity, between wild-type oocytes and oocytes with the R563Q 
mutation. An activating mutation of the sodium channel could alter the sodium 
current in this method but this would probably only be seen if there was a large 
change in current, as is seen with the R566X mutation [Schild et al., 1995]. Thus it 
appears that the potentially more subtle effects of missense mutations, when 
compared with those that cause Liddle’s Disease, are not as easily elicited using the 
available physiological techniques.  
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Expression of the ENaC in Xenopus oocytes is an accepted and well defined method 
to illustrate differences in ion channel activity. This method utilises the patch clamp 
technique to determine the direct effects of a mutation on the sodium channel. Patch 
clamping involves attaching a micropipette and sealing it to the cell membrane. (The 
micropipette usually contains a solution that is matched to the ionic composition of 
the solution in which the cells are incubated.) It is then possible to determine the 
current through the single ion channels in that patch of membrane. Xenopus oocytes 
do not express sodium channels, (the control sodium current was negligible at 
<0.2µA) so innate channel activity is not likely to influence the results. They do 
express Nedd4 [Staub et al., 1996], allowing internalisation of the channels that are 
inserted into the cells. In this experiment, both wild-type and mutant currents (which 
did not differ) were completely blocked by amiloride indicating that the recorded 
current was the result of the amiloride-sensitive ENaC. 
 
Another benefit of the Xenopus expression system is that it permits the determination 
of interactions between proteins (such as ENaC and Nedd4-2 [Bhalla et al., 2005]). 
This creates the opportunity to determine if there is a difference in channel activity 
due to different protein interactions, such as SGK1 or S1A [Alvarez de la Rosa et al., 
1999]. The Xenopus expression method may also permit the use of more than one 
mutation within a subunit. This would enable the use of a mutation with known 
effects, such as locking the channel in the open state, after which any changes would 
indicate a change in channel number. Use of more than one mutation with a subunit 
could also determine interactions between mutations. 
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There are some limitations to the expression system. Since mRNA needs to be 
injected into the oocytes to express the protein it is not practical to use this method for 
large numbers of oocytes, such as may be required to determine a subtle difference 
resulting from missense mutations outside the PY motif of the ENaC genes. A further 
limitation observed by Costa et al. [1994] is that it is not possible to change solutions 
quickly due to the vitelline membrane on the oocyte increasing diffusion time to the 
cell membrane, which decreases the sensitivity of the measurements when assessing 
the peak macroscopic and timing of currents. Furthermore, the large surface area of 
the cell decreases the reliability of the initial one to two milliseconds after a voltage 
change. Small changes in sodium channel activity are thus difficult to determine in 
this system (or in fact any system currently available). 
 
The R563Q mutation lies just within the cytoplasm, following the second 
transmembranous domain. Current differences could be the result of a change in N, 
Po or the conductance through the channel pore (which is constant for sodium 
channels). The position of the mutation suggests that it is more likely to influence N 
rather than Po. Surface N is influenced by the insertion into the membrane, removal 
from the membrane and length of time that it remains within the membrane (half life). 
The Xenopus expression system is better able to determine differences due to changes 
in channel Po rather than N so this system is perhaps not an optimal method to 
determine differences due to the R563Q mutation. 
 
Other techniques that have been used to determine differences in channel activity are 
summarised in Table 9.1. Ma et al. [2004] showed that B lymphocytes could also be 
used for patch clamp techniques and Snyder et al. [1995] labelled the channel with a 
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FLAG epitope in the extracellular domain and used an anti-FLAG antibody to show 
that β-R566X was found at higher concentrations at the cell surface. Bubien et al. 
[2001] showed that antibodies directed against the ENaC itself also show the increase 
in N in lymphocytes. They also showed that patch clamping of lymphocytes revealed 
an increase in sodium current in lymphocytes and an increase in Po of the channels. 
Intracellular abundance of channels has been shown by antibodies directed against 
each subunit and visualised using immunofluorescence [Loffing et al., 2000]. Baker et 
al. [1998b] described using nasal potential difference to illustrate the difference in 
sodium channel activity in a family with Liddle’s disease. Nasal potential difference 
measurements are not sensitive enough to show the small differences that may be 
present in mutations that do not cause the full Liddle’s phenotype.  In fact, none of 
these methods may be able to show a difference in a cell with or without the R563Q 
mutation but it may be possible to increase the sensitivity of these experiments for the 
R563Q mutation by using interactions of more than two proteins, as described by 
Bhalla et al. [2005].   
 
Table 9.2. Physiological Methods for Determining a Difference in Function 
Method Reference 
Xenopus Oocyte Patch Clamping Schild et al. [1995] 
B Lymphocyte Patch Clamping Ma et al. [2004] 
FLAG labelling with Anti-FLAG antibody Snyder et al. [1995] 
Radiolabelled antibodies to the surface ENaC Bubien et al. [2000] 
Radiolabelled antibodies to the cytoplasmic ENaC Loffing et al. [2000] 
Nasal potential Difference Baker et al. [1998] 
 
All of the above methods describe the physiological effects in vitro. This is very 
useful to delineate interactions and individual mutations, but practically, a mutation is 
just one of many genetic differences within each individual and the effects of a 
mutation need to be assessed within the individual. The saline challenge enabled the 
illustration of the effects of the mutation in vivo (Chapter 8) and assessing the clinical 
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characteristics of the hypertensives helped to delineate the long term effects. As the 
expression technique above did not delineate a difference in sodium channel 
conductance between the wild-type channel and the channel with the R563Q mutation 
other evidence suggesting a difference in the protein were sought. Figure 9.2 
illustrates that the R563Q mutation is in a highly conserved region of the β-ENaC. 
This arginine is preserved in all mammals, which indicates that this amino acid could 
be crucial to function or structure of the channel. 
 
 570      550       560       570       580       590      599 
Hs: GEIIIDFVWITIIKLVALAKSLRQRRAQASYAGPPPTVAELVEAHTNFGFQPDTAPRSP 
Pt: ----------------------------------------------------------- 
Cf: ---L-------------F------K----R-----------------------V-RPG- 
Rn: -------I---V-----SC-G--R--P-RP-T---------------CV-----TSCR- 
Mm: -------I---V-----SC-G--R--P-RP-T---------------CV-----TSCR- 
Gg: ------SL---V-NIISWC-G-K-K-VR-R-PDT----S--------LG--HEE-GTET 
  
Figure 9.2. Sequence homology (synteny) in exon 13 of the β-ENaC between 
species. Amino acids that differ from the human sequence are shown. In Homo 
sapiens sapiens (Hs) the sequence includes amino acids from 570 to 599. The 
numbered amino acids are shaded in green and amino acid 563 in yellow. Pt, Pan 
troglodytes (chimpanzee); Canis familiaris (dog); Rn, Rattus norvegicus (rat); Mm, 
Mus musculus (mouse); Gg, Gallus gallus (chicken). (Information from NCBI 
Sequence Viewer v2.0) 
 
Arginine is a positively charged amino acid and is often important in active regions of 
a protein. Arginine and lysine (both positively charged) usually maintain the charge 
balance of proteins. Of note, the deviation from arginine in the chicken is to lysine. 
This suggests that the presence of a positively charged amino acid in this position is 
essential for protein structure and function. 
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PIP3 (phosphoinositol 3,4,5, trisphosphate) was shown by Pochynyuk et al. [2005] to 
interact with the γ-ENaC at the conserved positive amino acids just distal to the 
second transmembranous domain. This then regulates the signalling cascades of the γ-
ENaC. The interaction of PIP3 and γ-ENaC at these positive amino acids appear to 
influence channel gating rather than internalisation and mutations in this region 
influenced the sodium current. Interestingly, the amino acid that is particularly 
susceptible to this alteration is an arginine (in a similar place to the β-ENaC R563Q 
mutation). Other possible proteins that interact with the ENaC in this region are PKC 
and SGK1. These intracellular proteins are potentially capable of phosphorylating 
certain amino acids causing down regulation of the channels [Alvarez de la Rosa et 
al., 2004; Cui et al., 1997]. However, this remains to be shown. 
 
Missense mutations may have an effect in vivo that is not easily reflected in in vitro 
experiments. Multiple factors influence BP within each individual, such as diet and 
genetics, as discussed earlier (Chapters 1 and 2). These factors may interplay with this 
mutation to make the heterozygous subjects more susceptible to hypertension. Other 
genetic mutations that could influence the effects of this mutation are yet to be 
determined as are the means of interaction.  
 
CONCLUSION 
It was however evident from these studies that this simple use of the Xenopus 
expression system did not show a difference in sodium conductance between wild-
type and the R563Q variant of the β-ENaC. 
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CHAPTER 10 
Interesting Cases 
1) An R563Q Homozygous Patient 
HISTORY 
Patient X is a 54 year-old Coloured female, whose family originates from the Western 
Cape. Her father died at age 29 due to a haemorrhagic stroke. Her mother died at age 
85 due to complications from hypertension and diabetes mellitus. One of her sisters 
died at age 57 due to complications from hypertension and diabetes mellitus, with 
chronic renal failure. One of her brothers has hypertension (and is known to the 
Hypertension Clinic) and the other has hypertension and diabetes mellitus. Most of 
her aunts and uncles died from the complications of hypertension and diabetes 
mellitus. 
 
She had fairly well controlled hypertension for the last 15 years and was 
hypercholesterolaemic. She was taking 2.5mg indapamide, 4mg perindopril, 20mg 
simvastatin and 150mg asprin once a day to control her BP and decrease her 
cholesterol level. She has not had any surgical problems but has cervical spondylosis 
for which she took Arthrotec® on one occasion. She did not take over-the-counter 
medications and seldom has headaches. She has tried to improve her diet and usually 
eats chicken or fish, seldom red meat. She said she has a weakness for salt and often 
eats tinned foods. 
 
EXAMINATION 
General examination was normal. All pulses were present, regular and had good 
volume. There was no radio-femoral delay and no carotid bruit. The BP averaged 
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155/80 with a wide range (Table 10.1) on the automated monitor when she arrived at 
the clinic for assessment. There was no postural difference in BP or a difference 
between the right and left arms. The chest, cardiac, neurological and abdominal 
examinations were normal; the kidneys were not palpable, and there were no renal 
artery bruits. Fundoscopy revealed early silver wiring. The ECG revealed that she was 
in normal sinus rhythm with no signs of left ventricular hypertrophy. Standard 
laboratory investigations were normal and are shown in Table 10.1.  
 
Table 10.1. Clinical and laboratory features for Patient X 
Clinical Examination Laboratory Investigations 
BMI, kg m-2 30 Potassium, mmol l-1 4.2 
Waist Circumference, cm 97 Creatinine, µmol l-1 55 
Neck Circumference, cm 33.5 Random Glucose, mmol l-1 4.8 
Mean SBP, mmHg 142 Random Cholesterol, mmol l-1 4.8 
Highest SBP, mmHg 175 Aldosterone, pmol l-1 152.5 
Lowest SBP, mmHg 155 ARR 10.1 
Mean DBP, mmHg 72 Renin, mmol l-1 15.1 
Highest DBP, mmHg 86 Urine Creatinine, mmol l-1 10 
Lowest DBP, mmHg 80 Urine microalbumin, mg mmol-1 15.4 
Sokolow Lyon (ECG), mm 19 Microalbumin-creatinine ratio 1.5 
Cornell (ECG) 1584   
ECG Axis, degrees 60   
Aortic Width, cm 3.6   
CTR 0.46   
Pulse, b min-1 66   
 
The presence of the R563Q mutation was determined using standard PCR and RFLP 
methods as described in Chapter 3. The result was checked with sequencing and the 
PCR was repeated with different primers. Interestingly, all methods confirmed that 
this patient appeared to be homozygous (i.e. has two copies) for the variant allele. 
Figure 10.1 shows the sequence for a homozygous individual. The amplified region of 
exon 13 of the β-ENaC sequence (around nucleotide 110 in Figure 10.1) is CTACAG 
not CTACGG (normal). (Note there is a peak only for adenosine, no glutamine, i.e. 
homozygous.) 
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Figure 10.1. Sequence of the β-ENaC gene showing normal (above) and the 
homozygous transition (bold arrow) causing the R563Q mutation 
 
After Patient X came to the Hypertension Clinic amiloride was added to her 
antihypertensive regimen, as her SBP was not sufficiently controlled (it reached 
175mmHg). She was also given dietary and lifestyle advice. Six months later she 
reported that she has been receiving amiloride from the GSH pharmacy and her BP 
had settled at 128/80.  
 
DISCUSSION 
This case study shows the presenting characteristics of the first identified 
homozygous person with the R563Q mutation examined at the Hypertension Clinic. 
Interestingly she did not differ phenotypically from patients who are heterozygous for 
the mutation. Her aldosterone and renin levels were not markedly suppressed, but she 
Presence of  
Guanine only 
Nucleotides 
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Adenosine 
only 
563 R 564 Q 562 L Amino Acids 
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was on a diuretic and an angiotensin-converting enzyme inhibitor. Both these agents 
would tend to interfere with the renin and aldosterone levels. This makes the 
aldosterone level unreliable in assessing the effects of the mutation on the RAAS. 
Also, both agents alter potassium handling so the potassium level is not a true 
reflection of sodium channel activity.  
 
This case study presents the features of an individual homozygous for the R563Q 
mutation which has been associated with hypertension in the heterozygous form. It 
appears that Patient X has inherited two copies of the variant allele as no normal copy 
was seen. While this is the likely scenario, in the absence of data from her biological 
parents it is possible to surmise that alternatively she may have inherited an allele 
with a large deletion spanning the entire amplified region which would result in only 
one variant of the channel (the one with the R563Q mutation). Importantly, it was 
predicted that the homozygous form would present as a more extreme case of 
hypertension with hypokalaemia. She appeared not to. The only characteristic that this 
subject presents with is a suppressed aldosterone level. As she did not stop her 
antihypertensive treatment before assessment the aldosterone and potassium results 
are poor reflections of sodium channel activity but stopping her medication would not 
be ethical unless in a tightly controlled environment. Ambrosius et al. [1999] found 
nine subjects homozygous for the β-G442V mutation. They were all hypertensive 
which resulted in the association of this mutation with hypertension in this study 
group. Unfortunately that is all the information that is given on these homozygous 
subjects, and there are few discussions of the effects of heterozygosity versus 
homozygosity on phenotype for the ENaC in the literature.  
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
w
 180 
After four months on 5mg amiloride Patient X’s BP was within the normal range. She 
reported no symptoms of a postural drop in BP or any side effects possibly related to 
the amiloride.  
 
This case study further illustrates the difficulties of associating a mutation in vivo with 
biophysical properties and shows that the R563Q mutation is compatible with life in 
the homozygous form. 
 
2) The R563Q mutation causes Liddle’s syndrome in pregnancy 
INTRODUCTION 
Liddle’s syndrome presents with hypertension, hypokalaemia, metabolic alkalosis and 
low renin and aldosterone levels. The full phenotype is not generally recorded in 
subjects with the R563Q mutation. However two cases of Liddle’s syndrome during 
pregnancy are described. The presence of the full phenotype is suggestive that the 
R563Q mutation results in an overactive sodium channel. 
 
1) Liddle’s Case 1  
Liddle’s Case 1 was referred to the GSH Hypertension Clinic from the Cardiac Clinic. 
She was 36 years old, unemployed and not married. She did not smoke or consume 
alcohol. Her parents live in the Eastern Cape. Her mother was alive and well, her 
father had diabetes mellitus and hypertension and her sister also had hypertension and 
diabetes. 
 
She was diagnosed with gestational hypertension when she presented in August 2004 
at seven months pregnant to the ante-natal unit at GSH. She was found to have a 
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potassium level of 2.1mmol/l and an aldosterone level of 73pmol/l. She also had atrial 
tachycardia and evidence of peripartum cardiomyopathy, and was referred to the 
Cardiac Clinic. Her potassium was aggressively supplemented and she was treated for 
cardiac failure. Amiloride 5mg was added because of suspected Liddle’s syndrome, 
and later she was confirmed to be R563Q heterozygous. She was later assessed at the 
GSH Hypertension Clinic when she was found to be well and taking all her 
medication (bromocriptine 2.5mg, enalapril 10mg and atenolol 50mg twice a day and 
amiloride 5mg and nifedipine 30mg daily), and her baby was thriving. The peripartum 
laboratory results are shown in Table 10.2 2 confirm the presence of Liddle’s 
syndrome with severe hypokalaemia in the face of highly suppressed renin and 
aldosterone concentrations in the absence of liquorice use. 
 
Table 10.2. Liddle’s Case 1: Blood Results from the time of presentation 
Date (2004) 08/08 08/09 08/12 08/13 08/14 08/23 11/15 
Sodium (mmol l-1) 136 135 137 143 138 134 143 
Potassium (mmol l-1) 2.6 2.9 3.1 4.5 3.3 5.9 3.6 
Urea (mmol l-1) 2.2 2.2 2.3 3.9 5.1 11.2  
Creatinine (µmol l-1) 58 49 43 57 60 112  
Glucose (mmol l-1)   4.2   5.1  
Cholesterol (mmol l-1)      7.9  
Uric Acid (mmol l-1) 0.39 0.5    0.74  
Calcium (mmol l-1) 2 2.04      
Magnesium (mmol l-1) 0.81 0.72      
Phosphorus (inorganic) (mmol l-1) 1.37 1.49      
Total Bilirubin (µmol l-1) 11 9      
Alanine Transaminase (U l-1) 9 9      
Aspartate Transaminase (U l-1) 25 26      
Lactate Dehydrogenase (U l-1) 1092 979      
U-Potassium (mmol l-1) 19.1       
U-Creatinine (mmol l-1) 4       
Iron (µmol l-1)   22.8     
Transferrin (g l-1)   2.4     
Transferrin saturation (%)   38     
Ferritin (µg l-1)   326     
CRP (mg l-1)   23.8     
Haptoglobin (g l-1)   0.92     
Aldosterone (pmol l-1)   73   524  
Renin (mmol l-1)   13   1665  
Aldosterone-Renin Ratio   5.6   0.3  
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On Examination she was found to have a BMI of 26.6kg/m2. All pulses were present 
and equal at a regular 60b/min. Her BP was low, at 90/60mmHg and she did not have 
pedal oedema. She did not have any signs of congestive cardiac failure but her apex 
beat was pressure overloaded and there was a fourth heart sound. Chest, abdominal 
and neurological examinations were normal but she did have grade II hypertensive 
retinopathy. Her ECG showed that left ventricular hypertrophy and left atrial 
enlargement were present, but there were no repolarisation changes. Se also had an 
echocardiogram which showed a thickened left ventricle with poor contractility and 
ejection fraction. Mild mitral and tricuspid regurgitation were present.  
 
Due to her low BP the nifedipine was stopped and the atenolol was decreased to 50 
mg daily. On 15/11/2004 she retuned for follow up at the Hypertension Clinic. She 
was found to be heterozygous for the R563Q mutation and her BP was 
120/100mmHg. Her pulse was 120b/min and regular and she was generally doing 
well and did not have any problems. She wished to return to the Eastern Cape to her 
parents and so was discharged to Cecelia Makiwane Hospital. 
 
2) Liddle’s Case 2  
Liddle’s Case 2 was a 25 year old Xhosa female who had previously been well. She 
had had two pregnancies in which she was found to have pregnancy induced 
hypertension and had had one miscarriage. She was pregnant (42 weeks) at the time 
of referral to GSH in 2001 and had recently developed gestational hypertension 
without proteinuria. The BP and biochemistry surrounding her delivery are recorded 
in Table 10.3. The results are highly suggestive of Liddle’s syndrome – hypertension, 
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hypokalaemia, and suppressed renin and aldosterone, and she was not taking any 
liquorice-containing agents. 
 
Table 10.3. Liddle’s Case 2: BP and biochemical parameters surrounding the 
delivery 
Date 4/03 5/03 6/03 7/03 8/03 9/03 10/03 11/03 
BP (mmHg) 130/90 120/80 150/100 160/110 160/82 160/90 170/100 150/90 
Clinical Event   C/sxn endometritis    
Sodium (mmol l-1)   139 145 142 142 147 143 
Potassium (mmol l-1)   2.1 2.5 2.7 2.8 2.7 2.8 
Urea (mmol l-1)   1.2 1 1.2 1.4 1.1 1.2 
Creatinine (µmol l-1)   55 61 50 47 47  
Aldosterone (pmol l-1)    101     
Renin (mmol l-1)    <0.1     
ARR    >1000     
Footnote: C/sxn, caesarean section 
 
Induction of pregnancy was not successful and she underwent a caesarean section on 
6 March after which she developed endometritis which was treated with antibiotics. 
During this time she developed profound hypokalaemia which did not respond to 
potassium supplements. She died suddenly at home shortly after discharge, possibly 
due to cardiac arrhythmias related to hypokalaemia. Due to the interest in this case 
she was investigated further and found to be heterozygous for the R563Q mutation. 
 
DISCUSSION 
These two cases that presented with Liddle’s syndrome were both heterozygous for 
the R563Q mutation. The explanation for the full expression of the phenotype is 
speculative, but it is known that progesterone has a similar structure to aldosterone 
and has some mineralocorticoid activity. The concentrations are markedly increased 
in pregnancy with levels reaching 320-700nmol/l in the third trimester. (The normal 
ranges depend on the stage of the menstrual cycle but range from 0.6nmol/l to 
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110nmol/l.) The pathway for progesterone and aldosterone production is shown in 
Figure 10.2.  
 
 
Figure 10.2. Steroid production from cholesterol in the adrenal gland 
(Enzymes required are highlighted in red.) 
 
Progesterone has a high affinity for the mineralocorticoid (MR) receptor, higher than 
aldosterone, but the agonist effect of progesterone on the MR receptor is only 27% of 
the effect of aldosterone on the MR receptor [Quinckler et al., 2002]. Thus 
progesterone, at high concentrations, effectively blocks the MR receptor from 
aldosterone, having a comparative antagonistic effect on the MR receptor. This 
antagonistic effect is probably countered (during pregnancy) by the potent inhibition 
of progesterone on 11-β-hydroxysteroid dehydrogenase type 2 (11-β-HSD-2) 
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[Quinckler et al., 1999] which will result in a build up of cortisol, which has agonist 
effects on the MR receptor (see Figure 1.1) [Feehally et al., 2007]. 
 
The S810L mutation of the MR receptor alters the conformation of the receptor 
making it sensitive to the effects of progesterone [Geller et al., 2000], exacerbating 
hypertension during pregnancy. Rafestin-Oblin et al. [2003] showed that cortisone 
and 11-dehydrocorticosterone bound to and activated the MR receptor with the S810L 
mutation resulting in hypertension. This suggests that progesterone could be involved 
in the hypertension associated with this mutation because of the inhibition of 11-β-
HSD-2. The difference in MR receptor and progesterone interaction during pregnancy 
could explain why these two female patients with the R563Q mutation presented with 
Liddle’s syndrome. Aldosterone is innately suppressed in subjects with the R563Q 
mutation (see Chapter 4) which would usually tend to up-regulate the receptor, 
making it sensitive to stimulation by mineralocorticoids, glucocorticoids and 
progesterone. High concentrations of progesterone would also result in high 
concentrations of progesterone metabolites, like 11β-hydroxyprogesterone which has 
been found to act as a mineralocorticoid [Rafestin-Oblin et al., 2002]. Together, these 
factors would result in an overactive MR causing increased transcription of the ENaC 
subunits which may be poorly down-regulated due to the R563Q mutation. This 
hypothesis is yet to be shown physiologically but these two cases do provide further 
evidence that the R563Q mutation is an activating mutation. However the occurrence 
of the R563Q mutation and Liddle’s syndrome is not universal as in the study by 
Dhanjal et al there were no cases of Liddle’s syndrome occurring in pregnant patients 
with the mutation. The reasons for the differences in phenotypic expression in 
pregnancy are not readily explained. 
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3) R565Q: A Novel Mutation of the ENaC causing Liddles’s Syndrome 
Patient Y 
Patient Y was a 65 year old Caucasian male who was referred to the Hypertension 
Clinic with uncontrolled hypertension and hypokalaemia. He was diagnosed with 
hypertension in 1950 when he was 20 years old but the first time he was noticed to 
have profound hypokalaemia was in 1998 when he was 58 years old. He used to 
smoke (for 25years) but never consumed alcohol and ate a normal healthy diet. There 
was no family history of cardiovascular disease or hypokalaemia. He had been treated 
with 100mg spironolactone daily and 100mg losartan for his BP and had been taking 
up to 10 tablets of Kloref®, each one containing 6.7mmol/l of potassium when 
dissolved in 500ml of water, to try maintaining normal serum potassium 
concentrations. 
  
Recently, Patient Y had been breathless, with low energy levels and proximal muscle 
weakness. He had had a recent episode of atrial flutter, at the same time his BP was 
noted to be 236/138, and he was treated with adenosine. His potassium level was 
noted to be 4.1mmol/l at this time. When he was seen at the Hypertension Clinic his 
pulse was 75bpm and his BP was 190/90mmHg. There was no pathology related to 
hypertension but his neurological examination revealed generalised muscle weakness 
that was subsequently diagnosed as chronic demyelinating polyradiculopathy. At this 
time his potassium and aldosterone levels were within the normal range (Table 10.4). 
He also had an abdominal CT scan which was normal. However, due to poor BP 
control and previous profound hypokalaemia he was referred for investigation for 
sodium channel mutations. The R563Q mutation was not found in this patient but he 
was heterozygous for a novel mutation of the 565
th
 amino acid. The mutation found 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 187 
was a guanine to adenine transition resulting in conversion of arginine to glutamine 
(R565Q). The nucleotide change is shown in Figure 10.3, and is two amino acids 
away from the R563Q mutation. 
 
Table 10.4. Laboratory findings for Patient Y 
  Patient Y Normal Ranges 
Potassium, mmol l-1 4.5 3.3-5.3 
Sodium, mmol l-1 138 135-147 
Cholesterol, mmol l-1 4.7 3.3-5.3 
Aldosterone, pmol l-1 297 255-860 
Renin, mmol l-1 38 5-47 
Aldosterone-Renin ratio 7.8 <70 
Calcium, mmol l-1 2.28 2.05-2.56 
Phosphate, mmol l-1 0.96 0.8-1.4 
Magnesium, mmol l-1 0.76 0.65-1.1 
Alkaline phosphatase, mmol l-1 31 40-120 
Total protein, g dl-1 63 60-85 
Albumin, g dl-1 38 35-52 
Urine albumin-creatinine ratio 0.4 <0.02 
 
 
Figure 10.3. Sequence for Patient Y showing the G>A transition of base 1694 (B) 
from the normal sequence (A). 
 
A 
B 
Presence of  
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The finding of the mutation in the sodium channel prompted the initiation of 
amiloride in this patient in 2008 which normalised his potassium and BP without the 
need for spironolactone or potassium supplements. 
 
DISCUSSION 
This patient presented with un-investigated severe hypokalaemia and uncontrolled 
hypertension at the age of 65 years. On amlodipine, spironolactone and losartan his 
aldosterone level was normal (297pmol/l), which essentially excludes primary 
aldosteronism and supports the diagnosis of Liddle’s syndrome. The patient was 
started on amiloride when he was found to have a mutation in the β-subunit of the 
sodium channel. The R563Q mutation was not found in this patient as was expected, 
because it has not previously been reported in subjects with only Caucasian ancestry. 
 
The mutation that this patient has is two amino acids downstream of R563Q mutation. 
This region of the β-ENaC is highly conserved in mammals (see Figure 9.2, Chapter 
9) and mutations in this region may result in phenotypic differences. Finding the 
R565Q mutation in a patient with full blown Liddle’s syndrome lends support to the 
hypothesis that the R563Q mutation may cause functional changes in the ENaC. It is 
interesting that the amino acid substitution is the same as that of the R563Q mutation. 
The R565Q mutation also results in the change from the basic amino acid to a neutral 
amino acid which has the potential to alter the three dimensional configuration of the 
channel changing the degradation of the channel by certain processes, as previously 
discussed. 
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CONCLUDING REMARKS 
 
 
The Serengeti Plains 
A scarce African landscape across which people and animals have had to migrate 
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CHAPTER 11 
General Discussion and Synopsis 
 
SYNOPSIS 
In this thesis a total of 2440 subjects were assessed for the presence of the R563Q 
mutation, either by personal examination or by accessing their records. 1057 of these 
subjects were genotyped for the R563Q mutation by restriction enzyme digestion or 
sequencing of the β-ENaC for the purposes of this thesis. The remainder (1383) had 
previously been assessed. Forty five of these individuals were included in the family 
study (Chapter 4) in which 22 were families visited. Forty four were included in the 
clinical assessment (Chapter 7). Twenty four of the 1057 subjects selected for this 
thesis gave consent for a saline infusion (Chapter 8) to assess the response of the 
sodium channel. The search for the origin of the mutation took the author across 
South Africa. Subjects were recruited from Johannesburg, Cape Town and the 
Northern Cape and represent multiple population groups: Caucasians (178), Coloured 
(829), Khoisan (167), Sotho (261), Venda (17), Xhosa (424) and Zulu (519). Five 
subjects were homozygous for the R563Q mutation, 167 were heterozygous and one 
new mutation (R565Q) was discovered. The author further collaborated with a team 
in England to assess the function of the mutated protein. 
 
1. HYPERTENSION 
a) The R563Q mutation was significantly more common in the hypertensive 
population of Coloured or Black African ancestry compared with the 
normotensive controls (Chapters 4 and 5). 
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b) Within families the mutation strongly associated with both hypertension and 
blood pressure levels (Chapter 4).  
c) The BP was significantly higher in the positive group when pooling all R563Q 
positive and normal subjects, either normotensive or untreated hypertensive 
(Chapter 6). 
d) In the small Khoisan sample the R563Q mutation was extremely common but 
did not associate with hypertension, presumably because of their low sodium 
diet. The R563Q mutation may have offered a survival advantage in the arid 
areas of South Africa where sodium was a scarce resource (Chapter 6). 
e) Within hypertensives the R563Q mutation was associated with an increased 
risk of CKD compared with comparable age and sex matched hypertensive 
controls (Chapter 7). 
f) R563Q hypertensives treated with amiloride had a significant and clinically 
relevant improvement in BP levels (Chapter 7). 
g) The R563Q mutation was not associated with the Liddle’s phenotype except in 
two cases during pregnancy (Chapter 10). The mutation was previously 
associated with hypertension during pregnancy [Dhanjal et al., 2006]. 
 
Thus the association with hypertension has been considerably strengthened by this 
thesis and the effect appears to be clinically relevant with a significant BP response to 
amiloride (a specific inhibitor of the ENaC). Furthermore, the previous observations 
that the mutation does not cause full blown Liddle’s disease is confirmed apart from 
isolated cases during pregnancy. The possible association with CKD deserves further 
study as it may be an explanation for the higher prevalence of CKD in indigenous 
populations. 
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2. ORIGINS 
Evolution allows for selection of variants that will improve survival. A mutation in a 
gene that alters function will not be sustainable if it decreases an individual’s ability 
to survive or reproduce. If, however, a mutation has no affect on the individual’s 
survival or reproductive ability then the mutation will not be favoured and will not 
increase in frequency. Only if the mutation improves survival will it be selected for 
and will increase in frequency in further generations. The ability for a mutation to 
alter survival will depend on the environment in which the individual lives. If the 
mutation improves survival in one environment, it may decrease survival in another 
environment with differing circumstances. The R563Q mutation illustrates this point 
by being associated with hypertension in the urbanised Black African and Coloured 
groups but not in the Khoisan population. 
 
The R563Q mutation has been found in Black African and Coloured groups in South 
Africa, who both have Khoisan genetic admixture. The mutation has not been found 
in the Black African population that has been screened for in London [Hartmann, 
2007] who are usually migrants from central and northern Africa. This suggests that 
the mutation did not originate from the Black African population from central Africa 
and strongly suggests that this mutation arose in the Khoisan. This is a plausible 
hypothesis as the Khoisan often lived in extremes of salt scarcity where an 
intrinsically active ENaC would provide a survival advantage. 
 
In the Khoisan the R563Q mutation is found at a high frequency (see Chapter 6). The 
lower sodium excretion illustrates that they had a lower dietary intake of sodium. This 
could account for the lack of difference in the BP and sodium and potassium levels, as 
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could the small sample size. The frequency of the mutation also warns that 
hypertension could be a serious problem in these populations as the sodium intake 
increases with the westernisation of Africa. 
 
3. FUNCTIONAL STATUS 
a) This thesis has demonstrated strong circumstantial evidence for intrinsic over 
activity of the β-ENaC in subjects with the R563Q mutation. This missense mutation 
is found in what is generally considered the unconserved region of the carboxy 
terminal. While this region is not part of the highly conserved PY motif it does 
contain certain amino acids that are conserved across the species, including the 
arginine at position 563 (Chapter 9), suggesting that it is important for structure and 
function. 
 
b) The saline challenge (Chapter 8) supports the hypothesis that the R563Q 
mutation increases the activity of the sodium channel. Those with the mutation had 
intrinsically higher serum sodium levels and suppressed aldosterone levels which 
suppressed to a lower level during the challenge, suggesting an innately overactive 
channel. An overactive sodium channel would result in an increase the activity of 
control mechanisms, (e.g. Na+/K+ ATPase being stimulated by dopamine which is 
increased with higher concentrations of sodium [Pestana et al., 2001; Vieira-Coelho et 
al. 2000]) in order to ensure normal homeostasis. This is illustrated by the normal 
potassium levels and increased sodium excretion. 
 
The BP were not different between the groups, which is not surprising as the small 
changes in BP in an acute setting usually vary widely between individuals making it 
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difficult to detect a change. This has previously been observed by Weinberger et al. 
[2001]. The saline challenge did not prove that the mutation increases the activity of 
the sodium channel but did illustrate the effects of the mutation in its normal 
environment. This is important to improve our understanding of the effects of the 
R563Q mutation. 
 
c) This thesis was unable to prove that the mutation resulted in intrinsic over 
activity of the channel as the oocyte expression system used in this study did not show 
that cells expressing the sodium channel with the R563Q mutation had a different 
sodium conductance when compared with the wild-type channels. This method is a 
basic method with limitations as discussed in Chapter 9. A more extensive analysis 
would be required to assess the physiological effects of this mutation completely. 
 
d) The Khoisan data are interesting in that there was an isolated decrease in 
aldosterone levels in the subjects with the mutation. This is interesting as an increase 
in activity of the channel could only disturb the aldosterone level as the sodium and 
potassium balance is essential for cellular function and disturbances would not be 
homeostatically acceptable, so a multitude of mechanisms are in place to ensure these 
electrolytes are within the normal range. 
 
e) The presence of Liddle’s disease presenting in two pregnant patients with the 
R563Q mutation is further evidence that the mutation alters the activity of the sodium 
channel.  During pregnancy there is an excess of progesterone which activates the 
mineralocorticoid receptor, albeit at a lower efficacy than aldosterone, and thus has 
the potential to create an environment where there is excessive activation of the 
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ENaC. In susceptible patients, with impaired down-regulation of the channel or 
increased up-regulation of the ENaC, this could impair sodium homeostasis. 
 
IMPORTANCE AND RECOMMENDATIONS 
This thesis challenges the current understanding of the genetics of hypertension and 
tends to support the hypothesis proposed by Platt [1947]. There is evidence in this 
thesis that the R563Q mutation is a single genetic defect that is the major contributor 
to hypertension in these subjects (Chapter 4). Mendelian forms of hypertension have 
been described but do not account for the majority of EHT, and are influenced by 
environmental factors. The R563Q mutation is found frequently in resistant 
hypertensives (Chapter 5) and so could account for a major proportion of EHT in 
South Africa. This is contrary to the current teaching of hypertension as a 
multifactorial disorder influenced by multiple genes and environmental factors. 
 
The major importance of this thesis is the impact it could have on the policies in 
Hypertension Clinics in South Africa. A major result of the findings in this thesis is 
the opportunity it could create to improve treatment plans for hypertensive individuals 
heterozygous for the R563Q mutation. The observation that amiloride improves BP in 
patients from the Hypertension Clinic at GSH suggests that amiloride is the treatment 
of choice in these patients (Chapter 5). However, further studies are recommended 
before such a policy is put into practice. It is recommended that, once the presence of 
the mutation has been determined in hypertensive patients, careful monitoring for 
CKD is implemented. It would also be advised that young family members of patients 
with the mutation, who develop hypertension, are screened for the mutation. If the 
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mutation is found in a pregnant woman there should be careful monitoring for the 
development of Liddle’s syndrome and hypertension in pregnancy. 
 
A further important finding, resulting in a change in clinical practice, is that the 
R563Q mutation is found in multiple ethnic groups in South Africa and is associated 
with hypertension within these groups (Chapter 5). These findings suggest that it 
would be recommended to screen patients referred to Hypertension Clinics for 
resistant hypertension of unknown origins in all major centres in South Africa.  
 
It is further recommended that lifestyle modifying behaviour is taught to the Khoisan 
who have been found to succumb to lifestyle disorders on exposure to environmental 
stressors. Previously the Khoisan groups have been found to have a low prevalence of 
the disorders of lifestyle [Nurse and Jenkins, 1977] but this appears to be changing 
and they may be a highly susceptible group due to a difference in adaptive 
requirements. 
 
Lifestyle modifying behaviour should be taught in all the population groups in South 
Africa because polymorphisms such as the R563Q mutation are found more 
frequently in the Black African groups. This creates a genotype more susceptible to 
interaction with environmental factors, such as sodium intake, that can alter 
phenotype.  
 
FURTHER RESEARCH 
This project contributes considerably to strengthening the association and linkage of 
the R563Q mutation to hypertension. It does not however provide robust 
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physiological evidence of the increased activity of the mutation. There are a few 
further areas that could be explored to try and show physiologically and 
biochemically that this mutation does actually affect the activity of the channel. 
 
Function 
1) Physiologically, the activity of the ENaC can be illustrated by expressing the 
channel in Xenopus oocytes [Schild et al., 1995]. This method has been employed as 
an estimate of the function of the channel with and without the R563Q mutation in 
Oxford, using rat DNA. There was no direct obvious effect of the mutation using this 
crude method (Chapter 9). However this method could be extended and an interaction 
with hormones could be determined. The channel could be expressed with the R563Q 
mutation in human DNA and with an alanine instead of the arginine or glutamine. 
(Arginine is a positively charged amino acid and glutamine is a negatively charged 
amino acid whereas alanine is neutral.) The charge of the amino acids could affect the 
three dimensional configuration of the protein and thus the activity and interaction 
with other proteins. 
 
Expression of the channel with and without the mutation and some of the proteins 
that are known to influence channel activity (such as SGK1 and S1A) may show a 
difference in interaction with these proteins. There may be more subtle differences 
that are not visible with the current methodology. 
 
2) The functional expression techniques may not be able to show a difference but 
it could be possible to see a difference when using imaging techniques [Blazer-Yost et 
al., 2004]. Immunofluorescence could be used to show a difference in channel number 
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at the cell surface or show a difference in channels that are contained within the cell. 
Direct imaging has the advantage of visualising the difference within the cell 
expressing the protein, but can still be difficult to show subtle differences. 
 
3) Another method of showing a difference in interaction with different proteins is 
the yeast two hybrid system [Jahn et al., 1997]. This system uses a yeast cell with a 
library of the complementary DNA of the hormones that are available in the cortical 
collecting duct cells. The ENaC DNA then would be inserted into the yeast cell. After 
incubating the yeast cell any proteins that interact would bind together.  
 
This method can determine if there is a difference in the interaction of two proteins 
(e.g. the ENaC and S1A) or it can find out if there is an interaction with various 
unknown proteins. This method is not able to determine a change in function due to a 
mutation but it could determine if there was a difference in binding ability between 
proteins and the ENaC with or without the R563Q mutation. 
 
4) Crystallisation techniques have been used to show a difference in protein 
configuration leading to an alteration in function. The sodium channel has not been 
crystallised but if it were it could be possible to show a difference in protein 
configuration between the normal and the protein with glutamine at position 563. 
Many efforts have been made to crystallise the protein and the closest result is 
crystallisation of the acid-sensing-ion channel [Jasti et al., 2007]. (This channel is 
related to the ENaC.) Unfortunately, when this channel was crystallised the 
intracellular portion was not part of the crystallisation process. The R563Q mutation 
is found in the intracellular carboxy-terminal domain which means that the 
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intracellular portion would need to be crystallised. This method is, thus far, not a 
feasible option, as many teams have been trying to crystallise the ENaC. 
 
5) The response to a specific inhibitor of the sodium channel could be elicited. 
There are two drugs available to humans that are known to inhibit the sodium 
channel: amiloride and triamterene. Triamterene was used by Liddle [1963] to treat 
his original patients. They responded well to triamterene when included with a low 
sodium diet. Amiloride was shown to control BP in patients in London with the 
T594M mutation of the β-ENaC [Baker et al., 2002]. The T594M mutation was not 
shown to be associated with hypertension in South Africa [Nkeh et al., 2003] and so is 
not routinely determined in the hypertensive patients at GSH. The R563Q mutation 
has repeatedly been associated with hypertension but amiloride is not registered in 
South Africa and so is not available, except for a few patients with the R563Q to treat 
their hypertension. A formal controlled clinical trial is warranted to assess the 
response to amiloride in patients with the R563Q mutation. This could strengthen the 
association and could enable registration of amiloride in South Africa, so improving 
the treatment of hypertension. 
 
6) The association of the mutation with CKD seen in Chapter 7 is not 
completely explained in these data. Further research into the association with CKD 
using prospective analyses is warranted. The possible mechanism for this association 
could be determined by ongoing clinical assessments of the patients and by kidney 
biopsy. The clinical assessments need to be initiated before the onset of hypertension 
and CKD.  
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Origins 
The frequency with which this mutation is found in the Khoisan groups assessed 
suggests that this mutation originated from this population. This could well have been 
an adaptation to the harsh environment in which they lived. However the frequency 
only suggests the origins and more evidence would be required to prove that this 
mutation did in fact originate from this group.  
 
Two methods are a possibility to strengthen the hypothesis: 
1) This mutation could be compared with the frequency of the clades within the 
mitochondrial DNA and Y chromosome, similar to the comparison by Lane et 
al. [2002]. The Y chromosome and mitochondrial DNA illustrate some of each 
individual’s genetic background. The clades that are known to be from the 
Khoisan are the L1d and L1k clades from the mitochondrial DNA [Salas et al., 
2002]. If there is a strong association with these clades and the R563Q 
mutation it could suggest that this mutation did originate from the Khoisan. 
This method may also show an association of the R563Q mutation with either 
the Khoikhoi or the San. 
 
2) Another method is to look at the microsatellite markers in the β-ENaC gene 
itself, such as the Alu insertion polymorphisms discussed by Stoneking et al. 
[1997]. Similarities between the haplotypes with the mutation between the 
Xhosa, Zulu, Coloured and Khoisan could also suggest that this mutation 
originates from the Khoisan. 
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APPENDICES 
 
Appendix I: Quantitative Transmission Disequilibrium Testing 
The transmission disequilibrium test was developed by Spielman et al. [1993] as a 
direct test of linkage between a marker and a disease in a population which already 
shows association. The test uses the genetic data from an affected offspring and 
heterozygous parents. It tests the number of times the heterozygous parents transmit a 
marker or the alternate allele to an affected child. One of the strengths of the test is 
that it does not require data from unaffected siblings or other affected family 
members. 
 
It is a form of Χ2 analysis testing the significance of linkage between a disease and a 
genetic marker. The pure Χ2 test is inadequate in a situation where there is a lack of 
independence between individuals, i.e. family members. This analysis will not show a 
significant result in a situation where there is association without linkage. 
 
In diseases that are of later onset the TDT is inadequate as parental data are usually 
not available. Spielman and Ewens [1998] modified the TDT to the sib TDT (S-TDT) 
to allow comparison between affected and unaffected siblings. S-TDT requires that 
there is at least one affected and one unaffected sibling and that there is a difference in 
marker status between the siblings. This enables the test to determine if there is a 
difference in marker frequency between affected and unaffected siblings, but requires 
larger numbers than the TDT. 
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The TDT was designed for dichotomous traits. However, many disorders are assessed 
as continuous traits (e.g. BP for hypertension) and, in general, quantitative phenotypes 
are more informative than dichotomous traits, providing stronger statistical evidence 
of association in linkage studies.  
 
The QTDT analysis [Abecasis et al., 2001] allows the use of continuous variables in 
family based association studies. It does not require the parental genotypes. It can 
compare within family and between family effects. The QTDT assesses linkage, LD 
and population admixture from all offspring. It does this to model the phenotypic 
similarities that are common in the family data. The test is not affected by 
confounding variables like population stratification, and can include nuclear families 
of any size and composition. It also takes into account the degrees of the relationships. 
The QTDT analysis is available via the Abecasis homepage. 
 
Appendix II: Glossary 
Hardy Weinberg Equilibrium shows whether or not gene frequencies have changed 
within a population. If the criteria for equilibrium are met the allele frequencies will 
equal 1. If frequencies have changed in a population it indicates that evolutionary 
pressure has occurred. This will alter the frequency of one of the alleles. 
 
If there are two alleles in a population: A and a, and the frequency of A is p and the 
frequency of a is q then p + q = 1. As people have two copies at each locus the 
possible combinations are p
2 
+ 2pq + q
2
 = 1. 
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There will be no change in frequency in the different generations if certain criteria are 
met. 
1) A large population – decreases the risk for random error 
2) Random mating – i.e. no selection of mate 
3) No Mutation at this allele 
4) No migration – no influx or efflux of this allele 
5) No natural selection – for or against the allele 
If these criteria are met then the frequencies of alleles A and a will remain constant 
throughout the generations. 
 
Heterozygosity refers to the inheritance of two different copies of an allele at the 
same locus on a pair of homologous chromosomes. 
 
Homozygosity refers to the inheritance of two copies of the same variant at a single 
locus on a pair of homologous chromosomes. 
 
Intermediary phenotype is a genetic trait that influences a certain multifactorial 
phenotype discriminating the phenotype between individuals. 
Linkage disequilibrium (LD) is high between two markers if there has been no 
recombination between them, which means that they must be physically very close to 
one another on a chromosome. One can do a statistical test of LD if the genotypes of 
the individuals at the two markers are known. 
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Mendelian Forms of Hypertension refer to inherited forms of hypertension with a 
clear autosomal dominant or recessive or X-linked pattern of inheritance. This form of 
hypertension develops when a single genetic variant causes the disorder.  
 
Mutation refers to any inheritable change in the DNA sequence. 
 
Nasal Potential Difference assesses the voltage across nasal epithelium, which 
correlates with the transport of sodium and chloride across cell membranes. 
 
Nedd 4-2 is a protein that functions as an ubiquitin ligase that has WW domains and 
is able to interact with the ENaC PY motif. Nedd stands for Neuronal Precursor Cell 
Expressed Developmentally Downregulated. 
 
Open probability (Po) refers to the chance that a channel is able to conduct a 
substance through the pore from one side of a membrane to the other. 
 
Polymorphism is the difference in DNA sequence between individuals. The different 
sequence is considered a polymorphism when it is too common to be considered a 
new mutation. A single nucleotide polymorphism (SNP) occurs when one base 
differs from the usual base at that particular position. 
 
Population Stratification refers to differences in allele frequencies between cases 
and controls due to systematic differences in ancestry rather than association of genes 
with disease. It has been proposed that false positive associations due to stratification 
can be controlled by genotyping a few dozen unlinked genetic markers. 
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PY motif is the proline rich motif that contains a tyrosine residue which is known to 
bind to proteins bearing tryptophan rich (WW) domain. 
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Appendix III: Consent and Ethics Approval 
III.1 Molecular Studies in the Khoisan 
 
 
 
 
REQUEST FOR MOLECULAR STUDIES 
(DNA) 
 UNIVERSITY OF CAPE TOWN 
   
   
   
Dr ESW Jones Research Ethics Committee DNA number:  
Groote Schuur Hospital Groote Schuur Hospital Volume:  
New Main Building Observatory 7925 Result:   
Nephrology Unit Old Main Building  
E12 Workshop E52-24  
021 404 2292 021 404 6338  
 021 406 6492   
   
Surname: First Name:  
Sex: Date of Birth:  
Number  of children:     
Ethnic Origin: (both your mother and father)   
Contact Address:     Tel:  
Hospital Address:    Tel:  
Additional family history:    
Clinical Details:     
      
Other:     
 
Consent for Blood Pressure Measurement 
 
I consent for my blood pressure to be taken using a standard non-invasive blood pressure measuring 
 
I have been informed that there are no complications of measuring blood pressure.  
I consen  
I consent to have my blood tested for aldosterone and renin levels, (normal hormones in the blood) and 
 
I consent for a sample of my urine to be tested for c  
 
 
Subject signature ____________________________    
 
Witnessed consent ____________________________ 
 
Date _______________________________________ 
BP 1:   BP 2:   
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III.2 Molecular Studies with the Hypertension Clinic 
 
 
 
REQUEST FOR MOLECULAR STUDIES 
(DNA) 
 
Inherited Metabolic Disease Laboratory R6.35 
 
Division of Chemistry 
Room 6.35 Level 6 
Blood should be drawn in 1 plastic EDTA 
Tube (Purple top) +/- 5ml each. 
Fulmouth Building 
CT Medical School 
Observatory 7925 
Each tube should be inverted to mix and 
should be clearly labelled with the patient’s 
name and DOB 
  
Tel: (021) 406 6219        Fax: (021) 448 8150 Keep blood in fridge at 4°C until able to 
send to laboratory 
  
 Please DO NOT send specimens on ice or 
frozen. 
Please fill in all the information requested:  
 
Surname:_____________________________________________ 
First Name(s):_________________________________________ 
Family name: _________________________________________ 
 
Sex: M    F   Date of Birth: (DD/MM/YY)___________ 
 
Number of children: ____________________________________ 
 
Ethnic Origin: (please indicate ancestry of both your mother and father) 
_____________________________________________________ 
 
Contact Address:  ______________________________________ 
Town: _______________________ Tel: ___________________ 
 
Referring Doctor/Sister: _________________________________ 
Town:  ______________________ Tel: ___________________ 
 
Hospital or Address:  ___________________________________ 
Town:  ______________________ Tel: ___________________ 
 
Reason for Referral (Clinical diagnosis): 
_____________________________________________________ 
Additional disorders (apparent or previously treated):  
_____________________________________________________ 
Additional family history   
_____________________________________________________ 
Other:  _______________________________________________ 
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CONSENT FOR DNA ANALYSIS AND STORAGE 
 
1. 
 
I, __________________________________________________________, 
request that an attempt be made using genetic material to assess the 
probability that I might have inherited a disease-causing mutation in the 
genes for HYPERTENSION. 
  
2. I understand that the genetic material for analysis is to be obtained from my 
blood cells. 
  
3. I request that no portion of the sample be stored for later use.  (MARK IF 
APPLICABLE ) 
 Or 
I request that a portion of the sample be stored indefinitely for (DELETE 
WHERE NOT APPLICABLE): 
 ( a ) possible re-analysis 
            ( b ) analysis for the benefit of my immediate family members 
 ( c ) research purposes, subject to the approval of the University of 
Cape Town Research Ethics Committee, provided that any information 
from such research will remains confidential. 
  
4. The results of the analysis carried out on this biological sample will be 
made known to me, via my doctor, if and when available, if there is 
compelling evidence that this information will improve my or my family’s 
medical care. Only then will the information be recorded in my medical 
records and I will undergo genetic counselling.  
In addition, I authorise that they may be made known to: (DELETE 
WHERE NOT APPLICABLE)  
other doctors involved in my care. 
The following family members:________________________________ 
other:_____________________________________________________ 
  
  
  
5. I have been informed that:  
( a ) there are risks and benefits associated with genetic analysis and 
storage of biological material and these have been explained to me 
but DNA analysis may not be informative for some families or 
family members.  
( b ) the analysis procedure is specific to the genetic condition 
mentioned above and cannot determine the complete genetic 
makeup of an individual. 
( c ) the genetics laboratory is under an obligation to respect medical 
confidentiality. 
( d )  even under the best conditions, current technology of this type is 
not perfect and could lead to incorrect results. 
( e ) where biological material is used for research purposes, there may 
be no direct benefit to me. 
  
6. I understand that I may withdraw my consent for any aspect of the above at 
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any time without this affecting my future medical care. 
  
7. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A 
LANGUAGE THAT I UNDERSTAND AND MY QUESTIONS 
ANSWERED BY: 
  
    Date:______________________________________ 
 
 
 
Patient signature____________________________ 
 
 
 
Witnessed consent___________________________ 
 
 
Dr ESW Jones 
Groote Schuur Hospital 
New Main Building 
Nephrology Unit 
E12 Workshop 
021 404 2292 
Research Ethics Committee 
Groote Schuur Hospital 
Observatory 7925 
Old Main Building 
E52-24 
021 404 6338 
021 406 6492  
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III.3 PATIENT INFORMATION AND INFORMED CONSENT 
R563Q Sodium Channel Activity Study 
INTRODUCTION 
 
You are invited to participate in this study. This information leaflet will help you 
decide if you would like to participate. Before you agree, you should fully understand 
what is involved. If you have any questions, which you do not understand, please do 
not hesitate to discuss this with the study doctor.  
WHAT IS THE PURPOSE OF THE STUDY 
 
The purpose of this study is to assess the function of a mutation of the epithelial 
sodium channel gene, R563Q, which we think predisposes people to salt sensitive 
hypertension. We would like to confirm this. 
 
We will look to see if this mutation causes a change in activity that can be controlled 
by amiloride. 
HOW MAY THE STUDY BENEFIT YOU? 
 
There may be no direct benefit for you but the results may improve your treatment 
and the treatment of other patients in the future. 
  
WHAT IS THE DURATION OF THE STUDY AND WHAT PROCEDURES 
WILL BE PERFORMED 
 
After an overnight fast you will be admitted to a metabolic unit. After obtaining 
signed informed consent you will be examined and blood and urine tests taken. 
Thereafter you will have an intravenous catheter inserted into a vein in your arm. 2 
litres of saline will be administered over 2 hours by the catheter (saline test) and all 
urine will be collected over the next 4 hours. Blood pressure will be measured every 
30 minutes, and at the end of the study more blood tests will be taken. The study will 
last 4-5 hours. Samples will be taken for genetic studies and a separate consent will be 
taken for this. 
HAS THE STUDY RECEIVED ETHICAL APPROVAL? 
 
The study protocol has been approved by the Research Ethics Committee of the 
University of Cape Town. 
WHAT ARE MY RIGHTS AS A PARTICIPANT IN THE TRIAL? 
 
Your participation is entirely voluntary and you can refuse to participate or stop at any 
time without stating a reason. Your withdrawal will not affect your access to future 
medical care.  
 
MAY THE TRIAL PROCEDURES RESULT IN DISCOMFORT OR 
INCONVENIENCE? 
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Blood tests may result in a bruise at the puncture site, swelling of the vein, infection, 
or bleeding. In experienced hands this is highly unlikely and only minor discomfort 
may occur. 
The saline test will involve the insertion of a drip into a vein in the arm and as for the 
blood test may cause minor discomfort listed above.  
WHAT ARE THE RISKS INVOLVED? 
 
In rare circumstances the saline test may cause fluid overload and you may become 
breathless but this can be treated with an injection of a diuretic. In experienced hands 
this is very unlikely to occur and is easily treated. If you are known to have heart 
disease or kidney disease you should not have the saline test. This study will be 
performed by an experienced medical practitioner, Dr Jones, who will administer the 
saline, and any diuretic should it be required. She will be assisted by a registered 
nurse during the procedure. Emergency resuscitative equipment will be available at all 
times. 
 
Saline is an isotonic (same as the blood concentration) salt solution that is frequently 
used in hospital for intravenous therapy.  
INSURANCE AND FINANCIAL ARRANGEMENTS 
 
All the study doctors are covered by insurance for medical liability. You will be paid 
R200.00 to participate in the study for transport costs and time spent at the study 
centre. 
SOURCE OF ADDITIONAL INFORMATION 
 
For the duration of the study you will be under the care of Dr Jones, and you are 
entitled to speak to her before entering the study.  
CONFIDENTIALITY 
 
All information obtained during the course of the trial is strictly confidential. Data 
will be reported in scientific journals, but will not include information that identifies 
you. 
 
It is important that the Research Ethics Committee of the University of Cape Town be 
able to review records of the trial, but only in relation to their regulatory obligations. 
INFORMED CONSENT 
 
I hereby confirm that I have been informed by the study doctor, Dr …………….., 
about the nature, conduct, benefits and risks of this clinical protocol. I have also 
received, read, and understand the written Patient Information and Consent form. 
 
I am aware that the results of the trial will be anonymously processed into a trial 
report. 
 
I may, at any stage, withdraw my consent and participation without prejudice. 
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I have had sufficient opportunity to ask questions and declare myself prepared to 
participate in the trial. 
 
Patient’s Name: …………………………………….(print) 
 
Patient’s Signature:……………………………………Date: …………… 
 
Study Doctor’s Name: …………………………………   (print) 
 
Study Doctor’s Signature: ……………………………..Date: ……………. 
 
Witness Name:       ……………………………………… (print) 
 
Witness Signature:  …………………………………… 
 
 
Dr ESW Jones 
Groote Schuur Hospital 
New Main Building 
Nephrology Unit 
E12 Workshop 
021 404 2292 
Research Ethics Committee 
Groote Schuur Hospital 
Observatory 7925 
Old Main Building 
E52-24 
021 404 6338 
021 406 6492
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III.4 REC Khoisan Approval 
UNIVERSITY OF CAPE TOWN 
 
Health Sciences Faculty 
Research Ethics Committee 
Room E52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021] 406 6338    Facsimile [021] 406 6411     
e-mail: preaward@curie.uct..ac.za 
 
09 November 2007 
 
REC REF: 269/2006 
 
 
Dr ESW Jones 
Nephrology, E12  
Groote Schuur Hospital 
 
Dear Dr Jones 
 
 
PROJECT TITLE: THE ACTIVITY OF THE R563Q MUTATION OF THE B 
ENaC 
 
Thank you for your letter to the Research Ethics Committee dated 18th October 2007. 
 
It is a pleasure to inform you that the Ethics Committee has noted and approved an 
aliquot of the DNA sample that is going to be collected to test for the R563Q mutation 
in the βENaC gene. It is also noted that blood sample for aldosterone, rennin and 
electrolytes and a urine sample for urea-creatinine ratio to determine if they are affected 
by the presence of mutation will be taken. 
 
Please note that the ongoing ethical conduct of the study remains the responsibility of 
the principal investigator. 
 
Please quote the REC. REF in all your correspondence. 
 
Yours sincerely 
 
 
 
 
 
PROF M BLOCKMAN 
CHAIRPERSON, HSF HUMAN ETHICS 
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III.5 REC Initial Approval 
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